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Primary cardiomyopathies (CMPs) are genetically heterogeneous disorders with a large 
number of disease-causing genes. The underlying genetic mechanisms and early pathological 
events of children with primary CMP are poorly characterized. This work aimed to identify 
genetic causes of childhood CMP, and to understand the development of early-onset and 
severe heart muscle disease. Mutation of PR/SET domain 16 (PRDM16) was shown to be 
associated with two types of CMP, dilated CMP (DCM) and left ventricular non-compaction 
CMP (LVNC). PRDM16 encodes for a transcriptional regulator with a previously unknown 
function in the heart. 
Eighty unrelated index patients with pediatric primary CMP underwent genetic testing with a 
panel-based next generation sequencing (NGS) approach of 89 genes. Adverse events such 
as heart transplantation (HTX) and death were higher for individuals affected by DCM and 
restrictive CMP than for other types of CMP. Patients with a higher number of variants of 
interest (VOI) had an increased risk to experience an adverse event. At least one pathogenic 
or likely pathogenic variant was identified in 30/80 (38%) index patients. In all CMP subgroups, 
patients carried most frequently VOI in sarcomere genes suggesting them as a major 
contributor in pediatric primary CMP. Protein and transcript level analysis on heart biopsies 
from individuals with homozygous mutation of troponin I3, cardiac type (TNNI3) revealed that 
the TNNI3 protein was absent and associated with upregulation of the fetal isoform troponin 
I1, slow skeletal type (TNNI1). These observations support the clinical importance of 
sarcomeric mutation in primary CMP. TNNI3 is the third most important disease gene in 
pediatric CMP. 
The mutational spectrum of PRDM16 in an extended cohort of 285 patients with different types 
of heart muscle diseases revealed 16 VOI in total. These alterations occurred in six different 
cardiac diseases and comprised missense, splice site, frame shift, and stop gain variants. 
Pathogenic PRDM16 variants were only found in LVNC patients, confirming the important role 
of PRDM16 in LVNC pathogenesis. By prediction of posttranslational modification sites, 
structural features and functional interaction sites of the PRDM16 protein were identified. 
Functional and biochemical characterization of PRDM16 showed different subcellular 
localization of CMP variants and the influence of CMP variants on the protein stability of 
PRDM16. Patient specific CMP variants altered the cellular distribution of PRDM16, with 
condensed signals differing between the cytoplasm and the nucleus. 
In conclusion, the spectrum and number of genetic alteration in pediatric primary CMP 
determine clinical outcome. PDRM16 is a frequent CMP gene and translational approaches 





Primäre Kardiomyopathien (CMP) sind heterogene, genetisch determinierte Erkrankungen mit 
einer Vielzahl von krankheitsverursachenden Genen. Die zugrundeliegenden genetischen 
Mechanismen und früh vorhandenen pathologischen Vorgänge sind bei Kindern mit primärer 
CMP wenig untersucht. Diese Arbeit beschäftigt sich mit der Identifizierung von genetischen 
Ursachen der Kardiomyopathie des Kindesalters, insbesondere mit dem Auftreten von früh 
einsetzenden und schweren Krankheitsverläufen. Genetische Veränderungen von PR/SET 
domain 16 (PRDM16) führen zu zwei verschiedenen Arten von Kardiomyopathien, der 
dilatativen CMP (DCM) und der linksventrikulären Noncompaction CMP (LVNC). PRDM16 
kodiert für einen transkriptionellen Regulator mit bis dahin unbekannter Funktion im Herzen. 
Achtzig nicht verwandte Indexpatienten mit pädiatrischer primärer CMP wurden mit einem 
panel-basierten next generation sequencing (NGS) Ansatz einer genetischen Testung auf 
Veränderungen in 89 Genen untersucht. Unerwünschte Ereignisse wie Herztransplantation 
und Tod waren bei Individuen mit DCM und restriktiver CMP höher als bei anderen CMP. 
Patienten mit einer höheren Anzahl von genetischen Varianten von Interesse (VOI) hatten ein 
höheres Risiko für ein unerwünschtes Ereignis. Bei 30/80 (38%) Indexpatienten wurde 
mindestens eine wahrscheinlich pathogene oder pathogene Variante identifiziert. Bei allen 
CMP Subtypen waren VOI in Sarkomergenen am häufigsten und sind somit für die Entstehung 
der pädiatrischen primären CMP hauptverantwortlich. Auf Protein- und mRNA Ebene von 
Herzbiopsien von Individuen mit homozygoter Variante konnte gezeigt werden, dass TNNI3 
nicht nachweisbar war und stattdessen eine Hochregulation der fetalen Isoform TNNI1 
stattfand. Diese Beobachtungen unterstützen die klinische Bedeutung von genetischen 
Veränderungen in Sarkomergenen bei primärer CMP. TNNI3 ist das dritthäufigste 
Krankheitsgen bei pädiatrischer CMP. 
Das Spektrum der VOI bei PRDM16 in einer erweiterten Kohorte von 285 Patienten mit 
verschiedenen Herzmuskelerkrankungen ergab insgesamt 16 verschiedene VOI. Diese 
Veränderungen traten bei sechs verschiedenen Herzerkrankungen auf und umfasste Punkt-
Varianten, Spleiß-Varianten, Frameshift-Varianten und Stopp-Varianten. Pathogene PRDM16 
Varianten wurden nur bei Patienten mit LVNC gefunden, was die Bedeutung von PRDM16 in 
der Entstehung der LVNC unterstreicht. Durch die Vorhersage von Stellen für 
posttranslationale Modifikationen wurden strukturelle Eigenschaften und funktionelle 
Interaktionsstellen des PRDM16 Proteins identifiziert. Die funktionelle und biochemische 
Charakterisierung von PRDM16 zeigte unterschiedliche subzelluläre Lokalisationen von CMP 
Varianten und auch die Stabilität vom PRDM16 wurde unterschiedlich durch die jeweiligen 




Verteilung von PRDM16 dahingehend, dass kondensierte Signale zwischen Zellkern und 
Zytoplasma jeweils differierten.  
Abschließend fanden wir, dass das Spektrum und die Anzahl der genetischen Veränderungen 
bei pädiatrischer primärer CMP für den klinischen Ausgang verantwortlich sind. PRDM16 ist 
ein häufiges Krankheitsgen für CMP und translationale Ansätze für mögliche Therapien sollten 
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In 2016 according to World Health Organization (WHO) data cardiovascular disease 
represented with 31% the number one cause of death worldwide (https://www.who.int/news-
room/fact-sheets/detail/cardiovascular-diseases-%28cvds%29). The most frequent diseases 
in this group are ischemic heart disease, where restricted blood supply leads to adverse events 
in the heart, strokes, where limited blood flow affects the brain, and hypertensive heart disease 
caused by high blood pressure. Nevertheless, cardiomyopathy (CMP), myocarditis and 
endocarditis pooled into one category by the WHO, are included in this group of life-threatening 
diseases and constitute to 374000 casualties worldwide each year (0.7%, estimates for 2016). 
This category comprises malformations of the heart due to congenital alterations or 
inflammatory events. Therefore, these numbers present a necessity to investigate 
mechanisms leading to these diseases to reduce death rates. Especially congenital forms of 
cardiomyopathies can be related to genetic alterations and are suited for genetic screening. 
While mechanisms leading to cardiomyopathy in adults are well-established, the underlying 
genetic mechanisms, early pathological events and other disease promoting factors are poorly 
characterized in children. Thus, in this work a pediatric cohort consisting of patients affected 
by primary, non-syndromic cardiomyopathies was tested for its genetic background. 
Furthermore the function of many proteins involved in cardiomyopathy relevant processes is 
well understood, but the impact of small genetic alterations is difficult to predict and requires 
further investigation. Additionally to well-known cardiomyopathy genes like myosin heavy chain 
7 (MYH7) and myosin binding protein C, cardiac (MYBPC3) genetic testing led to newly 
discovered disease genes and approximately 100 different genes are associated so far with 
cardiomyopathy (R. E. Hershberger, Hedges, & Morales, 2013). Many of these genes are 
poorly characterized in the cardiac setting. Therefore, another purpose of this work was to gain 
functional knowledge of the involvement of the transcriptional regulator PR/SET domain 16 
(PRDM16) for the progression of cardiomyopathies due to small variants. 
1.1 Classification of cardiomyopathies and prevalence 
The word cardiomyopathy originates from the Greek language and means disease of the heart 
muscle (καρδίᾱ - heart, mỹs – muscle, πάθος – suffering, disease). It is characterized by 
complex malformations of the myocardium and manifests itself as abnormalities in the 
structure and function of the heart (Burke, Cook, Seidman, & Seidman, 2016). Especially 
resulting in arrhythmia, heart insufficiency and hypoxia can lead to adverse events and death. 
Cardiomyopathies are distinguished into primary and secondary. Secondary cardiomyopathies 




disease (metabolic) or Diabetes mellitus (endocrine). Primary cardiomyopathies are defined 
as predominantly affecting the myocardium in the clinically relevant disease processes. 
Furthermore, primary cardiomyopathies are distributed into the categories genetic/congenital, 
acquired and mixed. Acquired diseases of the heart muscle can be caused by environmental 
factors like stress or infection of the myocardium through bacteria and viruses (Takotsubo 
cardiomyopathy and myocarditis). Further risk factors such as overweight, pregnancy or drug 
and alcohol abuse may cause acquired cardiomyopathy or at least contribute to the congenital 
forms. Genetic cardiomyopathies however are caused by alterations of the genome. Some of 
the congenital forms of cardiomyopathies can also be acquired through environmental factors 
and therefore represent a mixed form (Maron et al., 2006; Cecchi, Tomberli, & Olivotto, 2012). 
Such case may occur when a myocarditis develops into a more severe dilated cardiomyopathy. 
Historically the term idiopathic was used due to unknown mechanisms as to why 
cardiomyopathies develop and progress. Ongoing investigation relates genetic burdens to the 
initiation and progression of primary cardiomyopathies. These genetic forms are further 
distributed into the specific cardiomyopathy phenotypes of dilated cardiomyopathy (DCM), 
hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), arrhythmogenic right 
ventricular cardiomyopathy (ARVC, due to involvement of both ventricles in new publications 
referred to as arrhythmogenic ventricular cardiomyopathy - AVC), left ventricular 
noncompaction cardiomyopathy (LVNC) and ion channelopathies. The subtypes of 
cardiomyopathy will be further described in the following sections. Because ion channels can 
also lead to other affected organs and syndromic diseases, they are not further described or 
discussed in this work. 
1.1.1 Dilated cardiomyopathy 
Dilated cardiomyopathy is the most common cardiomyopathy form (McKenna, Maron, & 
Thiene, 2017; Herkert et al., 2018). DCM is characterized by the dilatation of the left ventricle. 
Additionally global systolic dysfunction has to be observed leading to an ejection fraction 
smaller than 50%. For the congenital form further factors like coronary artery disease, systemic 
hypertension or inflammatory heart disease have to be absent. Wall thinning is believed to 
contribute to the contractile deficiencies. The right ventricle can be affected similarly. These 
physiological features can manifest in ventricular heart failure (right-, left- and biventricular), 
arrhythmias, syncope or sudden death (Lipshultz et al., 2019). The prevalence of DCM is 
estimated at 1:250 to 1:500 in adults and uncommon in children with an accumulation of cases 





1.1.2 Hypertrophic cardiomyopathy 
Hypertrophic cardiomyopathy is characterized by an enlargement of the septum or ventricular 
wall, whereas the right ventricles are rarely affected. The hypertrophy can occur in confined 
segments. Due to wall thickening tachycardia, arrhythmia and sudden cardiac death can occur 
(often in undiagnosed athletes with HCM through burden of the heart, Cecchi, Tomberli, & 
Olivotto, 2012). Therefore, implantation of pacemakers are common for advanced HCM 
additionally to pharmaceutical treatment. Otherwise many HCM patients are asymptomatic or 
show only mild signs of the disease. The onset of disease is often with advanced age and thus 
uncommon in children, although often occurring in adults with an estimated frequency of 
1:250/500 (Semsarian, Ingles, Maron, & Maron, 2015; McKenna, Maron, & Thiene, 2017). Still, 
HCM is believed to be rarer than DCM and the second most frequent cardiomyopathy in 
children (R. E. Hershberger, Hedges, & Morales, 2013; Lee et al., 2017). 
1.1.3 Restrictive cardiomyopathy 
Restrictive cardiomyopathy is a rare phenotype and characterized by diastolic impairment or 
abnormal compliance often of both ventricles. The ventricles therefore seem rigid or restricted 
and as a result the atria are often affected by enlargement, whereas the ventricles are 
presented normal (not dilated or hypertrophic, normal wall thickness). RCM can result in heart 
failure, arrhythmias or sudden death and conduction abnormalities and atrial/ventricular 
arrhythmias as first signs of the disease (M. A. Walsh et al., 2012). As mentioned, RCM is 
uncommon in adults and children (McKenna, Maron, & Thiene, 2017; Lee et al., 2017). 
1.1.4 Arrhythmogenic right ventricular cardiomyopathy 
Arrhythmogenic right ventricular cardiomyopathy is also rare and only restricted data of 
population data is available for this CMP. Nevertheless, a frequency of 1:2000/5000 is 
estimated and rarer in children (Marcus et al., 2010; Nava et al., 2000; Lee et al., 2017). The 
disease is characterized by fibrofatty replacement of the myocardium in the ventricles and thus 
restricted conduction. Ventricular arrhythmias are the consequence and atrial fibrillation can 
occur (Cecchi, Tomberli, & Olivotto, 2012; Corrado et al., 2015). 
1.1.5 Left ventricular noncompaction cardiomyopathy 
Left ventricular noncompaction cardiomyopathy is characterized by “spongy” and therefore 
noncompacted appearance of the left ventricular myocardium due to massive trabeculation 




2019). Typical symptoms are palpitations, non-specific chest pain, heart failure symptoms and 
arrythmias. LVNC is often observed in combination with other cardiomyopathies and without 
or mild symptoms (Maron et al., 2006). Therefore it is highly debated, if LVNC is a distinct 
cardiomyopathy leading to adverse events or only prominent with other diseases and thus not 
an isolated cardiomyopathy. The prevalence of LVNC cases is difficult to estimate, because 
available large population reports are lacking and diagnosis criteria leading to adverse events 
are highly discussed. Additionally, it is unclear, if LVNC is a developmental condition or can 
also be acquired in advanced age (Tian et al., 2017; Kodo et al., 2016). 
1.2 Genes causing cardiomyopathies 
In contrast to acquired forms of cardiomyopathy, congenital CMPs are caused by genetic 
alterations, predominantly small changes leading to amino acid changes at one position or 
modifying the reading frame and therefore resulting in a frameshift. Meanwhile a wide spectrum 
of genes was associated with this category of disease. 
1.2.1 Functional groups of cardiomyopathy-related genes 
Only for HCM over 2000 variants have been associated with the onset of this cardiomyopathy 
detected in over 40 genes (Bondue et al., 2018; Cirino et al., 2017). These findings show, that 
CMPs are heterogenous diseases considering that DCM is associated with considerably more 
cardiac genes. Thereby, variation in genes are not entirely specific for one phenotype and 
mechanisms how different variants in the same gene result in different cardiac phenotypes are 
hardly understood (R. E. Hershberger et al., 2018; Burke, Cook, Seidman, & Seidman, 2016; 
Pugh et al., 2014). Genes investigated regarding the onset and progression of CMPs can be 
classified in functional groups and a set of major genes is presented in Figure 1. Genes 
included in the functional group of the sarcomere are detected in CMP cases with the highest 
rate. The sarcomere is the functional unit of the muscle and generates the contractile force for 
movement due to the interaction of myosin and actin filaments. Therefore, impairment of this 
system leads to compensative remodeling of the heart and thus to cardiomyopathies (Dadson, 
Hauck, & Billia, 2017). Alteration of proteins in the Z-disc, the complex scaffold separating two 
sarcomeres, often leads to structural modifications and again adverse remodeling of the heart 
(Towbin, 2014). Defects in proteins of desmosomes, cell-cell contacts in cardiomyocytes, can 
result in decreased capability to withstand mechanical strains in the heart and mitochondrial 
proteins may influence metabolic features of cardiomyocytes (Lipshultz et al., 2019). 
Further classification categorizes CMP-related genes into cytoskeleton (dystrophin-




membrane and a few others (Burke, Cook, Seidman, & Seidman, 2016). Due to divergence of 
genetic burden suggestions have been phrased to change the classification from 
morphological phenotypes to molecular genetic defect (sarcomeric cardiomyopathy, cell 
junction cardiomyopathy, ion channel cardiomyopathy, cytoskeletal cardiomyopathy, etc., 
Thiene, Corrado, & Basso, 2004). Either way, newly discovered genes associated with CMP 
are discovered repeatedly like PRDM16 (Arndt et al., 2013) and diagnostical criteria have to 
be as distinct as possible to choose the clinical treatment accordingly. 
 
 
Figure 1: Spectrum of genes associated with CMPs in different cell compartments. Genes are associated 




1.2.2 Abundance of variants in genes causing cardiomyopathy 
For the cardiomyopathies DCM, HCM, RCM, ARVC and LVNC distinct gene spectra were 
detected. A former study suggested, that HCM is a force generating disease of the sarcomere 
and DCM a force transmitting disease of the mostly the cytoskeleton, whereas ARVC is caused 
by defects in desmosome and therefore a cell junction disease (McKenna, Maron, & Thiene, 
2017). The occurrence of variants in sarcomeric genes in patients with DCM, RCM and LVNC 
contradicts the afore mentioned suggestion and presents the difficulty to genetically define the 
different cardiac phenotypes (Bollen & van der Velden, 2017). One precise example is MYH7, 
a major factor for the contraction of sarcomeres. Variants in this gene were detected in more 
than one type of CMP. Therefore, variants in different functional domains of a protein may 
contribute differently to the phenotype. 
Nevertheless, tendencies can be detected and in HCM cases mainly sarcomere genes are 
observed (Ingles et al., 2019; Rupp et al., 2019). The majority of variants is observed in the 
genes MYBPC3 and MYH7 (19% and 14.2%), whereas variants in other sarcomere genes are 
considerably less frequent (R. Walsh et al., 2017). Other non-sarcomeric genes associated 
with HCM are galactosidase alpha (GLA), protein kinase AMP-activated non-catalytic subunit 
gamma 2 (PRKAG2) and lysosomal associated membrane protein 2 (LAMP2) but may present 
the cardiomyopathy as a secondary symptom (R. E. Hershberger et al., 2018). 
DCM is associated with a heterogenous spectrum of genes. Most frequently with 15-25% 
variants were detected in titin (TTN, Akinrinade et al., 2019, Schafer et al., 2017). Thereby, 
only truncating variants were considered for analysis. TTN is the longest known protein with a 
number of alternatively spliced transcripts. Due to its challenging length it is difficult to predict 
the effect of single amino acid or short in-frame changes. A cardiac-specific transcript has been 
analyzed to predict the expression of truncating variants (Roberts et al., 2015). Other less 
frequent but statistically enriched genes compared to healthy individuals were MYH7 (5.3%, 
sarcomere), lamin A/C (LMNA, 4.4%, nuclear envelope), troponin T2, cardiac type (TNNT2, 
2.9%, sarcomere), tropomyosin 1 (TPM1, 1.9%, sarcomere,) and desmoplakin (DSP, 
truncating variants with 2.8%, desmosome, R. Walsh et al., 2017). 
For LVNC patients the highest genetic burden was observed with variants in MYH7, MYBPC3 
and TTN (Oechslin & Klaassen, 2019; Kolokotronis et al., 2019). Therefore again, LVNC cases 
show similarities to HCM and DCM. Additionally, mitochondrial and desmosomal genes were 
associated with the disease (Lipshultz et al., 2019). 
Patients affected with ARVC present the most distinct and non-overlapping genotype in the 
group of cardiomyopathies. In 50-60% of ARVC cases variants were detected in desmosomal 




Cases with RCM are mainly affected by alterations in sarcomeric genes (Kaski et al., 2008). 
The abundance of variants in RCM-specific is only estimated because epidemiological 
research is lacking so far. Therefore, mainly single cases or individual consanguineous families 
are reported with the onset of RCM. In less frequent cases RCM patients were described to 
be affected with variants in desmin (DES) and filamin C (FLNC, Lipshultz et al., 2019). 
1.3 Next generation sequencing 
Due to the need to understand mechanisms on how cardiomyopathies develop, genetic 
screening of CMP patients becomes more important. Although genetic cause is associated 
with cardiomyopathies since 1990 (Geisterfer-Lowrance et al., 1990) the genetic basis for this 
group of diseases remains challenging and new genes are associated repeatedly with the 
onset of cardiomyopathies partly due to rapid development of new sequencing methods. Since 
the decoding of the human genome during the Human Genome Project (IHGSC, 2004) the 
sequencing of a collection of genes (panel-based sequencing), the protein coding exome or 
the whole genome is improving steadily. 
 
 
Figure 2: Schematic presentation of the Illumina next generation sequencing (NGS) method. The stepwise 
sequencing of a DNA fragment in four cycles shows marking of each nucleotide with an additional fluorophor in 
each cycle (Illumina Inc., 2010). 
 
One major contributor in this field is the company Illumina. The method preferred by Illumina 




(Figure 2, Pettersson, Lundeberg, & Ahmadian, 2009; Reuter, Spacek, & Snyder, 2015). The 
process is using fluorophor conjugated nucleotides and stepwise sequencing of each DNA 
position in cycles. The fluorophor is used as terminator group and therefore inhibits further 
DNA polymerization at the 3´ end of the newly synthesized chain in the same cycle (one 
nucleotide per cycle). After the positional readout the fluorophor is cleaved from the sequence 
and the next cycle is initiated (cleavage of fluorophor removes terminating feature, Buermans 
& den Dunnen, 2014; Illumina Inc., 2010). Each nucleotide is according to its base emitting 
light with specific wavelengths. The complementary DNA strands were captured on a flow cell 
through previously conjugated adaptor sequences and amplified/clustered to strengthen the 
signal (Meyer & Kircher, 2010). 
1.4 PRDM16 as cause for cardiomyopathies 
As mentioned before, genes newly associated with cardiomyopathy are discovered steadily. 
Currently genetic diagnostic rates are still low. Therefore, a necessity to increase genetic 
screening in patients is given. Further need to understand the impact of detected variants in 
regard to the occurrence of more than one genetic alteration (modifying variants) or newly 
associated genes remains, especially functionally or mechanistically. One such gene is 
PRDM16. 
1.4.1 PRDM16 in fat tissue and as important factor for the state of progenitor 
and stem cells 
The function of the transcriptional regulator PRDM16 was described in different tissues and 
first associated with the development of positive leukemia cells (Mochizuki et al., 2000). 
However, it is best known for its involvement in the differentiation of fat tissue, especially brown 
and beige adipocytes. It pushes the cell fate of myoblastic and adipocyte precursors to 
adipocytes and therefore interacts with different transcription factors (Ohno, Shinoda, 
Spiegelman, & Kajimura, 2012; Ohno, Shinoda, Ohyama, Sharp, & Kajimura, 2013). 
Therefore, PRDM16 has been shown to direct brown and beige fat determination and 
differentiation, acting as a major contributor in a critical complex to control the cell fate switch 
from myoblastic precursors to brown fat cells. Peroxisome proliferator-activated receptor 
gamma (PPARγ) agonists induce a white-to-brown fat conversion through stabilization of 
PRDM16 Protein (Figure 3). On the molecular level, PRDM16 interacts with several 
transcription factors like CCAAT/enhancer binding protein beta (C/EBPß) regulating 




interaction with the euchromatic histone lysine methyltransferase 1 (EHMT1). Thus, PRDM16 
seems to be involved in many signal pathways or is regulated by such. 
 
 
Figure 3: Schematic development of brown and beige adipocytes driven by PRDM16-specific initiation and 
stabilization. The upper part shows the development of brown adipocytes from myoblasts and trough PRDM16 
activated transcription processes and the lower part shows differentiation to beige adipocytes from preadipocytes 
through stabilization of PRDM16 (Ohno, Shinoda, Spiegelman, & Kajimura, 2012). 
 
Additionally, PRDM16 was observed with crucial roles in other tissues. Hence, this protein was 
described to be involved in the processes of palatogenesis, hematopoiesis, neurogenesis and 
angiogenesis and is defined by a major role in stem cell regulation and homeostasis (Bjork, 
Turbe-Doan, Prysak, Herron, & Beier, 2010; Chuikov, Levi, Smith, & Morrison, 2010; Aguilo et 
al., 2011; Baizabal et al., 2018; Su et al., 2020). 
1.4.2 Heart phenotype of PRDM16 deactivation 
Apart from the afore mentioned tissues PRDM16 was associated with the onset of 
cardiomyopathies. First evidence for cardiac involvement of PRDM16 was generated through 
a knockout mouse model carrying a splice site alteration resulting in a premature stop and 
therefore impaired PRDM16 expression (Bjork, Turbe-Doan, Prysak, Herron, & Beier, 2010). 
The variant was lethal in pre- and early postnatal stages in homozygous form. Although the 
mouse mainly was described for a cleft palate defect, it was shown, that mice were affected 




Further evidence was presented in a study, where 1p36 deletion syndrome patients with 
additional occurring cardiomyopathy were analyzed (Arndt et al., 2013). With this syndromic 
disease individuals are affected by the partial deletion of the first chromosome. It was 
suggested that cardiomyopathy is only occurring when certain parts of the chromosome are 
deleted. The common minimal region of deletion of 18 individuals was positioned in the gene 
PRDM16 including the exons 4 to 17. Furthermore, through genetic screening of patients 
affected by primary non-syndromic cardiomyopathies missense and truncating variants were 
detected in seven DCM and LVNC cases. One of the truncating variants was then investigated 
in zebrafish, leading to severe heart phenotypes. 
 
 
Figure 4: Expression of PRDM16 in mice heart and cardiac hypoplasia due to PRDM16 ko. (A) Expression of 
PRDM16 in ventricles marked with blue. (B) Cardiac proportions of a normal heart (wt) are shown. (C)/(D) Through 
deactivation of PRDM16 the mice heart was affected by hypoplasia (Bjork, Turbe-Doan, Prysak, Herron, & Beier, 
2010). 
 
Since then, further PRDM16-specific publications associated with cardiac research were rare. 
However, in a study investigating a nonsense variant in the T-box transcription factor 20 
(TBX20) PRDM16 was determined as a downstream target of TBX20 and therefore a 
transforming growth factor beta (TGF-β) signaling modifier. In patient-specific human induced 
pluripotent stem cell–derived cardiomyocytes and cardiac biopsies the regulation of PRDM16 
through TBX20 was observed and its effect on the TGF-β pathway determined 
Just recently further proof for the involvement of PRDM16 in cardiac phenotypes was published 
(Nam, Lim, Ha, Oh, & Kang, 2020). A null variant of PRDM16 was introduced into a cardiac 
conditional knockout mouse model. With electrocardiographic diagnosis considerable 
alterations were observed (QRS duration and QTc interval increased). Fibrosis and 
hypertrophic cardiomyocytes were detected in the affected mice and the expression of cardiac 




These findings mainly proof that PRDM16 is involved in the development of the heart and 
cardiac impairments. Molecular mechanisms mainly remain uncertain and further investigation 
to understand the effect of genetic alterations in PRDM16 is necessary for prospective 
therapies. 
1.5 Aims of the dissertation 
This work aims to identify genetic causes of childhood CMP and to understand the 
development of early-onset and severe heart muscle disease. Only recently, mutation of 
PRDM16 was shown to be associated with two types of CMP, DCM and LVNC. PRDM16 
encodes for a transcriptional regulator with a previously unknown function in the heart. The 
mutational spectrum of PRDM16 in extended cohorts of patients with different types of heart 
muscle diseases will be examined. Furthermore, biochemical exploration of PRDM16 in the 
context of CMP is another aim of this work. 
1. We start with a targeted panel NGS approach covering the established CMP disease 
genes. The cohort of patients with pediatric CMP will be characterized using clinical 
parameters. The impact of age of onset of CMP, type of CMP, and genetic vs. sporadic 
CMP will be evaluated for event-free survival.  
2. We ask if the number and type of VOI have an impact on the occurrence of adverse 
events in patients. The genetic variants will be classified according to ACMG for their 
pathogenicity. This aim requires to develop and apply specific rules for interpretation in 
the context of CMP and to establish an in-house evaluation scheme. 
3. We hypothesize that we find a gene or a functional subset of genes that are of either 
high or low risk to develop severe CMP courses. With these patients we will perform 
further characterization on RNA and protein level.  
4. As PRDM16 seems to be important for heart function, we anticipate that genetic 
alterations in PRDM16 will be associated with several types of heart muscle disease of 
different age groups. We will perform mutational analysis of CMP associated genes, 
specifically in myocarditis, and in a set of adult patients with LVNC. For prediction of 
posttranslational modification sites and structural elements of PRDM16, protein 
prediction tools will be used. 
5. In addition, this work will cover research on genetic CMP disease mechanisms and 
biochemical characterization of PRDM16. Specifically, we will explore the subcellular 
localization of CMP variants and the influence of CMP variants on the protein stability 
of PRDM16. 
This approach is of vital interest to explore CMP pathogenesis, appropriately manage CMP 







Plastic consumables such as Eppendorf tubes, Falcon tubes or cell culture dishes and plates 
were purchased from companies mentioned in the following list. 
 
Manufacturer Location 
Biozym Scientific GmbH Hessisch Oldendorf, Germany 
Eppendorf AG Hamburg, Germany 
INTEGRA Biosciences GmbH Biebertal, Germany 
Merck KGaA (Sigma-Aldrich, Millipore) Darmstadt, Germany 
Sarstedt Nümbrecht, Germany 
Thermo Fisher Scientific/Applied Biosystems Darmstadt, Germany 
VWR International GmbH/NanoEnTek Darmstadt, Germany 
2.1.2 Sequencing 
2.1.2.1 DNA isolation from blood and saliva 
DNA was isolated and purified from blood or saliva. The following kits were used. 
 
Chemical/Kit Manufacturer Ref 
NucleoSpin Blood MACHEREY-NAGEL 740951 
PrepIT-L2P Kit DNA Genotek PT-L2P 
2.1.2.2 Sanger sequencing 
Sanger sequencing was used to verify the results of NGS and investigate the segregation of 
variants within families. Furthermore, the quality of cloned vectors was validated with this 







Gene (Transcript) Primer Primer sequence Length 
Primer for genomic exon amplification 
LDB3 
(NM_007078) 
ghLDB3_ex10_f AAGTGATGCAACAATGAACACC 22 
ghLDB3_ex10_r GTTCCACCACCACTTCAAGC 20 
MYBPC3 
(NM_000256) 
ghMYBPC3_ex10-11_f CAACAGTCATCCTCACAGTG 20 
ghMYBPC3_ex10-11_r CAGGACCAAGGAGCTGTAG 19 
TNNI3 
(NM_000363.4) 
ghTNNI3_ex2_f AAGTGGGTTTGCGAGTCA 18 
ghTNNI3_ex2_r CCATCACCACCAAGACCC 18 
 ghTNNI3_ex5_f GGAGCTTGAGAATGGGTGGG 20 
 ghTNNI3_ex5_r GAGCCAAGACTCCACAGACC 20 
 ghTNNI3_ex8_f(a)  AGATACTTAGGCATCCAGGGTAG 23 
 ghTNNI3_ex8_r(a) ACAGCCAAGAGTGCTTCACAT 21 
 ghTNNI3_ex8_f(b)  GCTACTATTGACCTGAGAATCC 22 
 ghTNNI3_ex8_r(b) ACAGCCAAGAGTGCTTCACAT 21 
Primer for amplification of coding sequence embedded in plasmid 
PRDM16 
(NM_022114.3) 
235-256 CCGATCCCAGCAGACTTCGAGC 22 
260-241 CGGAGCTCGAAGTCTGCTGG 20 
 621-641 GGTGCACGTGAAGGAAGGCG 20 
 872-892 CCAACAAGTACAGCCTGGAGC 21 
 1062-1081 GCACATCCGCTCGCAGCACG 20 
 1450-1469 GGCTTCAACGAGTACTTTCC 20 
 1800-1819 CGGCAGTGACTTTGAGGACG 20 
 2009-2028 CCCAGCACTCATTCTTCCCG 20 
 2112-2093 CCATTGCCGAGAAGTACTTT 20 
 2238-2257 CCACAACTTGCTGGTCAAGG 20 
 2553-2572 CCCGCTCCACTACGCCAAGC 20 
 2712-2730 GACAGAGAAGCTGGAGAGC 19 
 2994-3013 CCGGAACATCCACAACAAGG 20 
 3241-3259 GCCAATAGTGAGATGAACC 19 
 3498-3518 GGGCTTTGACCACACCCGAAG 21 
Primer for cDNA exon amplification for splice site analysis TNNI3 c.24+2T>A  
TNNI3 
(NM_000363.4) 
chTNNI3_ex1_f1 TCACTGACCCTCCAAACG 18 
chTNNI3_ex1_f2 GGGAGTCTCAAGCAGCCC 18 








Chemical/Enzyme/Kit Manufacturer Ref 
BigDye Terminator v3.1 Thermo Fisher Scientific 4337455 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich D4540 
dNTP set Rapidozym GEN-009-250 
Ethidium bromide, 1% in H2O SIGMA-ALDRICH 46067-50ML-F 
Exonuclease I New England Biolabs M0293 
FIREPol DNA polymerase SOLIS BIODYNE 04-11-00115 
GeneRuler 100bp DNA ladder Thermo Fisher Scientific SM0242 
GeneRuler 1kb DNA ladder Thermo Fisher Scientific SM0313 
Hi-Di Formamide Thermo Fisher Scientific 4311320 
Illustra Sephadex G-50 DNA Grade GE Healthcare Life Sciences 17-0573-02 
LE Agarose Biozyme 840004 
Phusion High-Fidelity DNA Polymerase New England Biolabs Inc. M0530 
rAPid Alkaline Phosphatase Roche/MERCK 4898141001 
Taq DNA polymerase Qiagen 201205 
TERMIPol DNA polymerase SOLIS BIODYNE 01-03-00500 
2.1.2.3 Next-generation sequencing (NGS) 
Next-generation sequencing (NGS) was used to identify genetic variants in CMP patients by 
massive parallel sequencing in a high throughput method. The TruSight Cardio Sequencing 
panel, including a primer mix to detect 174 cardiac disease genes, was applied. Utilized 
devices and chemicals are listed below. Corresponding software is listed in the section 2.1.6. 
 
Device Company 
2100 Bioanalyzer Agilent Technologies 
DynaMag-2 Magnet Applied Biosystems, Thermo Fisher Scientific 
DynaMag-PCR Magnet Invitrogen, Thermo Fisher Scientific 
Hybex Microsample Incubator SciGene 
NextSeq 550 Illumina 
Qubit 3.0 Fluorometer Invitrogen, Thermo Fisher Scientific 
Device Company 
DNA Engine Tetrad 2, Peltier Thermal Cycler Bio-Rad 
NanoDrop ND-1000 Spectrophotometer Thermo Fisher Scientific 





Chemical/Kit Manufacturer Ref 
Agilent DNA 1000 Kit Agilent Technologies 5067-1504 
Agilent High Sensitivity DNA Kit Agilent Technologies 5067-4626 
Ethanol ≥99,8 % Carl Roth 9065.1 
NextSeq 500/550 High Output Kit v2 Illumina FC-404-2005 
Qubit dsDNA HS Assay Kit Invitrogen, Thermo Fisher Scientific Q32854 
TruSight Cardio Sequencing 





2.1.3 Cell culture 
For cell culture approaches mainly the human embryoid kidney cell line HEK293 was used. 
Only for initial experiments other cell lines like HeLa (cervical cancer cell line extracted from 
patient Henriette Lacks) or MCF7 (Michigan Cancer Foundation - 7) cell lines were tested for 
the expression of specific proteins but were less suited. For the maintenance and transfection 
of these cell lines the following materials were used. 
 
Chemical/Enzyme/Medium/Kit Manufacturer Ref 
Cycloheximide SIGMA-ALDRICH C7698 
FBS Thermo Fisher Scientific 10270106 
HEK293 cells ATCC ATCC-CRL-1573 
jetPEI kit Polyplus 101-10N 
MEM Thermo Fisher Scientific 31095-052 
OptiMEM Thermo Fisher Scientific 31985070 
PBS pH 7.4 Thermo Fisher Scientific 20012-068 
Trypsin Thermo Fisher Scientific 25200056 
2.1.4 Cloning of newly ligated expression vectors 
To transfer genes with patient specific variants into expression vectors suited for expression 
of proteins in human cell lines specific primer, adding distinct restriction sites into the newly 








Primer Primer sequence Length Target vector 










































After amplification of the gene target (insert) the PCR product was ligated into the new vector 
and transformed into competent E. coli. Additional antibiotic selection and purification 
completed the cloning process. All necessary components are listed below.  
 
Component Manufacturer Ref Restriction site 
Restriction enzymes used for cloning  
EcoRI 
 






























Plasmids used as target vector  
pEGFP-C1 BD Biosciences Clontech 6084-1 MCS* 
pFLAG-CMV5a Sigma-Aldrich E7523 MCS* 
pFLAG-CMV6a Sigma-Aldrich E1900 MCS* 









Chemical/Enzyme/Kit Manufacturer Ref 
Ampicillin Sigma-Aldrich A0166-25G 
Kanamycin Sigma-Aldrich 60615-5G 
LB Broth with agar (Miller) Powder Sigma-Aldrich L3147 
LB medium (Luria/Miller) Carl Roth X968 
NucleoBond Xtra Midi EF MACHEREY-NAGEL 740420.50 
NucleoSpin Plasmid MACHEREY-NAGEL 740588.250 
Phusion DNA Polymerase New England Biolabs M0530L 
rAPid alkaline phosphatase Sigma-Aldrich 489813300 
T4 ligase New England Biolabs M0202 S 
XL1 blue competent Agilent 200249 
2.1.5 DNA and protein expression analysis 
2.1.5.1 Preparation of human tissue 
2.1.5.2 qPCR 
For the isolation of RNA, synthesis of cDNA and quantitative PCR the following components 
were necessary. 
 
Chemical/Enzyme/Kit Manufacturer Ref 
Ethanol Thermo Fisher Scientific 20012-068 
Isopropanol Thermo Fisher Scientific 31095-052 
PrimeScript RT Reagent Kit TaKaRa RR037A 
SYBR® Premix Ex Taq™ II (Tli RNase HPlus) TaKaRa RR820W 
Trizol Thermo Fisher Scientific 31985070 
 
The Taqman 7500 system from Applied Biosystems, USA, was used for all qPCR 
measurements. Specific primers were designed to detect and amplify mRNA expressed DNA 









Gene (Transcript) Primer Primer sequence Length 
Primer for cDNA amplification with quantitative PCR 
ACTN2 
(NM_001278343) 
qhACTN2_ex13-14_f  TTGGAACACCTGGCTGAGA 19 
qhACTN2_ex13-14_r  GCCGACTCGTAATCCTTCTG 20 
MYBPC3  
(NM_000256) 
qhMYBPC3_ex11-12_f GCATGAGGCGCGATGAGAAGA 21 
qhMYBPC3_ex11-12_r CAGCCAGTTCCACGGTCAGC 20 
TNNI1  
(NM_003281) 
qhTNNI1_ex5-6_f GGATGAGGAGCGATACGACA 20 
qhTNNI1_ex5-6_r GGCGCTTGAACTTCCCAC 18 
TNNI3  
(NM_000363.4) 
qhTNNI3_ex3-4_f CACCAGCCCCAATCAGACG 19 
qhTNNI3_ex3-4_r CTGCAATTTTCTCGAGGCGG 20 
TNNT2  
(NM_000364) 
qhTNNT2_ex14-15_f  GAGCTGTGGCAGAGCATCTA 20 
qhTNNT2_ex14-15_r  ATCCTGTTTCGGAGAACATTG 21 
2.1.5.3 Western blotting 
For Western blot analysis standard procedures and protocols were used (running and washing 
buffers for BioRad protocols). Tissue and cells were harvested by adding RIPA buffer. To 
separate a cytoplasmic fraction from the nucleus of a cell a hypotonic buffer with 20 mM Tris-
HCl pH 7.4, 10 mM NaCl and 3 mM MgCl2 was prepared to separate the lysis of each 
compartment. Further components used for Western blot are listed below.  
 
Chemical/Enzyme/Kit Manufacturer Ref 
20X Bolt™ MES SDS Running Buffer Thermo Fisher Scientific B0002 
Ammonium peroxydisulfate Carl Roth 9592.2 
Bolt™ 4-12% Bis-Tris Plus Gels Thermo Fisher Scientific NW04125BOX 
DNase I, 20.000 U Thermo Fisher Scientific 18047019 
Hypotonic buffer* In-house  
Methanol Carl Roth 8388.2 
NP-40 Sigma-Aldrich 74385 
Powdered milk Carl Roth T145.2 
Precision Plus Protein™ Dual Xtra  





RIPA buffer 10x Cell Signaling 9806S 
Rothiphorese NF-Acrylamide/Bis-Sol. 30% Carl Roth A124.1 
SDS Carl Roth 2326.2 
TEMED, ≥99 % Carl Roth 2367.3 





Mini-PROTEAN® Tetra electrophoresis system BioRad 
Chemiluminescence imaging system CHEMI only VWR 
PVDF membrane, roll, pore size 0.2 µm Thermo Fisher Scientific 
2.1.5.4 Immunohistochemistry 
Samples prepared for immunohistochemistry were first fixated with a formaldehyde solution 
and then permeabilized with saponin. In further incubation steps antibodies and staining 
chemicals were applied and supernatants were washed away with PBS. All used chemicals 
are listed below. 
 
Chemical/Enzyme/Kit Manufacturer Ref 
Fetal Bovine Serum, heat inactivated, US origin Thermo Fisher Scientific 16140071 
Fluoromount-G Mounting Medium Science Services E17984-25 
Formaldehyde solution 37% Sigma-Aldrich 47608-250ML-F 
PBS pH 7.4 Thermo Fisher Scientific 20012-068 
Saponin Sigma-Aldrich 47036-50G-F 
 
Cells were seeded on cover slips to prepare samples for immunostained fluorescence 
microscopy. Therefore, the LSM700 microscope of the Advanced Light microscopy core facility 
of the MDC Berlin was used. 
 
Device/Material Company 
Cover slips for microscopy (13 mm Ø) Neolab (Marienfeld) 
Microscope slides, VWR superfrost BLUE CUT EDGE VWR 
LSM700 Zeiss 
2.1.5.5 Antibodies and cellular imaging chemicals 
In the following list there are all antibodies used for this thesis. These antibodies were used in 









 Antibody Host Class Manufacturer REF 
Characterization of TNNI3 
Anti-GAPDH Mouse monoclonal Life Technologies AM4300 
Anti-HSC70/HSP70 Mouse monoclonal Enzo Life Science ADI-SPA-820 
Anti-MYBPC3 Sheep polyclonal R&D Systems AF7439 
Anti-TNNI1 Rabbit polyclonal Sigma-Aldrich HPA028190 
Anti-TNNI3 Rabbit polyclonal Thermo Fisher Scientific PA5-28964 
Anti-TNNT2 Mouse monoclonal Thermo Fisher Scientific MA5-12960 
Characterization of PRDM16  
Anti-EGFP Rabbit polyclonal Sigma-Aldrich G1544 
Anti-FLAG Mouse monoclonal Sigma-Aldrich F1804 
Anti-LMNA Mouse monoclonal Cell Signaling 4777S 
Anti-PRDM16 Rabbit polyclonal Abcam ab106410 
Anti-PRDM16 Sheep polyclonal R&D systems AF6295 
Anti-PRDM16 Rabbit polyclonal Thermo Fisher Scientific 720206 
Anti-β-Tubulin Mouse monoclonal UBPBio Y1060 
DAPI   Thermo Fisher Scientific D1306 
Phalloidin Alexa 647   Thermo Fisher Scientific A22287 
Secondary antibodies  
Anti-mouse Alexa 488 Goat  Thermo Fisher Scientific A-11029 
Anti-mouse IgG-HRP Horse  Cell Signaling 7076 
anti-rabbit Alexa 568 Goat  Thermo Fisher Scientific A-11036 
Anti-rabbit IgG-HRP Goat  Cell Signaling 7074 
Anti-sheep Alexa 488 Donkey  Thermo Fisher Scientific A-11015 
Anti-sheep IgG-HRP Donkey  Thermo Fisher Scientific A16041 
2.1.6 Software 
To analyze the data generated in various experiments different software packages were used. 
Licenses for these packages for these applications were obtained through institution involved 











Varfish Core Unit Bioinformatics (CUBI), Charité Berlin 
CorelDRAW Home & Student 
2019 
Corel Corporation 
Microsoft Office 2010/365 Microsoft 
SPSS IBM 
GelQuantNet BiochemLabSolutions 
ZEN 3.0 (blue edition) ZEISS 
2100 Bioanalyzer Expert Agilent Technologies 
IGV Version 2.3.97 Broad Institute/Regents of the University of California 







2.2.1 Genetic characterization of cardiomyopathy patients 
2.2.1.1 Clinical assessment of cardiomyopathy patients 
Recruitment of CMP patients has been done at the Charité - Universitätsmedizin Berlin and 
the German Heart Center Berlin (DHZB), Berlin, Germany. Between November 2011 and 
February 2017 unrelated probands carrying a CMP and equal to or under the age of 18 (≤) 
were phenotyped according to the design of the study related to this thesis (Figure 5). 
 
Figure 5: Schematic study design with clinical assessment and genetic analysis for evaluation of genetic 
variants and their pathogenicity. 
 
Informational consent according to the Declaration of Helsinki was obtained from each patient 
or their legal guardians (study approval by the local institutional review board: ID EA2/083/13, 
EA2/131/10, Charité Universitätsmedizin Berlin). For each subject and their available family 
members evaluation of medical history, physical examination, 12-lead electrocardiography, 
and transthoracic echocardiography was recorded. A retrospective approach for clinical and 
echocardiographic data has been realized for patients recruited after heart transplantation 
(HTX). Probands included in this study had to be diagnosed with a primary CMP, comprising 
HCM, DCM, RCM, LVNC and ARVC, and occurred non-syndromically. CMPs were classified 
according to the guidelines of the American Heart Association (Maron et al., 2006). Patients 




study. Blood samples from the recruited subjects and their available family members were 
taken for further genetic analysis. 
2.2.1.2 Targeted next-generation sequencing 
For genetic characterization with NGS DNA was isolated from blood samples of the CMP 
patients with the NucleoSpin Blood kit (2.1.2.1) or were already available as DNA samples. 
Amounts of DNA were measured with a Qubit 3 fluorometer using Qubit reagents for dsDNA 
(2.1.2.3). To investigate alterations in exonic regions of 174 cardiovascular disease genes, a 
cardio-panel from Illumina was used for NGS (2.1.2.3, Pua et al., 2016). Information of these 
genes and their implication in structural heart diseases and arrhythmias can be found on 
https://support.illumina.com/sequencing/sequencing_kits/trusight-cardio-sequencing-kit.html. 
After diluting the DNA to prescribed amounts library preparation and enrichment has been 
realized in a multiplex approach. Therefore, DNA fragments of defined length were marked by 
specific flanking sequences (protocol according to manufacturer). To quantify the DNA libraries 
a Bioanalyzer 2100 was used, applying the high sensitivity DNA kit or DNA 1000 kit (2.1.2.3). 
For sequencing the NextSeq 500 system was implemented with mid output cartridge v2 with 
paired end sequencing (150 cycles) and dual indexing. 
2.2.1.3 Alignment and variant calling of NGS data 
The multiplexed libraries were decoded using bcl2fastq v2.17.1.14. Alignment of the reads was 
realized with BWA-MEM v0.7.15 (Li, 2013) aligning to the reference genome GRCh37 
(hs37d5.fa). Separate read groups were assigned for all reads from one lane, and duplicates 
were masked using Samblaster v0.1.24 (Faust & Hall, 2014) was used to mask duplicates and 
separate read groups were assigned for all reads from one lane. Quality control was realized 
with FastQC (Andrews, 2010) and due to analyzing the minimal coverage of all sections 
covered by the Illumina TruSight Cardio Sequencing Kit. To finish the alignment, variants were 
called with GATK UnifiedGenotyper v3.7 (DePristo et al., 2011). 
2.2.1.4 Bioinformatic evaluation and variant classification 
For further analysis the called variants were imported into Variant Studio (Illumina, USA) to 
filter all non-synonymous and splice site variants with a minor allele frequency (MAF, the 
frequency at which the second most common allele occurs in a given population) < 0.001. After 
additional filtering with a MAF < 0.001 in the Genome Aggregation Database (gnomAD, Lek et 




CMP genes was further analyzed (Table S 1). The coverage quality control of the variants was 
again examined with the Integrative Genomics Viewer (2.1.6). 
 
Table 1: Online tools to filter for rare variants and predict the effect and pathogenicity of base exchanges 
















*Predicts effect of all small base changes (missense, splice site changes, frameshift, indel)  
 
The pathogenicity of the variants was evaluated according to the guidelines of the ACMG 
(Richards et al., 2015). For the presence of variants in disease databases such as Human 
Gene Mutation Database (HGMD) and Atlas of Cardiac Genetic Variation (ACGV) were 
checked. Computational and predictive data like PolyPhen-2 and Sorting Intolerant From 
Tolerant (SIFT) for missense variants or Human Splice Finder (HSF), Neural Network Splice 
(NNSplice) and Maximum Entropy Scan (MaxEntScan) for splice site variants was used to 
predict the impact of the filtered variants. Mutation Taster (MT) served as a multifunctional tool 
for the impact of all amino acid changing variants. Other criteria comprised functional data, 
including data from variant and literature databases for information about mutational hotspots, 
functional domains or well-established functional studies (Ensembl, UniProt, HGMD, ARVD/C 
Genetic Variants Database and PubMed), segregation data from family members and 
phenotypical compliance. Corresponding to the guidelines of the ACMG variants were 
classified as pathogenic (P), likely pathogenic (LP) and variant of uncertain significance (VUS). 
After application of the filter criteria mentioned in Figure 6 all variants interpreted as VUS, LP 
and P were summarized with the term variant of interest (VOI). To investigate the influence of 
different functional origins of the variants, the 89 CMP genes were categorized into functional 





Figure 6: Schematic overview of genetic analysis and evaluation of pathogenicity according to the 
guidelines of the ACMG. In each category of the guidelines the strongest applicable argument was counted 
(double counting, Abou Tayoun et al., 2018). 
1PVS1: If borderline cases occurred, literature and ClinVar entries were taken into consideration. 
2PM1: Examples for mutational hotspot or well-studied functional domains are MYH7 with its head region 
(aa 181 to 937, Kelly et al., 2018) and TTN (PSI, Roberts et al., 2015). 
*gnomAD was not available for Illumina variant studio 
2.2.1.5 Validation and segregation of variants of interest 
To validate the variants detected in CMP patients and to examine the familial segregation (if 




procedure (Klaassen et al., 2008, 2.1.2.2). Primers for sequencing variants identified by NGS 
were constructed with Primer3web (Whitehead Institute for Biomedical Research, USA, 
2.1.2.2) and verified with the tools Blat and in-silico PCR from the UCSC genome browser 
(UCSC Genomics Institute, USA). Additional verification was realized with sequence alignment 
using Ensembl (EMBL-EBI, Great Britain). 
2.2.1.6 Statistical analysis 
Frequencies and percentages were used for variables defined as categorical. Continuous 
values were presented as means and interquartile ranges (IQR). Kaplan-Meier curves were 
generated to analyze the survival or event free progression of disease in the CMP cohort. The 
probability of survival was therefore contextualized with the phenotype (DCM, HCM, etc.), 
number of VOI and the sporadic or genetic appearance of the CMP. For calculations the time 
point zero was defined as the age at diagnosis. The log-rank test was used to compare the 
differences in estimated survival curves of ≥ 2 groups. Statistical significance was considered 
with p value < 0.05 (probability value). SPSS v24.0 was used for data analysis (2.1.6). 
2.2.1.7 Genetic variation in an extended cohort 
To further analyze the distribution of CMP related variants the initial pediatric CMP cohort was 
extended with CMP and myocarditis patients from all age groups. The samples were registered 
for an in-house cohort. The recruitment, which started in 1999, and the genetic handling were 
similar to the samples from the pediatric cohort. DNA was either extracted from blood samples 
or was already prepared. NGS, alignment, variant calling, bioinformatic evaluation and variant 
classification was done as described before (see 2.2.1.2 to 2.2.1.4). Family members were 
mostly not available.  
2.2.2 Functional analysis of cardiomyopathy genes 
2.2.2.1 Cloning of PRDM16 wildtype and variants 
Plasmids carrying the wt and variants containing PRDM16 gene were already available in the 
laboratory. The backbone of these plasmids was the pcDNA-Dest53 vector. Variants chosen 
for analysis comprised the amino acid exchanges p.E271K, p.P291L, p.R525Pfs*79, p.N816S 
and p.L887P. Therefore, four missense and one truncating (frameshift, which leads to a 
premature stop) variant were included. All of these variants were formerly described to cause 




For overexpression of PRDM16 in the human cell line HEK293 PRDM16 constructs were 
reamplified without the backbone and containing specific restriction sites using PCR (2.1.4). 
After cutting the plasmids pEGFP-C1, pFLAG-CMV5a and pFLAG-CMV6a with specific 
restriction enzymes and dephosphorylating their open DNA ends, the ligation into the vectors 
was realized with the T4 DNA ligase from NEB (2.1.4). The restriction enzymes used in this 
approach were EcoRI (pFLAG-CMV5a, pFLAG-CMV6a and pEGFP-C1), BamHI (pFLAG-
CMV5a), HindIII (pFLAG-CMV6a) and XhoI (pEGFP-C1).  
Then competent E. coli XL1-Blue cells were transformed with these vectors for positive 
selection and amplification of the plasmids. Therefore LB-plates containing the corresponding 
antibiotics kanamycin or ampicillin were inoculated with the transformed bacteria. After 
incubation overnight and at 37°C the grown colonies were used to inoculate LB-master plates 
and 1.5 ml of liquid LB medium with the corresponding antibiotic for doing a miniprep with the 
NucleoSpin Plasmid kit the following day (2.1.4, protocol according to manufacturer’s 
instruction). For higher yields of DNA and after quality control liquid LB medium of 160 to 200 
ml was inoculated and the midiprep NucleoBond Xtra Midi EF kit was used for plasmid isolation 
(2.1.4, protocol according to manufacturer’s instruction). 
2.2.2.2 Quality control of cloned vectors 
To check the quality and sequence of the PRDM16 constructs two general methods were used. 
The first step was to estimate the length of the newly ligated plasmids in an agarose gel run 
with a standard DNA ladder and to compare it to the calculated length available in online 
databases. Therefore a 1% agarose gel and the GeneRuler 1 kb DNA ladder were used 
(2.1.2.2). The gels were loaded with plasmids in supercoiled, linearized or double digested 
form (no restriction enzyme, one restriction enzyme or two restriction enzymes corresponding 
to the enzymes used in 2.2.2.2). 
The second step was to sequence the inserted PRDM16 constructs and its up and downstream 
transitions into the vector to check the right insertion into the vector and if false variants were 
inserted into the DNA during the cloning procedure. For the sequencing reaction the BigDye 
Terminator v3.1 cycle sequencing kit was used (2.1.2.2). The concentration of the DNA was 
spanning from 100 to 200 ng/µl. The protocol was adjusted to smaller amounts of BigDye 
Terminator solution and additional TERMIPol DNA polymerase to generate more stable and 
longer sequencing strands (2.1.2.2). For sequencing a 3730 DNA Analyzer was used. The 
sequences were base called with ABI sequencing analysis and analyzed with the software 




2.2.2.3 Maintenance of cell culture 
HEK293 cells were used for overexpression of PRDM16. They were thawed from stocks stored 
in liquid nitrogen with a low passage number and splitted twice a week using trypsin (0,25% 
Trypsin-EDTA, 0) to detach the surface attached cells (HEK293 cells splitted in the ratio from 
1:8 to 1:12). 
2.2.2.4 Cell count and seeding 
For experiments the cells were seeded in specific cell numbers and therefore counted with the 
automated cell counter system EVE (0). Accordingly, the cells were trypsinated, centrifuged 
(500 rpm, 5 min, RT) and resuspended in a defined volume of cell culture medium (DMEM low 
glucose/MEM plus 5% FBS). For counting the cells 10 µl of cell culture was mixed with 10 µl 
of trypan blue and pipetted into a counting slide available from the same manufacturer (10 µl 
into the slide). The cell counter system is giving the unit cells per ml. With this the number of 
cells can be calculated with the following formula. 
 
𝑣(𝑤𝑎𝑛𝑡𝑒𝑑 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟) µ𝑙 =
𝑤𝑎𝑛𝑡𝑒𝑑 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟
𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑 𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑚𝑙−1
∙ 1000 
 
For microscopy cells were seeded on glass cover slips. Therefore, up to three cover slips were 
put in a well of a six well plate. To increase the attachment of the cells to the cover slips and 
wells, the plates were incubated with 1 ml DMEM F-12 medium per well, including a 1:100 
dilution of Geltrex. Seeding without Geltrex was sufficient for samples used in Western blotting. 
2.2.2.5 Transfection of cells 
For transfection of HEK293 cells jetPEI was used (0). Therefore, cells were seeded in six-well 
or 12-well plates with a respective cell number for the relevant experiment and planed time for 
transfection (250k to 400k cells per well for six-well plates and one to two days of incubation 
and 150k to 200k for 12-well plates one to two days of incubation). The transfection protocol 
was started with a confluency of the cells at 70 to 80%. Dilution of 3 µg of DNA with water 
resulted in 100 µl of DNA solution. After 6 µl of jetPEI were diluted with 94 NaCl solution it was 
mixed with the DNA solution with following vortexing immediately and spinning down to 
incubate for 15 to 30 minutes. In the meantime, cell culture medium was changed to 1 ml of 
OptiMEM for better transfection results. After incubation the DNA/jetPEI mix was added 
dropwise to the wells. To distribute the mix equally in the wells the plates were agitated gently 
(not circular to avoid concentration of cells in the middle). To prepare cells to investigate under 




2.2.2.6 Determination of protein concentration (BCA assay) 
To compare different cell or tissue lysates and quantify amounts of detected proteins it is 
important to use the same concentration of proteins. To determine the concentration a 
bicinchoninic acid (BCA) assay was applied. Within this assay the reduction of Cu2+ ions to 
Cu+ in highly basic medium due to proteins is used to chelate bicinchoninic acid with Cu+ , 
which produces a purple colored complex with strong light absorption at 562 nm and 
proportional to the protein concentration. Therefore, lysates were treated according to the 
manufacturer’s protocol and the respective absorption was measured to calculate the 
concentration (Thermo Fisher Scientific, USA, REF 23250). 
2.2.2.7 Stabilization assay of proteins 
The stability or turnover of proteins was tested to investigate the effect of variants compared 
to the wild type form. To gain this information HEK293 cells were transfected as described in 
2.2.2.5. After 24 h of transfection incubation, cycloheximide (CHX) was added to the wells to 
inhibit the expression of new proteins. Therefore, protein levels decreased, and the different 
amounts could be detected after certain time points of 0h, 8h, 16 h and 24 h. The cells were 
then harvested with RIPA buffer, treated with DNase I to digest DNA and centrifuged (14800 
x g, 5 min, at RT) to separate debris from the lysate. The samples were frozen at -20°C for 
later use or directly used for further experimentation like BCA assay and Western blotting. To 
calculate the half time of the proteins an exponential fit was applied, and the corresponding 
formula was used to calculate the time at 50% of maximal protein detection. 
 
𝑦 = 𝑒−𝑎𝑥 𝑤𝑖𝑡ℎ 𝑛𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑣𝑎𝑙𝑢𝑒𝑠 (𝑠𝑡𝑎𝑟𝑡𝑖𝑛𝑔 𝑎𝑡 1 𝑎𝑡 𝑖𝑛𝑡𝑒𝑟𝑠𝑒𝑐𝑡𝑖𝑜𝑛 𝑤𝑖𝑡ℎ 𝑦 − 𝑎𝑥𝑖𝑠) 
 
With y being the signal from protein detection follows for 50% protein (0.5 for normalized 
protein signals): 
0.5 = 𝑒−𝑎𝑥    →    𝑥 =
ln 0.5
−𝑎
= 𝑇1 2⁄  
2.2.2.8 Nuclear separation 
To separate a cytosolic from a nuclear fraction to observe the distribution of specific proteins 
in these compartments, cells were first harvested by scraping to loosen them from the surface. 
After collecting the cells in a new tube, they were washed with PBS (1 ml per well in a six-well 
plate, centrifuged for 5 min at 1000 rpm at 4°C). In the next step the cells were treated with a 




was added to approx. 5 x 105 cells. After resuspension and incubation for 15 minutes on ice 
the detergent NP40 was added in a final concentration of 0.5%. To mix the samples they were 
vortexed for ten seconds on the highest setting and centrifuged with 3000 rpm for 30 minutes 
at 4°C to separate the cytoplasmic fraction from the nuclei. Therefore, the supernatant was 
collected in a new tube and stored at -20°C for further use. The pellet containing the nuclei 
was then resuspended in 50 µl RIPA buffer with protease inhibitor for 30 minutes on ice, 
vortexing the mix every ten minutes. To separate the nuclear fraction from debris and 
precipitated DNA the samples were centrifuged for 30 minutes at 14000 x g and 4°C and the 
supernatant was transferred to a new tube for storage at -20°C or further experimental use. 
2.2.2.9 Immunofluorescence staining 
To stain different proteins in HEK293 cultures on cover slips cells were fixated with 4% PFA 
and incubated for 30 min at 4°C (2.1.5.4). From this point on every step was carried out at RT. 
After the fixation the cells were washed three times with PBS for five to ten minutes and the 
membrane of the cells was permeabilized for ten minutes with a solution of 0.1% saponin and 
3% BSA solved in PBS buffer. After three further washing steps in PBS for five to ten minutes 
the samples were blocked with 3% BSA in TBS for one hour. Again, a washing step was 
applied with PBS for five to ten minutes and the primary antibody was added to the samples 
in the corresponding dilution released by the manufacturer. For incubation the samples were 
left in the antibody dilution for one hour with four additional washing steps afterwards. The 
secondary antibodies, conjugated with a fluorophor, were added for another 20 minutes. 
During the first of the last four washing steps DAPI was added to PBS in a 1:300 dilution to 
mark the nuclei. After washing the cover slips in water to remove salt remnants, they were 
embedded onto object slides with fluoromount-G (2.1.5.4). After drying the samples were ready 
for observation. 
2.2.2.10 Preparation of human heart tissue 
Cardiac biopsies from patients with severe CMP phenotypes were obtained during cardiac 
surgery. To analyze the protein and mRNA expression levels of these samples they were 
frozen with liquid nitrogen and mechanically crushed. For measuring mRNA levels, total RNA 
isolation was applied and therefore the crushed samples were collected with a cooled spatula, 
weighed and solved in 1 ml of TRizol reagent (2.1.5.2). Further steps are described in the 
section RNA isolation (2.2.2.9). For the investigation of proteins in these samples 100 µl of 
RIPA buffer mixed with protease inhibitor (Pierce, Thermo Fisher Scientific, Waltham, USA) 




disperser. A centrifugation step pelleted the debris and the protein concentration was 
measured with a BCA assay (2.2.2.6). 
2.2.2.11 RNA isolation 
To isolate RNA cells seeded in a six-well plate or prepared cardiac tissues were harvested 
with adding 1 ml of TRizol (2.1.5.2) to the samples. Then the cells/tissues of interest were 
centrifuged for five minutes at full speed and RT (14800 x rpm) before starting with the RNA-
isolation and to purify the sample from cell debris (cell pellet). To separate RNA from other cell 
components 0.2 ml chloroform was added to the mix and centrifugation (10000 x g for 15 min 
at 4°C), after vigorously shaking the samples for at least 15 seconds, led the separation of 
three different phases (upper aqueous phase, interphase, lower chloroform phase). The upper 
phase, which contained the RNA, was then pipetted into a new RNase-free tube. The lower 
organic and the interphase, which contained DNA and proteins, were discarded. For 
precipitation of RNA 0.5 ml isopropanol was added to the samples and incubated for ten 
minutes. After a further centrifugation step for ten minutes with 10000 x g at 4°C a white RNA 
pellet should be visible if the amounts were sufficient. In the next step the samples were 
washed with 1 ml of 75% Ethanol (diluted in DEPC water) and centrifuged for five minutes at 
RT with 21100 x g (full speed) followed by discarding the supernatant and letting the samples 
dry at 80°C. The pellets were then solved in 100 to 200 µl of DEPC water and stored at -20°C 
or directly used for experimentation. 
2.2.2.12 Real time quantitative PCR 
Expression levels of mRNA were measured using the standard method real time qPCR. 
Therefore, tissue of interest was prepared as described in 2.2.2.8 and 2.2.2.9. Transcription of 
RNA to cDNA was done according to the standard protocol of the PrimeScript RT reagent kit 
(Takara, Kusatsu Japan). For the detection of cDNA the TB Green Premix Ex Taq II from 
Takara was used (Kusatsu, Japan). After mixing reaction reagents with the cDNA samples and 
primers DNA levels were measured with a Taqman 7500 (2.1.5.2). Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as an endogenous control and the detected 
signals were normalized with the ΔΔCT method (Kolanczyk et al., 2011; Seifert et al., 2009). 
Different primers to amplify die cDNA during the PCR are listed in 2.1.5.2. 
2.2.2.13 Western Blotting 
The presence or absence and the distribution of proteins can indicate mechanisms for 




performed. First protein samples were loaded onto SDS-PA gels. After running the gels the 
proteins were loaded onto PVDF membranes using a wet blot system from Bio-Rad (2.1.5.3). 
Blocking of membranes was done with 5% milk powder and 0.2% NP-40 in TBS-T buffer 
(blocking buffer). After incubation with the primary antibody for 3 h or overnight in blocking 
buffer (used primary antibodies in 2.1.5.3) the membranes were washed three to four times 
with TBS-T for 10 min. In the next step the membranes were incubated with the secondary 
antibody (conjugated with HRP) for 1 h in blocking buffer and again washed three to four times 
with TBS-T for 10 min. For detection of the marked proteins a mix of luminol/ECL enhancer 
and peroxide was added to the membrane in a 1:1 ratio as reaction mix for the HRP (2.1.5.3). 
After incubation for 1 min the membranes were drained from excess reagent and the emitted 
light was detected with a Chemiluminescence imaging system CHEMI only system. 
2.2.2.14 Prediction of post-translational modification sites and structural elements 
To predict structural features and functional interaction sites, online prediction tools were used. 
Therefore, the amino acid chains from proteins of interest were loaded into the programs. For 
post-translational modification (PTM) tools common tools were used to predict sites for 
acetylation, methylation, phosphorylation, etc. (Audagnotto & Dal Peraro, 2017, 
http://gps.biocuckoo.cn). Additional information for structural and conserved features was 
collected from programs like PSIPRED, RaptorX, Spider2 or ConSurf. All applied online tools 
with positive results are listed in the supplement (Table 2). PTM prediction was always applied 
with the highest stringency. With more than one tool per PTM category only hits at the same 
amino acid position with ≥ half of the applied prediction programs were considered as true hit. 
Exceptions are marked in figures. For the secondary structure the most frequent predicted 
structure (α-helix, β-sheet, coil) was determined for each amino acid position. The average of 
normalized values for disorder were used to predict ordered regions in proteins. Only ConSurf 













Table 2: Online Prediction tools used to determine possible functional sites or domains from proteins of 
interest (SUMOylation coming from small ubiquitin-related modifier – SUMO) 





























































3.1 Phenotypic and genetic characterization of pediatric patients affected 
by primary cardiomyopathy 
To investigate the genetic mechanisms of primary CMPs in pediatric cases not affected by 
systemic or syndromic disorders a prospective study at the DHZB and Charité Berlin was 
established. During enrollment of this study 83 pediatric patients (age ≤ 18 years) were 
recruited and examined for analysis of their cardiac phenotype and the underlying genetic 
variation. 80 subjects of this cohort (CMP-80) were genotyped with NGS (3.1.1/3.1.2), whereas 
a sub cohort of 60 patients in this study (CMP-60) underwent additional follow-up examinations 
(3.1.3, overlap of 57 patients). For all index patients the pathogenicity of the genetic information 
originated from NGS was determined according to the guidelines of the ACMG (Figure 6) and 
available family members were checked for segregation of the detected CMP-relevant 
variants. 
3.1.1 Characteristics of pediatric patients with primary cardiomyopathy 
During the study period 80 patients (CMP-80) were recruited for testing genetic variants in 89 
CMP-relevant genes included in the Illumina TruSight Cardio Panel. Therefore, cases affected 
by DCM (34), HCM (23), LVNC (14), RCM (7) and ARVC (2) were analyzed. Only two 
individuals had ARVC and were excluded in further analysis. The overall gender distribution 
was almost equal with 38 females (f) and 42 males (m), but differentiated for the single CMP´s, 
most notably for DCM with 23 females and 11 males and HCM with 5 females to 18 males. 
The mean age of the pediatric cohort was 4.8 years. In general DCM, LVNC, RCM and ARVC 
patients were slightly younger than the average age, whereas HCM patients were older and 
had by far the widest range in the distribution of age (IQR = 0.6 – 12.8). Within the cohort CMP-
80, 63 patients were younger than 10 years at the date of diagnosis (79%) including 34 patients 
younger than 1 year (43%). Considering these age groups the distribution of the different 
phenotypes did not differ drastically (Figure 7 A - C) although the rate of DCM cases decreased 
slightly with ageing in comparison to the total cohort, whereas the rate of HCM patients 
increased. With the shortest range in the distribution of age (IQR = 1.5 – 4.2 years) the RCM 
subgroup had the most defined age and therefore appeared in the age group younger than 10 
years. Family screening was available in 61 families with positive CMP results in 27 (available 
family members in 76.3 % of all patients), where at least one additional family member was 
affected by CMP. The highest number of positive family screenings was observed in the 




familial CMP was observed in the subgroup of DCM with 8 (23.5%) out of 23 families included 
(67.7%). For a short clinical characterization IVSd, LVEDD, LV-EF and FS are listed in Table 
3. The IVSd, presenting the thickness of the septum, was increased for the HCM subgroup, 
displaying hypertrophied myocardium (Z-score of 10.6). 
 
Table 3: Characterization of CMP-phenotypes during enrollment and diagnosis of pediatric cohort CMP-80 
Phenotype (n) All (80) DCM (34) HCM (23) LVNC (14) RCM (7) 
ARVC 
(2) 
Sex       
Females, n (%) 38 (47.5) 23 (67.7) 5 (21.7) 7 (50) 3 (42.9) 0 (0) 
Males, n (%) 42 (52.5) 11 (32.3) 18 (78.3) 7 (50) 4 (57.1) 2 (100) 
Age       
in years, mean 4.8 3.2 7.2 3.9 4.4 n.a. 
IQR 0.2-9.0 0.1-4.8 0.6-12.8 0.2-8.2 1.5-4.2 n.a. 
Family screening       
Included, n (%) 61 (76.3) 23 (67.7) 19 (82.6) 12 (85.7) 5 (71.4) n.a. 
Positive result, n (%) 27 (33.8) 8 (23.5) 12 (52.2) 5 (35.7) 1 (14.3) n.a. 
IVSd       
mean mm (±SD) 9.1 (7.6) 5.5 (1.8) 16.7 (9.6) 5.5 (1.3) 5.0 (1.3) n.a. 
mean z-score (±SD) 3.6 (6.8) 0.4 (1.6) 10.6 (8.4) 0.4 (0.6) 0.2 (0.8) n.a. 
LVEDD       
mean mm (±SD) 39.4 (13.0) 46.2 (13.7) 33.8 (11.1) 38.6 (7.1) 26.0 (4.4) n.a. 
mean z-score (±SD) 2.8 (5.1) 7.0 (4.2) -1.4 (2.8) 2.5 (3.0) -2.0 (0.7) n.a. 
LV-EF, mean % (±SD) 46.5 (22.4) 29.7 (15.4) 66.8 (14.7) 44.0 (19.5) 62.1 (12.6) n.a. 
FS, mean % (±SD) 27.6 (16.8) 15.1 (6.7) 44.7 (16.5) 26.2 (11.5) 31.5 (11.6) n.a. 
MACE, n (%) 39 (48.8) 22 (64.7) 8 (34.8) 3 (21.4) 6 (85.7) n.a. 
AICD, n (%) 8 (10) 1 (2.9) 7 (30.4) 0 (0) 0 (0) n.a. 
VAD/BVAD, n (%) 22 (27.5) 16 (47.1) 1 (4.4) 2 (14.3) 3 (42.9) n.a. 
ECMO, n (%) 6 (7.5) 5 (14.7) 0 (0) 0 (0) 1 (14.3) n.a. 
HTX       
with enrollment, n (%) 17 (21.3) 13 (38.2) 0 (0) 3 (21.4) 1 (14.3) n.a. 
during study, n (%) 9 (11.3) 4 (11.8) 1 (4.4) 0 (0) 4 (57.1) n.a. 
Deceased, n (%) 5 (6.3) 2 (5.9) 1 (4.4) 0 (0) 2 (28.6) n.a. 
Abbreviations: IVSd - interventricular septum thickness at end diastole, LVEDD - left ventricular end diastolic diameter (Z score, 
normal reference range -2 < +2, m-mode), LV-EF - left ventricular ejection fraction (auto 4CH monoplan) , FS - fractional 
shortening, MACE - Major adverse cardiovascular events, AICD - automatic implantable cardioverter defibrillator, VAD - ventricular 
assist device, BVAD - biVAD, ECMO - extracorporeal membrane oxygenation, HTX - heart transplantation; n.a. - not applicable, 
SD - standard deviation 
 
The LVEDD and LV-EF are measurements for the function of the left ventricle and pose the 




and the LV-EF was decreased for DCM and LVNC (LVEDD Z-Score of 7 and 2.5, LV-EF of 
29.7% and 44%, respectively). The fractional shortening is a term for the ratio between LVEDD 
and LVESD (normal range: 25% - 45%, LVESD – left ventricular end systolic diameter). 
Therefore, changes to the norm are another characteristic for DCM and was down to 15.1% 
for the DCM subgroup. The FS for LVNC was slightly reduced (26.2%). Other criteria not 
mentioned in Table 3 but used for the distinction of the CMPs are trabeculation and non- 
compacted myocardium for LVNC and remodeling of the atria and restricted movement of the 
heart for RCM. 
 
 
Figure 7: Distribution of CMP phenotypes in cohort with 80 primary and pediatric CMP patients (CMP-80). 
(A) All patients with indicated CMP subgroup. (B) Patients with an age <1 yearsindicated CMP subgroup. (C) 
Patients with an age <10 years with indicated CMP subgroup. (D) Patients who underwent heart transplantation 
(HTX) or deceased patients with indicated CMP subgroup. 
 
To assess the severity of the phenotypes the events implantation of an automatic implantable 
cardioverter defibrillator (AICD), a ventricular assist device (VAD) or a device for 
extracorporeal membrane oxygenation (ECMO), heart transplantation and death were 
summarized as major adverse cardiovascular events (MACE). In total 39 patients (48.8%) 
were affected by MACE. With 85.7% and 64.7% RCM and DCM patients had the highest rates 
and therefore a more severe disease progress. In contrast, the percentage of MACE in 
individuals with HCM and LVNC was considerably lower with 34.8% and 21.4%, respectively. 




of 53% and 85.7% in this category whereas the average was 36.4% (Figure 7 D, distribution 
of CMP phenotypes in the subgroup of HTX and deceased patients). 
3.1.2 Distribution and pathogenicity of rare genetic variants 
The analysis process is exemplarily shown for family 11 (Figure 8). In this family with five 
members three were affected by HCM (11-I:1/11-II:1/11-II:2, Figure 8 A) whereas one showed 
first signs of a CMP (11-II:3). Therefore, only the mother (11-I:2) was unaffected. After the 
signals from the NGS runs were aligned to the corresponding genes, the data was further 
processed with Variant Studio to eliminate synonymous variants, technical artefacts and 
variants occurring in variable regions and repeats from rare missense, in frame indel or 
truncating variants (nonsense, frameshift or splice site).  
 
 
Figure 8: Example for analysis with data generated from NGS. (A) A pedigree of family 11 affected by HCM is 
presented. (B)/(C) Two gnomAD entries of variants detected in family 11 are shown. (D) NGS data was analyzed 




In Figure 8 D there are 14 variants listed for family 11. All genetic alterations with a MAF of 
higher than 0.001 in ExAC, an alternative variant frequency of lower than 30% (all sequences 
covering the same region presented the alternative allele with less than 30%) and detected as 
synonymous variants were previously excluded. After elimination of false positives only the 
variants in MYBPC3 and LIM domain binding 3 (LDB3) were considered as VOI. Examples for 
false positives are the deletion of an adenine (A) at the end of an A repeat in ATP binding 
cassette subfamily C member 9 (ABCC9, Figure S 4) and the exchange of thymine to guanine 
(G) between two G repeats in potassium voltage-gated channel subfamily H member 2 
(KCNH2, Figure S 5). Strong arguments for both variants not to be considered for further 
analysis are the appearance in controls and the relatively low alternative variant frequency 
(near 30%). In comparison the variants in LDB3 and MYBPC3 are absent in controls and both 
alleles are distributed almost evenly with 3% and 1% difference (Figure S 6, Figure S 7). 
Because in Variant Studio only data from ExAC was available the MAF of all relevant variants 
were checked again in gnomAD (Figure 8 B/C). In the case of MYBPC3 the MAF was 
considerably smaller than the threshold of 0.001 whereas the MAF of the notch receptor 1 
(NOTCH1) variant was above the threshold and was therefore excluded from further analysis. 
Families were then checked for segregation. In the case of family 11 MYBPC3 
NM_000256.3:c.927-2A>G segregated with all affected family members.11-II:1 is not carrying  
 







Variants according to 
phenotype, n 
17 (14%) 15 (12%) 94 (74%) 
126 
(100%) 
DCM 4 4 44 52 
HCM 11 2 26 39 
LVNC 1 4 13 18 
RCM 1 2 10 13 
ARVC 0 3 1 4 
Category of variants, n     
De novo 5 2 0 7 
Not de novo (inherited) 4 9 55 68 
Novel2 2 9 42 53 
Not novel (known) 15 6 52 73 
Missense 11 9 83 103 
Indel/frameshift 2 4 3 9 
Stop gain 1 1 1 3 
Splice site 3 1 7 11 
1Classification according to Richards et al., 2015 
2Novel indicates variants that have not been annotated in genetic disease reference databases 




LDB3 NM_001171610.1:c.1807T>C indicating that the variant does not segregate with the 
disease phenotype in all family members. With a complete and checked dataset for each 
patient and family the pathogenicity of the variants was determined according to the ACMG 
guidelines (Figure 6). All 80 patients and family members were analyzed in the same way. 
In all patients of the CMP-80 cohort 126 VOI were detected (Table 4). 17 and 15 
variants were classified as pathogenic (P) and likely pathogenic (LP, 14% and 12%). Variants 
of uncertain significance occurred 94 times (74%). Most P and LP variants were detected in 
HCM patients, whereas individuals affected by DCM were carrying the most VUS variants. 
Seven of all VOI were detected as de novo. Five of these variants were interpreted as P and 
two as LP. With 58% over half of all VOI were already detected in disease databases like 
ClinVar. The frequency of novel variants considered as P/LP or VUS did not differ considerably 
with 34% and 45%. Not surprisingly most VOI were caused by single missense exchanges 
(103). Stronger alterations such as frameshift or nonsense variants were much rarer, but also 
shifted to be P/LP (frameshift: six out of nine P/LP; Stop gain: two out of three P/LP; splice 
site: four out of 11 P/LP). 
VOI were then considered per number of patients. 1.58 variants were detected per patient. In 
the subgroups these numbers differed slightly (DCM: 1.53, HCM: 1.7, LVNC: 1.29, RCM: 1.86). 
In 16 patients no VOI were observed and 36 patients were carrying more than one VOI (1 VOI, 
n = 28; 2 VOI, n = 20; 3 VOI, n = 12; >3 VOI, n = 4). P and LP variants occurred in 30 of 80 
index patients (38%). Complex genotypes were only detected in two individuals carrying two 
LP variants each (Table S 5). In 21 patients with and 34 patients without a P/LP variant (26%, 
43%) sequencing resulted in an additional VUS variant. P and LP variants were detected with 
a higher rate in HCM patients with over half of all patients carrying at least one variant (0.57 
variants per patient; values for other CMP: DCM 0.24 variants per patient, LVNC: 0.357 
variants per patient, RCM: 0.429 variants per patient). 
3.1.3 Spectrum of rare variants 
A more detailed analysis of the VOI detected in the pediatric CMP-80 cohort showed that 
mainly changes in major CMP genes were observed. Thus, VOI were most frequently identified 
in MYH7 (16%), MYBPC3 (9%), troponin I3, cardiac type (TNNI3, 7.5%), DSP (7.5%), LDB3 
(6%), and myopalladin (MYPN, 6%) (Figure 9). The order was slightly changed in the different 
subgroups, but MYH7 remained the most frequent gene except for RCM patients (Figure 9 B 
- E). In individuals diagnosed with RCM truncating TTN variants were the most frequent with 
three splice site variations. In general truncating TTN DNA changes were very rare with one 
additional single base deletion in a DCM case (4). The distribution of rare variants in the HCM 




most abundant genes with observed variation. With VOI in 31 different genes the subdivision 
of DCM patients was the most heterogeneous one. 
 
 
Figure 9: Distribution of genes with VOI in CMP patients (CMP-80). (A) The number of CMP patients with a VOI 
in the indicated CMP gene is shown in a pie chart. (B) The number of patients affected by DCM (B), HCM (C), 
LVNC (D) and RCM (E) with a VOI in the indicated CMP gene is shown (full name of genes in Table S 1). 
 
To get an overview of the general mechanisms for the manifestation of CMP in this cohort all 
89 CMP genes were pooled into functional groups (Table S 1). As expected, sarcomere genes 
were most frequent in pediatric CMP patients in general and likewise in the subgroups (Figure 
10 A - E). Surprisingly VOI in desmosome genes were second most frequent in the complete 
cohort and mainly detected in DCM and LVNC patients (in total cohort: 20%, in DCM subgroup: 
26%, in LVNC subgroup: 21%). Nearly as frequent as VOI in the desmosome group were VOI 
detected in Z-disc genes. Sarcomere and Z-disc genes mainly contribute to the build-up of the 
sarcomere, the structural element of muscle cells, and were most abundantly detected with 
VOI in the HCM group (sarcomere genes: 57%, Z-disc: 26%). Additionally of notice is the fact, 




only ones with VOI in the category protein quality control, whereas VOI in the group of 
dystrophin complex were very specific to individuals affected by HCM and RCM. VOI in genes 
affecting the mitochondria were only observed in the subgroup of LVNC. The group 
transcription/splicing was most specific for RCM and DNA changes for extracellular matrix 
(ECM) genes were only observed in DCM and HCM patients. The distribution of rare variants 
in the different functional groups from patients younger than one year was similar to the 
complete cohort with only minor differences (Figure 10 F). The order from highest to lowest 
frequency of the groups was nearly the same starting with sarcomere (49% to 35%), 
desmosomes (20% to 24%) and Z-disc (19% to 18%) and only considerably different in cellular 
signaling (6% to 15%). Of note are possible overrepresentations of groups comprising a large 
number of genes or exons in Figure 10.  
 
 
Figure 10: Relative frequency of VOI in CMP genes detected in samples from CMP patients (CMP-80) divided 
into functional groups. The relative frequency of VOI in functional groups is shown for all (A), DCM (B), HCM (C), 
LVNC (D) and RCM (E) patients and patients with age < 1 year (F). The classification of CMP genes into functional 
groups can be seen in Table S 1. 
 
Most VOI were detected in the heterozygous state. Exceptions were observed with two 
homozygous (nexilin abbr. NEXN, TNNI3) and two compound heterozygous variants 




considered notable, because one allele was affected by the exchange p.S858R and the other 
allele was completely deleted (Table S 5). Hemizygous variants occurred in dystrophin (DMD, 




HTX and deceased patients (n = 28) represented a faction of this cohort with a very severe 
form of CMP and are therefore separately mentioned (Figure 7 D). Most frequently VOI were 
detected in DSP (4 VUS), TTN (2 LP, 2 VUS), DMD (3 VUS), NEXN (3 VUS), PRDM16 (3 
VUS) and TNNI3 (1 LP, 2 P). Thus, all four truncating TTN variants in the CMP-80 cohort were 
also present in the HTX and deceased patients more precisely in 3 cases of RCM and in one 
case of DCM (Table S 5). Compared to all patients the frequency of VOI in the functional 
groups was similar with most detected VOI in the groups of sarcomere, desmosomes, 
transcription/splicing and Z-disc, although the values for transcription/splicing and 
desmosomes were slightly increased and frequencies for cellular signaling, mitochondria, 
nuclear envelope and endo-lysosomes were absent. Two or more VOI occurred in 15 HTX and 
deceased patients, seven were carrying one VOI and six individuals were observed to carry 
no VOI. 
3.1.4 Clinical course of early onset cardiomyopathy in a selected pediatric 
cohort 
To further investigate the process and severity of CMPs in children a selected group of the 
pediatric cohort CMP-80 was examined in follow up investigations (CMP-60). To calculate a 
value for the development of the disease the occurrence of major adverse cardiovascular 
events (MACE) like implantation or application of defibrillators, ventricular assist devices, heart 
transplantation or death was observed over time. 60 CMP patients were repeatedly examined. 
This sub cohort included 21 cases of DCM, 17 cases of HCM, 15 cases of LVNC, five cases 
Figure 11: Relative frequency of VOI in CMP genes detected in samples 
from HTX and deceased patients from the CMP cohort (CMP-80) divided 
into functional groups. In addition to Figure 10 the distribution of VOI 
categorized into functional groups is shown for severe CMP cases who 




of RCM and two cases of ARVC. The phenotypic characteristics were similar to the general 
cohort. Therefore, the gender was slightly shifted to males with exceptions for DCM (slightly 
shifted to females: 12 f, 9 m) and HCM (drastically shifted to males: 4 f, 13 m). The mean age 
was 5.4 years and again the group of HCM was an outlier with 7.5 years (IQR = 0.3 – 9.1 
years).  
 
Table 5: Characterization of selected CMP patients (CMP-60) for correlation of major adverse cardiovascular 
events (MACE) over time 
Phenotype (n) All (60) DCM (21) HCM (17) LVNC (15) RCM (5) ARVC (2) 
Sex       
Females, n (%) 25 (41.7) 12 (57.1) 4 (23.5) 7 (50) 2 (42.9) 0 (0) 
Males, n (%) 35 (58.3) 9 (42.9) 13 (76.5) 8 (50) 3 (57.1) 2 (100) 
Age       
in years, mean 5.4 4.3 7.5 3.5 5.5 n.a. 
IQR 0.3-9.1 0.2-6.2 1.5-12.1 0.2-6.0 1.8-4.6 n.a. 
MACE, n (%) 24 (40) 11 (52.4) 5 (29.4) 3 (20) 5 (100) n.a. 
AICD, n (%) 6 (8.3) 1 (4.8) 5 (23.5) 0 (0) 0 (0) n.a. 
VAD, n (%) 13 (21.7) 8 (38.1) 0 (0) 2 (13.3) 3 (60.0) n.a. 
ECMO, n (%) 3 (5.0) 2 (9.5) 0 (0) 0 (0) 1 (20.0) n.a. 
HTX       
with enrollment, n 
(%) 
8 (13.3) 5 (23.8) 0 (0) 3 (20.0) 0 (0) n.a. 
during study, n (%) 8 (13.3) 4 (19.0) 0 (0) 0 (0) 4 (80.0) n.a. 
Deceased, n (%) 2 (3.3) 0 (0) 0 (0) 0 (0) 2 (40.0) n.a. 
 
Regarding MACE’s most events occurred in DCM patients although RCM cases showed the 
highest frequency (11 from 21 DCM and five from five RCM patients with MACE’s, Figure 12 
B). Due to arrhythmias often occurring in HCM patients, defibrillators were mostly implanted in 
this group (HCM: five, DCM: one). For preventive reasons and due to no recorded shocks from 
these devices AICD’s were not included for further calculations. Otherwise other events were 
absent with HCM. The requirement to introduce supporting circulatory devices like ventricular 
assist device or extracorporeal membrane oxygenation was often leading to further procedures 
and therefore ending in HTX or death. Deceased patients were only present in the RCM group. 
ARVC patients were not analyzed due to low sample size. 
With these results Kaplan-Meier plots were generated and analyzed (Figure 12). Hence, event-
free survival in percent was correlated with age in years. Adverse events were observed in 
32% of index patients (Table 5, Figure 12, be aware of defibrillator implantations not taken into 




survival was investigated regarding the different CMP subgroups. As described RCM had the 
lowest rate followed by DCM, LVNC and HCM. With a p-value of p<0.001 the groups had a 
significantly different outcome for adverse events. Also of interest was the disease course with 
different numbers of VOI detected in the index patients (Figure 12 C). Individuals with >1 VOI 
observed, had a significant higher rate for adverse cardiac events (p-value = 0.021). 
Furthermore the difference in outcome for sporadic and genetic CMP was tested and resulted 
in worse prognosis for genetic CMP patients (not significantly: p-value = 0.305, Figure 12 D). 
 
 
Figure 12: Kaplan-Meier curves of event-based survival in pediatric cohort of 60 CMP patients (CMP-60). 
The event-free survival percentage of CMP patients is presented over the years. (A) The correlation was observed 
in all patients, (B) between CMP subgroups, (C) between subjects carrying no, one or more than one VOI and (D) 
between the groups diagnosed with sporadic and genetic CMP. Events are defined as death, heart transplantation, 
and mechanical circulatory support. No VOI but positive family history of CMP was only seen in one index patient 




3.1.5 Early onset of cardiomyopathy in cases carrying variants in TNNI3 
As mentioned in 3.1.3, variants of sarcomere genes were most common in the pediatric CMP 
cohort and within this group MYH7, MYBPC3 and TNNI3 exhibited the most genetic alterations 
(number variants (P or LP): MYH7 – 13 (7), MYBPC3 – 8 (6, two variants in one patient), TNNI3 
– 6 (5), Figure 9 A, Figure 10 A). In this selection TNNI3 was of notice because of two reasons. 
Firstly, a set of variants agglomerated in the c-terminus of the protein and secondly, in one 
patient a homozygous truncating variant was detected. Therefore, available tissue and blood 
samples from these patients and inherent family members were further analyzed (Figure 13, 
Table S 5, Table S 6). An additional case of DCM from an in-house cohort was included in 
these analyses due to a detected homozygous truncating variant in TNNI3. In conclusion, 
seven genetic alterations of TNNI3 were detected in seven patients (DCM n = 2, HCM n = 2, 
RCM n = 2, LVNC n = 1). Six of these variants were interpreted as P or LP (VUS variant was 
not considered in further analysis). Two variants were inherited as homozygous and truncating. 
One variant presented a splice site modification directly after the second exon. The other 
variant resulted in a frameshift leading to a premature stop codon in the IT arm region shortly 
behind a troponin C1, slow skeletal and cardiac type (TNNC1) binding region of TNNI3 (Figure 
13). The other four variants clustered at the c-terminus, which is expected to be important in 
actin and tropomyosin binding. All four variants occurred in a heterozygous state and three led 
to an amino acid exchange (missense), whereas one was a truncating variant at the very end 
of the amino acid chain at position 209 from 210 amino acids (Figure 13). 
 
 
Figure 13: TNNI3 functional protein domain and gene structure with six indicated TNNI3 variants. (A) The 
protein domain structure of TNNI3 includes binding sites to TNNC1 (purple), TNNT2 (cyan), ACTC2 (blue) and 
TPM1 (light purple). Therefore, truncating variants near the n-terminus lose the ability to bind to most of these 
proteins whereas binding capabilities of C-terminal variants to actin and tropomyosin are influenced. (B) Two 
truncating variants in exons two and five are predicted to lead to early truncation of TNNI3 and four missense 
variants in exon eight indicate a mutational hotspot for variants to cause CMPs. 
 
In both homozygous truncating cases, affected by DCM/LVNC and an early disease 




consanguineous, which led to the homozygous inheritance of the genetic variants. In family 1 
blood samples from both parents were available and therefore checked for the segregation of 
the variant (Figure 14 A, Figure S 3). In family 2 only heart tissue from the index patient 2-II:3 
was available, and segregation could not be checked, but an extended pedigree was available 
(Figure 14 B, Figure S 2). To analyze the expression of TNNI3 qPCR and Western blotting 
approaches were used. In Figure 14 C TNNI3 mRNA levels were drastically reduced in patient 
1-II:1 whereas patient 2-II:3 showed only little differences. In both samples a distinct increase 
in signal was detected for the gene troponin I1, slow skeletal type (TNNI1), the fetal form of 
TNNI. Smaller changes were also detected in TNNT2 (increase) and MYBPC3 (decrease). 
 
 
Figure 14: Pedigrees, mRNA analysis and protein expression analysis of two patients with a homozygous 
and truncating variant in TNNI3. (A)/(B) Pedigrees of two families carrying truncating variants in TNNI3 are 
presented. Genotypes are shown as wt or mut, representing the wildtype or altered allele. For individuals with no 
genotype no samples for sequencing were available. Phenotypes and the variants on coding sequence and protein 
level are indicated. Males are represented with squares and females with circles. Affected individuals have a filled 
form and deceased family members are marked with a diagonal line. (C) Analysis of mRNA levels show transcription 
of different targets (TNNI3, TNNI1, TNNT2 and MYBPC3). Expression of mRNA was normalized to GAPDH with a 
following Student’s t-test to determine statistical significance (* for p<0.05). Heat shock 70 kDa protein 1A (HSP70) 
was used as loading control (normalization) and Student’s t-test was performed to determine statistical significance 
(* for p<0.05). (D) Protein levels from heart tissues were analyzed to compare the expression of different targets 




Similar events were examined on protein level. Changes in protein concentrations are shown 
in Figure 14 D. Whereas TNNI3 was absent in both index patients, TNNI1 was drastically 
increased. Levels of TNNT2 and MYBPC3 showed small changes. Quantification of these 
signals showed significant changes for TNNI3 and TNNI1 (Figure 14 E). 
 
 
Figure 15: Prediction, mRNA expression and sequencing of the TNNI3 splice site variant c.24+2T>A. (A) In 
silico analysis of the base exchange TNNI3 c.24+2T>A with HSF (http://www.umd.be/HSF3/index.html) predicted 
a negative effect and an altered splice site. (B) A PCR product, amplified from cDNA originating from heart tissue 
samples of patient 2-II:3, shows altered length in fragments (yellow star). (C) Sequencing of the elongated cDNA 




To further investigate the effect of the splice site variation in TNNI3 c.24+2T>A in silico 
prediction, amplification from TNNI3 of affected parts in the mRNA and sequencing were used. 
The prediction of the online tool HSF was positive for changes of the wt donor splice site 
(Figure 15 A). Thus cDNA was generated from isolated RNA originating from the patient 2-II:3. 
Primer designed to amplify parts of TNNI3 between exon 1 and 5 were used to generate the 
altered splice products seen in Figure 15 B. In comparison to control PCR products mRNA 
affected by TNNI3 c.24+2A>A was elongated and alternated by alternative or mis-splicing. In 
the following sequencing of these products five additional amino acids were identified and a 
premature stop codon was implemented as illustrated in Figure 15 C. 
In the same manner a case of RCM diagnosed at the age of 3.8 years and with HTX at 4.5 
years was analyzed. The phenotype of this patient was associated with a heterozygous variant 
in TNNI3 occurring as truncating at the end of the protein. The base insertion c.624t>TT led to 
a premature stop at the amino acid position 209 and therefore concluded in the truncation of 
the last two amino acids in TNNI3. The variant occurred de novo and was not detected in the 
parents (Figure 16 A). This LP variant is likely to have an effect because the parents without 
the variant are not affected by a cardiac phenotype. On mRNA level tissue samples of patient 
3-II:1 showed increases in signals for TNNI3 and TNNI1. The gene MYBPC3 was slightly 
downregulated, whereas mRNA levels of actinin alpha 2 (ACTN2) and TNNT2 were similar to 
the control signals. In Western blotting experiments TNNI3 was still present in same amounts 
of protein as in controls. Only the signal for TNNI3 in the sample 2-II:3 was absent (Figure 14 
D). Regarding TNNI1 there was no increase in signal observed for patient 3-II:1, which 
distinguished again from the homozygous truncating variant. 
As mentioned before, three cases of CMP with a detected heterozygous missense variant in 
TNNI3 were observed in the pediatric CMP cohort. Like p.Glu209* these base exchanges 
clustered near the c-terminus in a region associated with actin and tropomyosin binding 
(p.Asp190Glu, p.Arg192Cys and p.Asn194Lys, Figure 17). The three index patients were 
affected by HCM, RCM and DCM, whereas the RCM patient had the most adverse disease 
development diagnosed with CMP at the age of 1.8 years and undergoing HTX at age 3.4 
years. The individuals affected by HCM and DCM were diagnosed at the age of 11.2 and 9.3 
years. In family 4 the father was already deceased, and a history of sudden cardiac death was 
documented in the family. Thus, the segregation was not fully checked, but the probability is 
high that the LP variant p.Asp190Glu in TNNI3 segregated in the affected members of this 
family. For the other two families parental blood samples were available. In both cases the 
variants occurred de novo and were not detected in the parents. Therefore, the observed 
TNNI3 alterations, similar to the heterozygous truncating variant, are likely to influence the 
heart in these patients, because the individuals without p.Arg192Cys and p.Asn194Lys are not 




implantation and patient 6-II:1 was at risk for potential heart failure, because similar events 




Figure 16: Pedigree, mRNA analysis and protein expression analysis of a patient with a truncating and C-
terminal variant in TNNI3. (A) A pedigree of a family carrying a truncating and C-terminal variant in TNNI3 is 
presented. Genotypes are shown as wt or mut, representing the wildtype or altered (mutated) allele. For individuals 
with no genotype no samples for sequencing were available. Phenotypes and the variants on coding sequence and 
protein level are indicated. Males are represented with squares and females with circles. Affected individuals have 
a filled form and deceased family members are marked with a diagonal line. (B) Analysis of mRNA levels show 
transcription of different targets (TNNI3, TNNI1, TNNT2, MYBPC3 and ACTN2). Expression of mRNA was 
normalized to GAPDH. (C) Protein levels from heart tissues were analyzed to compare the expression of different 
targets (TNNI3 and TNNI1). (D) Expression levels from signals in (C) were quantified. HSP70 was used as loading 





In conclusion, two homozygous variants in TNNI3 leading to truncations near the n-terminus 
showed absent signals for TNNI3 on protein level probably due to non-sense mediated decay 
and a drastic increase in expression of TNNI1. Both cases showed a very severe and early 
disease development. Experiments with a heterozygous truncating variant at the c-terminus 
did not show any significant alteration in protein expression. In this case the CMP progression 
was still severe, but the onset of the phenotype was with higher age. Similar statements can 
be made for the three mentioned missense variants. Of note is the heterogeneity of the disease 
development with TNNI3 variants. Four CMP subtypes were associated with TNNI3 variants 
in the CMP-80 cohort and the onset varied from 0.8 to 11.2 years. 
 
 
Figure 17: Pedigrees of patients with C-terminal missense variants in TNNI3. (A) – (C) Pedigrees of three 
families carrying C-terminal variants in TNNI3 are presented. Genotypes are shown as wt or mut, representing the 
wildtype or altered (mutated) allele. For individuals with no genotype no samples for sequencing were available. 
Phenotypes and the variants on coding sequence and protein level are indicated. Males are represented with 
squares and females with circles. Affected individuals have a filled form and deceased family members are marked 






3.2 Detection of PRDM16 variants in patients with cardiac phenotypes – 
Genetic and functional analysis 
VOI were most frequently detected in the genetic groups of sarcomere, Z-disc and 
desmosomes genes. With four detected variants PRDM16 was as frequent as plakophilin 2 
(PKP2), TNNT2 or TTN (truncating) and an exception outside of the afore mentioned groups. 
PRDM16 is a transcriptional regulator and therefore listed in the group of transcription and 
splicing. Further genetic and functional analysis of PRDM16 can help to better understand 
cardiac mechanisms and signal pathways in the heart. Hence, this chapter investigates the 
genetic and functional impact of PRDM16 variants for CMP in an extended genetic cohort. 
3.2.1 High number of PRDM16 variants in an extended cohort of cardiac disease 
phenotypes 
To further investigate the frequency of PRDM16 variants in patients with the phenotype of CMP 
and myocarditis an in-house cohort was added to the existing pediatric CMP-80 cohort. CMP 
specific genes of an additional 205 patients with CMP or myocarditis (Heart-205) were tested 
for genetic alterations. In total an assembly of 285 individuals was investigated (Heart-285). In 
this cohort individuals of all age groups were included (181 pediatric cases with age ≤ 18 
years). The gender was shifted to males (112 f, 174 m). VOI were detected in 226 cases with 
320 missense, 58 splice site, 33 frame shift and 15 stop gain variants. On average a patient 
was carrying 1.49 VOI. The in-house cohort comprised mainly LVNC cases and therefore the 
distribution of phenotypes shifted in comparison to the pediatric CMP cohort (Figure 18 B). 
Most patients were diagnosed with LVNC (n = 119) followed by similar amounts of myocarditis, 
DCM and HCM patients with around 50 cases each (Figure 18 A). RCM and ARVC were again 
underrepresented with eight and four cases. The five genes with most detected VOI were 
MYH7 (n = 36), TTN (n = 27, only possible truncating variants), MYBPC3 (n = 20), DSP (n = 
16) and PRDM16 (n = 16, Figure 18 C). Whereas MYH7, MYBPC3 and TTN were expected 
with high numbers of variations in this cohort, cases with cardiac phenotypes caused by 
PRDM16 variants are rarely known. Therefore, the detected frequency was surprisingly high. 
The frequency of VOI in major CMP genes like TNNI3, TNNT2, LDB3 or TPM1 was 
considerably lower (n = 11/11/10/10). 
To gain deeper understanding about the effect of PRDM16 variants, further investigations were 
performed. An overview of PRDM16 variants showed altered sequences in 16 different 
patients, whereas two variants occurred in one patient and one variant was detected twice 
(Table 6). Most of these patients were diagnosed with LVNC (n = 7) followed by two cases of 




were detected in all investigated phenotypes. The gender of the 16 patients prevailed slightly 
to males (f = 6, m = 10) and with a range from 0.6 to 55 years all age groups were present.  
 
 
Figure 18: Distribution of cardiac phenotypes from additional in-house cohort and frequency of VOI in CMP 
relevant genes in patients. (A) The distribution of phenotypes from 285 CMP and myocarditis patients shows the 
composition of the initial pediatric cohort and an additional in-house cohort. (B) The distribution of phenotypes from 
205 CMP and myocarditis patients shows the composition of an additional in-house cohort. (C) The frequency of 
different genes with a variant detected in CMP patients is shown (full name of genes in Table S 1). 
 
The spectrum of the detected PRDM16 variants included 11 missense, three truncating and 
two splice site affecting variants. Two stop gain and one frame shift variant of the truncating 
variants were considered as P, whereas the rest was interpreted as VUS (11 missense and 
two splice site variants). Due to a MAF in the reference database gnomAD of smaller than 
0.1% all VOI were considered as rare, but variants with an amino acid position of 702 and 
smaller were at least detected with a MAF of 0.01% and lower. The only exception was variant 
p.G791D (gnomAD MAF = 0). Eight of these variants were not previously reported with cardiac 





















Myocarditis m 13,7 1:3102766 c.115G>A p.E39K 0.0000789 VUS yes no - 
HCM m 0,6 1:3313149 c.668G>T p.G223V 0.0000318 VUS yes no - 
ARVC1 m 38,6 1:3319454 c.776C>T p.A259V 0.0000572 VUS yes no - 
LVNC m 4 1:3322136 c.1110C>A p.D370E 0.0000041 VUS yes no - 
LVNC m 44,6 1:3328329 c.1573dup p.R525Pfs*79 0 P no P 23768516 
LVNC f 10,5 1:3328388 c.1627C>T p.Q543* 0 P yes no - 
LVNC f 28,9 1:3328646 c.1885G>C p.V629L 0 VUS yes no - 
ARVC1 m 38,6 1:3328817 c.2056A>G p.T686A 0.0000678 VUS yes no - 
LVNC f 21,5 1:3328865 c.2104A>T p.K702* 0 P no P 23768516 
DCM f 2,5 1:3328948 c.2187C>G p.F729L 0.00039 VUS no LBe - 
HCM m 15 1:3329057 c.2296G>A p.G766S 0.00029 VUS no LBe - 
RCM m 17 1:3329133 c.2372G>A p.G791D 0 VUS yes no - 
LVNC2 m 19,9 1:3329208 c.2447A>G p.N816S 0.000232 VUS no P 23768516 
RCM2 m 5 1:3329208 c.2447A>G p.N816S 0.000232 VUS no P 23768516 
DCM f 9,9 1:3329370 c.2603+6C>T - 0.000414 VUS no LBe - 
ARVC f 53,5 1:3331186 c.2666C>T p.P889L 0.000177 VUS no VUS - 
LVNC m 55,0 1:3331216 c.2691+5G>A - 0.000201 VUS no LBe - 
Abbreviations: MAF – minor allele frequency, ACMG – American college of Medical Genetics and Genomics, VUS – variant with uncertain significance, P – pathogenic, LBe – likely benign 
1two variants in same patient 




To analyze the distribution of known and novel PRDM16 variants, their amino acid position 
was highlighted in a schematic protein domain structure (Figure 19). Homology alignments and 
similarity tools predicted an n-terminal SET domain at amino acid position 82 to 211 and two 
separated zinc finger domains (aa position 230 to 445 and 951 to 1032). The first zinc finger 
domain contained seven zinc fingers and was located near and behind the SET domain. The 
second zinc finger was located near the c-terminus and consisted of three zinc fingers. At 
position p.459-557 a proline rich region was located and already published data provided 
information on isolated SKI proto-oncogene (SKI), c-terminal binding protein 1 (CTBP1), c-
terminal binding protein 2 (CTBP2) and zinc finger protein 516 (ZNF516) interaction sites in 
the second half of the sequence (PFDLT and PLDLS motifs at aa position 774 to 778 and 804 
to 808 mediate binding of CTBP, Kajimura et al., 2008, Takahata et al., 2009). The detected 
variants in this work were distributed evenly throughout the protein and no clear cluster 
emerged. Regions without any alteration so far were the SET domain, the second zinc finger 
domain and the following n-terminal region. The pathogenic nonsense and frameshift variants 
located between the two zinc finger domains were predicted to express approximately half of 
the protein and therefore leading to loss-of function of PRDM16.  Functional regions containing 
missense variants were observed between the amino acids 223 to 370, potentially changing 
properties of the first zinc finger domain and 629 to 889, maybe interfering with published 
protein binding sites. 
 
 
Figure 19: Schematic protein domain structure of PRDM16. Shown is the sequence of predicted functional 
domains in PRDM16. It consists of an n-terminal SET domain followed by seven zinc fingers of the C2H2-type. A 
second zinc finger domain near the c-terminus consists of three zinc fingers (C2H2 type). Shortly after the first zinc 
finger domain a proline rich region is following. At the c-terminus the interaction sites with SKI (TGF-β signaling), 
CTBP1/2 (PLDLS motif) and ZNF515 are shown. Above the scheme are variants colored in black (described in 




3.2.2 Bioinformatic characterization of PRDM16 
Additional features of PRDM16 were identified using protein prediction tools. PRDM16 was 
examined for PTM, secondary structure, conserved regions, disordered sections through the 
sequence and parts with high surface accessibility (Figure 20). Positive results for PTM were 
obtained for acetylation, methylation, phosphorylation, glycosylation, SUMOylation and S-
nitrosylation. Data was collected from different prediction tools and hits, exceeding certain 
thresholds, were considered as true results. Putative PTM sites were distributed over the entire 
PRDM16 protein. On note, in the region p.540- 608 six PTM clustered. This suggests an 
exposed surface accessibility and a potentially critical functional region. At position p.K915 an 
acetylation and SUMOylation site were predicted. This lysine residue was described to be 
involved in stabilization of PRDM16 through SUMOylation (Chen, Huang, Pan, Zhu, & Wang, 
2018). Stabilization of PRDM16 protects the protein from degradation and enables binding of 
downstream interaction partners for further stabilization and signaling. No PTM corelated with 
VOI detected throughout genetic analysis. Protein conservation tools, taking into consideration 
homology and similarity alignments, identified functional regions e.g. the zinc finger domains. 
Thereby nine grades of conservation were possible spanning from 1 to 9 and from low to high 
conservation. Positions exceeding the threshold of 5 for being conserved were marked by a 
red dot above the graph. Other sections were characterized by changing conservation values 
and only peaked for small sequences like the PFDLT and PLDLS motifs. Surprisingly the SET 
domain showed a relatively low conservation, although secondary structural elements were 
especially predicted in this region and the zinc finger domains and should be affected by steric 
properties of amino acid residues changes. Further structural elements, marked as red for α-
helices and as green for β-sheets, were located at the position from amino acid 680 to 762 and 
at the c-terminus. These findings coincided with results from surface accessibility calculations. 
Values for surface accessibility were normalized to 1 (exposed = maximal value 1, buried = 
minimal value 0). Again values exceeding the threshold were marked as red dot above graph 
(threshold = 0.25). In general, predicted structural elements seemed more buried than flexible 
regions. Therefore, low surface accessibility was observed for the SET and zinc finger 
domains, the region between amino acid 680 to 762 and the c-terminus. The presence of 
structural elements positively coincided with ordered protein regions. For these predictions 
again normalized values were used and 1 presented maximal disorder, whereas 0 was the 
minimal amount and 0.5 was used as threshold to characterize a position as disordered. The 
SET and zinc finger domains and the afore mentioned region from position 680 to 762 rarely 
passed the threshold for disorder and strengthened the prediction of secondary structure. Most 
disordered region located at the termini, between position 521 to 654 and between 784 and 








3.2.3 Cloning of PRDM16 and quality control 
For expression already available PRDM16 in wt (PRDM16_wt), p.E271K (PRDM16_v1), 
p.P291L (PRDM16_v2), p.R525Pfs*79 (PRDM16_v3fs), p.N816S (PRDM16_v4) and p.L887P 
(PRDM16_v5) form embedded in the pcDNA-Dest53 vector was used to amplify the gene, 
ligate it into the new vector and transform the constructs in E. coli (XL1-blue). Vectors used for 
expression in human cell lines with and without protein tags were pFLAG-CMV5/6a and 
pEGFP-C1. Selection of positively transformed E. coli was expressed through antibiotic 
resistance (pFLAG-CMV5/6a - ampicillin, pEGFP-C1 - kanamycin). After inoculation of LB 
medium with the transformed bacteria a midiprep was applied to purify the plasmid DNA from 
the cultures. This process with additional quality control steps is described in the following part. 
 
Table 7: DNA-constructs for the expression of PRDM16 in wt form and containing different variants 
Name Protein tag Expression 
Backbone Insert  Vector Variant 
pFLAG_CMV5a PRDM16_wt - PRDM16_no_tag wt 
pFLAG_CMV5a PRDM16_E271K - PRDM16_no_tag v1 
pFLAG_CMV5a PRDM16_P291L - PRDM16_no_tag v2 
pFLAG_CMV5a PRDM16_R525Pfs*79 - PRDM16_no_tag v3fs 
pFLAG_CMV5a PRDM16_N816S - PRDM16_no_tag v4 
pFLAG_CMV5a PRDM16_L887P - PRDM16_no_tag v5 
pFLAG_CMV6a PRDM16_wt n-term. FLAG FLAG+PRDM16 wt 
pFLAG_CMV6a PRDM16_E271K n-term. FLAG FLAG+PRDM16 v1 
pFLAG_CMV6a PRDM16_P291L n-term. FLAG FLAG+PRDM16 v2 
pFLAG_CMV6a PRDM16_R525Pfs*79 n-term. FLAG FLAG+PRDM16 v3fs 
pFLAG_CMV6a PRDM16_N816S n-term. FLAG FLAG+PRDM16 v4 
pFLAG_CMV6a PRDM16_L887P n-term. FLAG FLAG+PRDM16 v5 
pEGFP-C1 PRDM16_wt n-term. EGFP EGFP+PRDM16 wt 
pEGFP-C1 PRDM16_E271K n-term. EGFP EGFP+PRDM16 v1 
pEGFP-C1 PRDM16_P291L n-term. EGFP EGFP+PRDM16 v2 
pEGFP-C1 PRDM16_R525Pfs*79 n-term. EGFP EGFP+PRDM16 v3fs 
pEGFP-C1 PRDM16_N816S n-term. EGFP EGFP+PRDM16 v4 
pEGFP-C1 PRDM16_L887P n-term. EGFP EGFP+PRDM16 v5 
Figure 20: Analysis of predicted functional features from PRDM16. Shown is the schematic functional structure 
of PRDM16 at the bottom of the figure with novel (red) and published (black) genetic variants above the model. 
Predicted PMT are shown for acetylation, methylation, phosphorylation, glycosylation, SUMOylation and S-
nitrosylation. Predictions for other modification categories like palmitoylation were also applied . The following 
graphs show predictions for PRDM16 protein conservation, secondary structure (coil, α-helix, β-sheet), accessible 
surface area and disorder. The numbers of the corresponding amino acids are shown at the bottom. 
1Acetylation sites were predicted with three out of six online tools and not with at least four and were therefore 
selected with less stringency than the other predictions of PTM. 
2The SUMOylation at position K915 did not fulfill the criteria to be listed but was described experimentally in the 




All used constructs are listed in Table 7. These plasmids were created to express PRDM16 
with its mentioned variants in three forms, without any tag, with a FLAG-tag and with an EGFP-
tag. The protein tags were expressed n-terminally to ensure the expression of the tagged 
variant PRDM16_v3fs. For untagged protein, a plasmid with c-terminal FLAG-tag was chosen. 
Ligation primers in this case were designed to leave the stop codon of PRDM16 intact to 
exclude the protein tag. Upscaling to midi cultures and purification of plasmid DNA through 
midiprep resulted in plasmid concentrations of 0.8 to 3.4 µg/ml. 
The plasmids were then checked for the DNA length on agarose gels (Figure 21).The expected 
length of the backbone vectors with PRDM16 was 8.5 kb. For a quick check the plasmids were 
not linearized. Therefore, gel bands were visible for a lower and stronger supercoiled and a 
higher nicked form of plasmids. Supercoiled vectors move faster through agarose gels and 
thus appeared lower than the expected 8.5 kb (around 6 kb). In the example of Figure 21 all 
constructs had at least one clone with the corresponding height except PRDM16_wt. To get 
the full set, new clones had been picked and checked for the right height as seen in the right 
part of the figure. For further quality checks a sequencing step followed afterwards to detect 
possible base exchanges and small deletions or insertions. 
 
 
Figure 21: Ligation approach of PRDM16 inserts into the pFLAG-CMV5a vector. A minipreps preceded by 
PCR, ligation and transformation into XL1 blue E. coli cells with the pFLAG-CMV5a vector and PRDM16 inserts 
were loaded onto an agarose gel (1%) to check the corresponding length in supercoiled from. If one approach did 
not lead to a clone with the right height (wt cl1-4), new clones had to be picked (wt cl7). Clones containing the 
corresponding plasmids with the right height were picked to inoculate a miniprep culture for higher yields of DNA 
and deeper purification.  
 
In a final quality check, all cloned plasmids were validated with Sanger sequencing. In Figure 
22 two positive and two negative examples are shown. Most alterations of the DNA appeared 
at the termini. Base exchanges of altered start and stop codons would lead to missing initiation 
of PRDM16 expression or its elongation. Clone one and two in Figure 22 were affected by this 




exchange for the variant PRDM16_v2 normally coded by the codon CCC and changed to CTC. 
The entire gene was sequenced in this matter. 
 
 
Figure 22: Sequencing of pFLAG-CMV5a plasmids containing PRDM16_v2. After checking the size of newly 
cloned vector/PRDM16 constructs on an agarose gel (Figure 21), the DNA base sequence had to analyzed for 
small deletions/inserts and base exchanges. Therefore, the BigDye Terminator v3.1 protocol was applied, and 
samples were analyzed with the 3730 DNA Analyzer. 
 
A last step to ensure the correctly designed expression vectors were restriction enzyme digests 
(Figure 23). Due to restriction sites in the multiple cloning sites of vectors restriction enzymes 
could be used to confirm the length of insert and vector in linear form. Two approaches were 
followed. A single digest confirmed the length of the entire expression plasmid, expected to be 
8.5 kb and a double digest separated the backbone vector and the insert (backbone vector 
with 4.7 kb and PRDM16 insert with 3.8 kb). For the single digest the restriction enzyme EcoRI 
was used. For the double digest BamHI was added to the reaction. The linearization with EcoRI 
showed bands with heights at approximately 8.5 kb. No additional bands were observed and 
the expected difference in length to the empty vector was visible. The double digest clearly 




empty vector. Again no additional unexpected bands were visible and therefore the samples 
were clear of contaminations. 
 
 
Figure 23: Restriction enzyme digest of pFLAG-CMV5a with PRDM16 inserts. To prove the correct length of 
the PRDM16 insert into the vector pFLAG-CMV6a, a restriction enzyme digest with EcoRI in a single digest 
approach and EcoRI + BamHI in a double digest approach were used and loaded onto an agarose gel (1%). 
3.2.4 Overexpression of PRDM16 wt and variants 
All investigated PRDM16 variants were detected in patients with CMP. Zebrafish studies 
showed that PRDM16 truncation induces CMP. However, the impact of missense variants on 
PRDM16 function is unknown. Thus, further experiments were conducted to explore an impact 
of PRDM16 missense variants on subcellular localization and protein stability. 
3.2.4.1 Subcellular localization analysis of cardiomyopathy-associated PRDM16 
mutants with immunostaining 
To investigate the subcellular location of PRDM16, HEK293 cells were transfected with 
different PRDM16 constructs and subsequently analyzed with immunostaining and four-
channel confocal microscopy. Several cell types were tested for the overexpression of 
PRDM16. Cell lines like Hela and A549 are characterized by no intrinsic PRDM16 expression 
and therefore more sensitive to PRDM16 transfection and expression (unstable and early cell 
death after transfection). MCF7 cells exhibit endogenous PRDM16, but expression of this 
protein was more heterogenous than in HEK293 cells. Therefore, HEK293 cells were chosen 




PRDM16_wt subcellular localization was tested (Figure 24). Hence, with PRDM16_wt 
transfected HEK293 cells were fixated and analyzed with antibodies against PRDM16 and the 
FLAG-tag. EGFP emitted fluorescence without marking. The nuclei were detected with DAPI 
(grey) and phalloidin (magenta) was used to mark actin filaments. In each row of Figure 24 the 
expression of one construct is shown in three pictures. 
 
 
Figure 24: PRDM16 expression with protein tag or in untagged form in immunostained HEK293 cells. To 
investigate the location and distribution of overexpressed RPDM16 HEK293 cells were transfected with EGFP (top) 
and FLAG (middle) tagged PRDM16 and compared to cells with untagged overexpressed PRDM16 (bottom). 
Fluorescence signals were either directly detected with EGFP being a fluorophor or due to immunostaining, where 
fluorophor conjugated antibodies were used. Nuclei were stained with DAPI (white). Green represented detection 





HEK293 cells transfected with EGFP+PRDM16_wt expressed strong EGFP signals in the nuclei 
(green) and PRDM16 signals in nuclei as well as the cytoplasm (yellow) (Figure 24). 
Unexpectedly, both signals did not merge completely as the EGFP staining was not present in 
the cytoplasm. A similar pattern was observed for HEK293 cells transfected with 
FLAG+PRDM16_wt. With this approach the PRDM16 signal was more abundant in the 
cytoplasm. The samples transfected with PRDM16_no_tag_wt expressed signals in the 
cytoplasm and showed the localization of PRDM16 in the nucleus in different intensities, when 
compared from cell to cell. Therefore, the protein seemed to localize in both fractions, the 
nucleus and the cytoplasm. The subcellular analysis revealed discrepancies between 
untagged and tagged PRDM16 protein with pronounced nuclear accumulation of tagged 
PRDM16. These observations suggest an impact of n- or c-terminal tagging for correct 
PRDM16 dynamics between the cytoplasm and nucleus. For further analysis only 
PRDM16_no_tag proteins were used. For these initial approaches the antibody anti-PRDM16 
from Thermo Fisher Scientific was used. For further approaches (Figure 25, Figure 26) the 
antibody anti-PRDM16 from R&D systems was used except for the PRDM16_v3fs variant. 
 
 
Figure 25: Distribution of untagged overexpressed PRDM16 in three-dimensional microscopy images of 
HEK293 cells. HEK293 cells were transfected with untagged PRDM16 and stained with DAPI (white), PRDM16 
(yellow) and phalloidin (magenta). A series of images with different depths were taken for the same section (z-
stack). Therefore, the location of PRDM16 could be determined in three different dimensions. White boxes were 
used to enlarge and highlight specific sections. The five images in different planes (0 – 4.04 µm) were merged into 




To further investigate the subcellular distribution of PRDM16 in a cell three-dimensional 
records (z-stacks) were generated with confocal microscopy. The signals of PRDM16_wt were 
detected in the cytoplasm and the nucleus (Figure 25). At the lowest level the yellow signal 
was visible in small spots. In further planes the intensity of the signals increased in every 
compartment and detected PRDM16 concentrated at the edge of the DAPI marked nucleus 
(highlighted in the white box with white arrows). On the highest level the yellow signal 
accumulated and overlapped with DAPI detection in the nucleus. In conclusion PRDM16 was 
located in both the cytoplasm and nucleus and accumulated at the nuclear membrane. The 
maximum intensity projection (MIP) showed the accumulation at and in the nucleus. 
To test the impact of PRDM16 variants detected in CMP patients HEK293 cells were 
transfected with six PRDM16 mutant constructs (Table 7) and subsequently analyzed with 
immunostaining and confocal microscopy. These constructs comprised PRDM16_wt, 
PRDM16_v1, PRDM16_v2, PRDM16_v3fs, PRDM16_v4 and PRDM16_v5. In Figure 26 
signals detected for the PRDM16_wt protein were compared with immunostained samples 
from cells transfected with variants containing PRDM16. Three different stainings were used 
to analyze the samples. PRDM16 was detected in yellow whereas the nuclei and actin 
filaments were again stained with DAPI (grey) and phalloidin (magenta). The images for 
PRDM16_wt transfected cells showed similar results as observed before with PRDM16 
localization in the cytoplasm and nucleus. Thereby some cells showed a shift in localization to 
the nucleus or the cytoplasm (highlighted with an arrow for a shift to the nucleus or marked 
with a star for a shift into the cytoplasm). Overall the signal of PRDM16_wt was evenly 
distributed between nucleus and cytoplasm as observed before in Figure 24 and Figure 25. 
For PRDM16_v1 and PRDM16_v2 a change of localization to the cytoplasm was observed 
and signals in the nuclei were much less distinct as for the wt (missense variants in first zinc 
finger domain). The opposite was examined for PRDM16_v3fs (frame shift variant after the 
first zinc finger domain). Signals for PRDM16 were strongly accumulated in the nuclei (only an 
arrow to highlight cells with PRDM16 localized in the nuclei). Of note was also the availability 
of the signal for PRDM16_v3fs because a premature stop codon may lead to regulatory 
degradation of the partly expressed protein, which was not observed in this case. The sample 
PRDM16_v4 expressed similar results to the wt whereas the signals of PRDM16_v5 again 
shifted to the nuclei, but in a more attenuated form compared to PRDM16_v3fs. In conclusion, 
an even distribution for PRDM16_wt in cytoplasm and nucleus was confirmed, but the 
introduction of variants to this protein seemed to change the conditions for localization in the 
cell. Signals of PRDM16 shifted to the nucleus drastically for PRDM16_v3fs and with weaker 
effects in PRDM16_v5. For PRDM16_v1 and PRDM16_v2 PRDM16 was detected with weaker 
intensity in the nuclei and stronger signals in the cytoplasm. Therefore, further analyzing the 





Figure 26: Immunostaining of PRDM16_wt form and CMP variants in HEK293 cells. HEK293 cells were transfected with untagged PRDM16 and stained with DAPI (white), 
PRDM16 (yellow) and phalloidin (magenta). Variants detected in CMP patients were introduced into the wt protein to investigate functional effects. These five variants contained 




3.2.4.2 Localization and stability analysis of PRDM16 through Western blotting 
With immunofluorescence staining differences between tagged and untagged PRDM16 were 
observed. Thus, for more validity these findings were reevaluated with Western blotting (Figure 
27). HEK293 cells were transfected with the EGFP+PRDM16, FLAG+PRDM16 and 
PRDM16_no_tag constructs encoding the PRDM16_wt and PRDM16_v1 – 5 forms. With 
every approach PRDM16 was expressed and could be detected. In general, all variants and 
the wt protein could be detected in the three approaches (tagged expression with EGFP or 
FLAG and untagged expression). Interestingly for the frame shift variant PRDM16_v3fs, 
containing a predicted premature stop codon, stable signals were observed, and regulatory 
degradation did not lead to absence of PRDM16. For the proteins expressed with tags specific 
antibodies against their tags were used, which confirmed the expression of artificially 
introduced PRDM16 into the cells and the corresponding weights of the different constructs 
due to the detection with a variety of antibodies (anti-EGFP, anti-FLAG and anti-PRDM16). 
The theoretical molecular weight of PRDM16 is 140.3 kDa. PRDM16_no_tag_wt and 
PRDM16_FLAG_wt were detected with approx. 170 kDa PRDM16_EGFP_wt was detected at 
200 kDa due to the EGFP tag contributing 27.7 kDa to the overall protein mass. The detected 
signals for the tagged PRDM16 were sharp and no additional protein bands were visible. The 
shift in height compared to the untagged protein was accordingly due to conjugated tag. The 
signals for PRDM16_v3fs were appropriately reduced by 74 kDa due to the afore mentioned 
truncation (expected molecular weight without tag: 66.3 kDa). The results for untagged 
PRDM16 were similar but differed in the occurrence of a second band clearly marked by a red 
box. A second band also appeared for PRDM16_v4 and PRDM16_v5 with EGFP-tagged 
PRDM16 but will not be considered for further discussion due to the absence in other 
experiments. The tagged PRDM16 wt constructs were used as expression controls as seen in 
the detection of PRDM16_no_tag (in the right image of Figure 27, c1 – EGFP+PRDM16, c2 – 
FLAG+PRDM16). A second band was also visible in PRDM16 detection for c2. The expression 
of the different variants differed in intensity and was also observed in following experiments 
not shown, especially for the wt expression. Furthermore, a smear appeared with PRDM16 
specific detection and therefore different antibodies against this protein were tested (Figure 
28). In conclusion the expression of PRDM16 with protein tags again distinguished from 
untagged protein but confirmed the expression of the introduced plasmids used during 
transfection. Therefore, these constructs were further used as expression controls. The 
detected signals for PRDM16 were all considerably higher in molecular weight for unclear 
reasons. The truncating variant was stably expressed and showed expected reduction in 





Figure 27: Western blot detection of HEK293 lysates with overexpressed PRDM16 carrying a protein tag or 
in untagged form. HEK293 cells were transfected with EGFP (left) and FLAG (middle) tagged PRDM16 and 
compared to cells with untagged overexpressed PRDM16 (right). For constructs comprising the EGFP or FLAG-
tags, specific antibodies were used to only mark the protein tags. In the right part of the figure an antibody against 
PRDM16 was used to detect the untagged protein. EGFP- and FLAG-tag containing PRDM16 samples were used 
as controls (c1 – PRDM16 + EGFP, c2 – PRDM16 + FLAG) to verify the corresponding height and specificity. For 
every detection the wt and variants of PRDM16 were applied (v1 – E271K, v2 – P291L, v3fs – R525Pfs*79, v4 – 
N816S and v5 – L887P). 
 
As mentioned before three antibodies to detect PRDM16 were tested for the expression of this 
protein (Figure 28). Although for the first two antibodies operating instructions suggested a 
predicted molecular weight of 140 kDa, specific PRDM16 bands could be observed at 170 
kDa. Double bands were also common for the three different detections. Thus, the occurrence 
of the second PRDM16 specific band was confirmed. For the first antibody additional bands 
occurred with increased and decreased heights (above 250 kDa and below 150 kDa). Due to 
the immunization against a c-terminal peptide of PRDM16 during the creation of the Abcam 
antibody the frame shift variant PRDM16_v3fs was not detected. Therefore, the PRDM16_v3fs 
sample could be used as a c-terminal PRDM16 specific control and as seen in the left image 
of Figure 28 for detection of unspecific protein bands. Similar events took place for the R&D 
Systems antibody. The immunogen of the Thermo Fisher Scientific antibody was an n-terminal 
peptide and therefore PRDM16_v3fs could be detected. There were only minor additional 
bands with lower molecular weight detected for this antibody, but a severe smear was visible. 
Bands with lower weight were probably degraded elements of PRDM16 and therefore not 
evitable. The sharpest bands were detected with the R&D systems antibody. No smear and 
only minor additional bands with lower molecular weight were observed. As mentioned before 
the variant PRDM16_v3fs could not be detected due to a c-terminal immunogen used for 
antibody production. Nevertheless, further investigations were performed with the R&D 
Systems antibody. If detection of the truncating variant PRDM16_v3fs was necessary, the 





Figure 28: Antibody test specific for PRDM16 and detection of PRDM16 variants with Western blotting. 
Western blots were generated to compare the expression of PRDM16 wt and variants (v1 – E271K, v2 – P291L, 
v3fs – R525Pfs*79, v4 – N816S and v5 – L887P) with three different antibodies detecting PRDM16. 
PRDM16+EGFP_wt (c1) and PRDM16+FLAG_wt (c2) were used as a loading controls. PRDM16 specific bands 
were marked with a red box. 
 
Subcellular analysis of overexpressed PRDM16_no_tag in PRDM16_wt and PRDM16_v1 to 
v5 form revealed diverse localizations. With the following approach mainly changes between 
the concentration of PRDM16 in a cytoplasmic and nuclear fraction were examined. To quantify 
this shift a procedure to separate the cytoplasmic fraction from the nuclear fraction has been 
applied to HEK293 cells transfected with PRDM16_no_tag constructs. Following detection with 
Western blot was used to characterize the distribution of PRDM16 (Figure 29). First the nuclear 
separation method was tested with the PRDM16_wt construct. Similar to the general signal 
distribution in immunostained samples for PRDM16_wt no differences were visible for 
PRDM16 specific bands detected in the cytoplasmic and nuclear fraction (cytoplasm - cp, 
nucleus - n, overexpressed, Figure 29 A). The separation of both fractions could be confirmed 
with the control detection of β-Tubulin at 50 kDa. β-Tubulin appeared enriched in the cytoplasm 
due to its role for the microtubule network. For detection of the cytoplasmic or nuclear fraction 
β-Tubulin and LMNA, an inner nuclear membrane marker, emerged as suited control proteins. 
In comparison the detection of endogenous expressed PRDM16 showed very weak or no 
signals although the protein concentration was amplified considerably (adherent cells 
harvested from two 75 cm2 cell culture flasks for endogenous detection to two wells of a 
standard six-well plate with 9.5 cm2). Probably due to the high protein concentration in the 
endogenous samples there were not a distinct separation of the fraction as seen for the β-
Tubulin specific bands. To compare the expression of PRDM16 carrying different variants the 
same procedure was applied to the PRDM16_no_tag constructs PRDM16_wt and 
PRDM16_v1 to v5 (Figure 29 B/C). After blotting the protein samples from an SDS 
polyacrylamide gel onto a PVDF membrane the gel was stained with Coomassie staining 
solution to check for the protein transfer and homogenous protein loading (Figure 29 B). As 
seen for the ladder (La) the transfer worked although plenty of protein remained in the gel in 




pattern confirmed successful separation. Moreover, the samples were evenly loaded as seen 
in the image. Specific expression bands for PRDM16, typically examined in overexpression 
approaches, were not observed. More evidence for a successful separation of the two fractions 
could be confirmed due to the Lamin C and β-Tubulin signals (Figure 29 C). Lamin C was 
absent in the cp fraction and β-Tubulin was absent in the nuclear fractions. The signals 
detected for PRDM16 however differed slightly. In the wt sample the strongest signal was 
examined for the lower band in the cytoplasmic fraction and with the intensity of the other 
PRDM16 bands evenly distributed the localization of PRDM16 was slightly shifted to the cp. 
Differences for the samples PRDM16_v1 to v5 were observed for the upper band in the cp 
fraction resulting in weaker signals. Weaker signals in the lower band of the cp fraction also 
led to the impression, that PRDM16 was present with higher concentrations in n fraction for 
the variants PRDM16_v2, PRDM16_v4 and PRDM16_v5.  
 
 
Figure 29: Detection of PRDM16 wt and variants in separated cell fractions (nucleus and cytoplasm) with 
Western blotting. Western blots were generated to compare the expression of PRDM16_wt and variants 
(PRDM16_v1 – v5) in the cytoplasm (cp) and the nucleus (n). These two sections were separated and examined 
separately. (A) The two fractions for endogenous PRDM16 expression and overexpressed PRDM16_wt are shown 
and compared to PRDM16+EGFP_wt (c1) and PRDM16+FLAG_wt (c2) control expression. (B/C) Overexpression 
of PRDM16_no_tag constructs was then compared. The Coomassie staining of the SDS polyacrylamide gel further 
processed to the Western blot in C was used to show successful transfer to the blotting membrane (see ladder - 




For more validity the same experiment was performed at least four times under same 
conditions, but quantified signals differed too much and produced very heterogeneous results. 
The main problem here were considerably weaker signals for wt samples although same 
amounts of protein were loaded (confirmed by analysis of Coomassie stained gels). In 
conclusion differences in PRDM16 signals were observed, but the results were too 
heterogenous for further analysis. A major concern was the stability of the PRDM16_wt 
expression. Without distinct detection for this construct, results from the other variants cannot 
be compared. 
To further investigate the stability of PRDM16_wt and variants, HEK293 cells were transfected 
with PRDM16 and harvested after CHX incubation for 0h, 8h, 16h and 24 h). The samples 
were analyzed via Western blot. In Figure 30 a set of PRDM16_wt and the five different 
variants PRDM16_v1 to v5 from the stabilization approach are presented. For each 
transfection the four time points at 0, 8, 16 and 24 h of incubation after addition of CHX to 
inhibit protein expression are shown.  
 
 
Figure 30: Time series of PRDM16 expression after CHX incubation for stability determination. HEK293 cells 
were transfected with PRDM16_wt and PRDM16_v1 to v5 constructs. After 24 h of incubation with CHX (protein 
expression inhibitor) differences of stability in PRDM16 variants were determined. Lysates were generated after a 
series of time points (0 h, 8 h, 16 h, 24 h) and detected with Western blotting (left). The expression levels at different 






PRDM16 expression detected with a molecular weight of approximately 170 kDa or 66 kDa for 
the frameshift variant was compared to the expression control of β-tubulin at around 50 kDa. 
With the quantified intensities of these samples an exponential fit was applied and with the 
resulted formula the half-life of the protein was determined. Visually the PRDM16_wt, 
PRDM16_v1 and PRDM16_v2 were observed with strong decline of signal, whereas decline 
in signal for PRDM16_v4 and PRDM16_v5 was elongated and PRDM16_v3fs showed no 
decrease in intensity and seemed therefore stable through the entire incubation time. 
Noticeable here were the observed quantities of the β-tubulin detection. Homogenous protein 
loading was achieved with BCA analysis and subsequent adjusted protein loading. With 
consistent protein concentrations unstable proteins were degraded, whereas more stable 
proteins relatively increased. This seemed to be the case for β-tubulin most visible for the 
sample PRDM16_v2 (Figure 30). Quantities of β-tubulin again were used as loading controls. 
The calculated half-lives T1/2 in Figure 30 corresponded with the visual estimations. Whereas 
the wt expressed a T1/2 of 7.8 h, the variants PRDM16_v1 and PRDM16_v2 were determined 
with shortened half-lives of 4.8 h and 2.7 h. The T1/2 values for PRDM16_v4 and PRDM16_v5 
were elongated with 10.5 h and 12.2 h. The result with the biggest difference to the wt was 
observed in cells transfected with the frameshift variant PRDM16_v3fs. The signal intensity did 
not decrease considerably and therefore resulted in a calculated T1/2 with 49.5 h. These results 
suggest difference in protein stability of PRDM16 variants, but due to the heterogenous results 





In this thesis, the genetic basis of a cohort comprising 80 pediatric cases of primary non- 
syndromic CMP were analyzed. The frequency of VOI in CMP-relevant genes and genotype-
phenotype correlations were evaluated. DCM followed by HCM patients represented the 
majority of the CMP cases with decreased numbers for LVNC and RCM and nearly no cases 
of ARVC. Overall, the gender was distributed equally, but differed for DCM and HCM (more 
affected females for DCM and more affected males for HCM). Considering the age, the HCM 
group showed later disease onset and a wider range. Adverse events were considerably higher 
for individuals affected by DCM and RCM, including considerably more frequent heart 
transplantations and deaths. Adverse events were correlated with the number detected VOI 
and expressed a higher risk to experience such events with increasing number of VOI. 
Most frequently VOI were detected in sarcomere, Z-disc or desmosome genes. These groups 
contained the disease genes with most frequently detected VOI in MYH7, MYBPC3, TNNI3 
and DSP. Especially VOI in MYH7 and MYBPC3 accumulated in HCM patients. The other 
groups showed more heterogeneity and RCM cases represented an exception with truncating 
TTN VOI most frequently detected. 
In the group of most frequently detected VOI TNNI3 was the third most important gene. Of 
note were TNNI3 variants due to a homozygous splice site variant leading to a complete loss 
of TNNI3 in the myocardium and resulting in the compensatory increase of TNNI1. Confirmed 
was this case with a second homozygous frame shift variant examined with similar results 
detected in an additional pediatric CMP case. 
PRDM16 is a transcriptional regulator and several variants were detected in pediatric CMP. 
Further availability of patients with adverse cardiac phenotypes identified 16 variants detected 
in PRDM16. These alterations occurred in six different cardiac diseases and comprised 
missense, splice site frame shift and stop gain variants. Through bioinformatic analysis 
structural and accessible regions of the protein were revealed and associated with the detected 
variants. Immunohistochemistry experiments showed different properties for the expression of 
PRDM16 when tagged compared to untagged form. Furthermore, PRDM16 containing CMP 
variants mediated altered localization in the cell with condensed signals in the cytoplasm or 
the nucleus. Therefore, the cytoplasmic and nucleic fractions were analyzed separately in 
Western blot approaches. Stabilization test of PRDM16 wt and variants showed differences in 
the protein half-life time correlating with localization in the cells suggesting more stability of 




4.1 Clinical characterization of pediatric cohort 
In the recruitment period of pediatric patients with primary CMP mainly DCM and HCM cases 
were diagnosed. These results are consistent with current findings (Lee et al., 2017). Less 
frequently were cases with LVNC and RCM. Children affected by ARVC were rarely recruited. 
The sex of the patients was equally distributed overall but differed for HCM and DCM cases. 
The gender in the other subgroups was equally distributed (LVNC) or the group was too small 
to comment (RCM, ARVC). Males were affected more frequently by HCM, whereas more 
females were affected by DCM. For HCM cases both in adults and children a higher incidence 
for males is known (Lu et al., 2020; van Driel, Nijenkamp, Huurman, Michels, & van der Velden, 
2019). As for DCM patients, findings are contradictory. In adults, all-cause mortality was 
described as an independent predictor for females (Doesch et al., 2014). An Australian 
childhood cohort presented a gender distribution with 56% females affected by DCM (103 out 
of 184, Nugent et al., 2003), which coincides with characteristics of the cohort described in this 
thesis. Contradictory to that, in a cohort containing 1426 pediatric DCM cases 769 males were 
affected by the CMP (54%, Towbin et al., 2006). In these publications differences between 
ethnic groups were also described as an influential factor with indigenous and African 
American patients diagnosed with a higher incidence. These factors may alter the gender 
specific distribution. Additionally, DCM can be caused by different environmental factors and 
is therefore more susceptible to fluctuations in their patient’s characteristics (Lipshultz et al., 
2019). 
Age specific effects compared to the other phenotype groups were only observed for HCM. 
The onset was at later age and the age range was wider. In a study of childhood patients 
affected by HCM, the poorest prognosis has been examined with an age younger than one 
year. In cases with an age higher than one year no age specific associations were observed 
(Colan et al., 2007). Partly these findings were confirmed with results in this thesis. For HCM 
cases survival seems independent from the age of diagnosis. Only one patient in this sub 
cohort underwent heart transplantation and died half a year after the operation with an age at 
diagnosis of 0.3. Therefore, in this case the early onset of the disease increased the severity, 
but six different cases with patients younger than one year affected by HCM presented different 
results and did not show any occurrences of adverse events. Reasons for this observation 
could be a milder and elongated progression of the disease or higher thresholds to develop 
adverse events due to hypertrophy of the heart compared to other disease symptoms such as 
dilatation (see athlete's heart, Baggish & Wood, 2011). 
In our cohort, adverse events were mainly observed in DCM and RCM patients, whereas HCM 
patients were nearly event free. In other studies, an early onset is often described as risk factor 




al., 2018; Colan et al., 2007). Regarding age, 11 DCM patients observed with adverse events 
were younger than one year (seven were older). LVNC cases affected by MACEs seemed also 
age specific and were diagnosed with an age younger than one year, although the occurrence 
with three cases was rare. RCM patients were older than one year and up to 15.9 years old at 
diagnosis. Therefore, in this subgroup the development of adverse events seemed age 
independent, although these cases presented the worst prognosis together with DCM patients. 
4.2 Interpretation of genetic variants detected in 80 pediatric 
cardiomyopathy patients and efficacy of genetic screening 
According to the guidelines of the American College of Medical Genetics and Genomics 
variants were categorized as VUS, LP or P in this thesis (VOI, Richards et al., 2015). LP and 
P variants are considered to be disease-causing according to current ACMG guidelines for 
CMP. Therefore, in 30 of 80 patients at least one P or LP variant was detected concluding in 
38% of cases the underlying genetic alteration has been discovered. 
4.2.1 Cardiomyopathy specific observations 
The highest rate of VOI was observed in HCM patients with 57%. Most frequently VOI were 
detected in MYH7 and MYBPC3. In all HCM patients 37% of VOI were observed in these two 
genes (10 out of 37). In P and LP variants this term went up to 69% (9 out of 13). Former 
studies showed similar results with slightly higher frequencies over 75% (Morita et al., 2008). 
Categorized by functionality VOI detected in HCM patients were mainly observed in sarcomere 
and Z-disc genes (57% and 26%). Thus, HCM cases presented the most distinct genotype and 
as described in the literature HCM is a disease of the sarcomere (Thierfelder et al., 1994). 
Interestingly, the proportion of VOI in MYH7 and MYBPC3 decreases with earlier onset (three 
MYH7 and one MYBPC3 VOI in 14 patients < 10 years of age, one MYH7 VOI in seven patients 
< one year of age). Therefore, VOI in MYH7 and MYBPC3 seem to manifest in adult CMP 
patients with a later onset of the disease. 
DCM cases represented the biggest group in this work. VOI in these cases were detected in a 
heterogenous spectrum of genes. MYH7 remains the gene with most frequently observed VOI 
in this sub cohort with detection in four patients, but not as clearly as within HCM cases. Altered 
genes not considerably less frequent were BCL2 associated athanogene 3 (BAG3), DSP, 
NEXN, PKP2 and TNNT2 (detected in three patients). In P and LP variants only one variant 
was detected in MYH7 and MYBPC3 each. Interestingly, P and LP variants comprised only 
sarcomere genes. Including VUS, VOI were most commonly detected in sarcomere, 




disease genes for adult, pediatric and infant cases (Pugh et al., 2014). In adults truncating TTN 
and LMNA variants are predominating. In infants the occurrence of variants in these genes is 
described to be drastically decreased. Here, this statement is confirmed for infants. In contrast 
to the published data this observation is not limited to infants with an age younger than two 
years and in this work observed in all pediatric age groups. In infants it is also described that 
alterations in MYH7 are predominantly, which cannot be entirely confirmed in this work. 
Compared to HCM patients the frequency of MYH7 decreases partly with age and mainly with 
severity (occurrence of MACE’s or death as term for severity, 11 from 18 HTX or deceased 
patients ≤ 1 year old). 
RCM patients were primarily affected by VOI in sarcomere and transcription/splicing genes. 
Pathogenic and likely pathogenic variants were only detected twice in TNNI3 and once in TTN. 
In a former study variants in sarcomere genes were associated with the development of RCM 
in children, which coincides with the findings in this thesis (Kaski et al., 2008). In adults, genetic 
analysis is restricted to consanguineous families and case reports (Peled et al., 2014). The 
interpretation of these results is limited due to the small numbers of diagnosed RCM cases 
(Kaski et al., 2008). 
Patients affected by LVNC showed heterogenous genotypes. MYH7 again was the most 
frequent gene with detected VOI followed by ACTN2 and TAZ. Similar genotypes were 
detected in other studies, again with the absence of TTN variants in pediatric cases (van 
Waning et al., 2018; Wang et al., 2017). Complex MYBPC3 genotypes specific for pediatric 
cases were not examined in this work. Sarcomere, desmosome and Z-disc genes were most 
prominent in the spectrum of LVNC VOI. Here, the proportion of MYH7 and MYBPC3 VOI did 
not change considerably regarding age and severity of the disease. The P and LP variants 
contained mainly sarcomere genes. 
In conclusion, genes categorized into the functional groups of sarcomere, desmosome and Z-
disc genes were most frequently detected with VOI. Sarcomere and Z-disc genes are 
influencing the generation of the force and rhythm used for normal cardiac function and were 
expected to lead to adverse remodeling of the heart. Interestingly desmosome genes are not 
commonly associated with CMPs except of ARVC (58% of ARVC patients carried variants in 
desmosomal genes and 93.5% of all ARVC related variants were detected in desmosome 
genes , Lazzarini et al., 2015). In this work only two patients were diagnosed with ARVC. In 
these two patients three VOI in desmosome genes were detected accordingly (DSC2:p.I345T, 
desmoglein 2 (DSG2):p.340V*, PKP2:p.R573Efs*4). Desmosomes mediate strong cell-cell 
contacts and localize in tissues with intense mechanical stress like the heart. Thus, mutations 




4.2.2 Specific cardiomyopathy genes 
In general, MYH7 and MYBPC3 showed most frequently VOI in the pediatric CMP-80 cohort. 
VOI were frequently observed on HCM, DCM and LVNC patients. This observation changed 
with earlier onset and increasing severity. In conclusion, variants in MYH7 and MYBPC3 are 
mostly not as adverse as variants in other CMP relevant genes and therefore manifest in adults 
with a later disease development. In more detail, disease onset in 13 patients with MYH7 VOI 
ranges from infancy to adolescence. Five out of eight VOI were previously reported and 
detected in both adults and children (Table S 6). This again suggests an age independency of 
MYH7 variants causing the development of CMP. Seven MYH7 missense variants were 
interpreted as P or LP. All seven P or LP missense variants localize within the HCM cluster 
region ranging from amino acid position 167 to 931 supporting their pathogenic character (Kelly 
et al., 2018). Moreover, a reliable MYH7 disease and risk identification is necessary due to the 
high detection rate of already known missense variants (only four novel MYH7 variants out of 
13, Richards et al., 2015; Kelly et al., 2018). Nevertheless, the assessment and rate of 
pathogenic MYH7 variants is highly specific to the availability of comprehensive genetic and 
functional data. Similar events are applicable for MYBPC3. Three out of six VOI were detected 
in pediatric and adult cohorts and six out of eight variants determined as P or LP (Table S 7). 
Like for MYH7 disease specific effects of MYBPC3 are well known and often described for 
CMP patients especially cases with HCM (Toepfer et al., 2019). 
 As discussed before in section 4.2.1 observation of TTN VOI was of note. In this study, 
TTN missense variants were excluded, due to their currently uncertain interpretation. 
Nevertheless, four heterozygous VOI in TTN were detected. These genetic alterations included 
a frameshift variant, inducing a premature stop of translation and three changes near splice 
sites potentially affecting splicing. One DCM and two RCM cases, observed with VOI in TTN, 
underwent HTX. This may result from a link of TTN truncation with pediatric RCM, eventually 
influenced by a combination of a more complex genetic alteration, and a critical importance of 
both TTN alleles for postnatal development (Peled et al., 2014). In conclusion, VOI in TTN 
were rarely detected in all CMP groups with exceptions in RCM cases. In line with these 
results, former publications showed a much lower frequency of truncating TTN variants in 
pediatric cases with DCM in comparison to adults (Pugh et al., 2014; Fatkin et al., 2016). 
4.2.3 Analysis of segregation in family members 
In 77% of families, the inheritance of genetic alterations and clinical status in first degree 
members was tested. With this approach seven de novo variants (10%) were detected. In 
another study a higher ratio of de novo variants was previously described (Vasilescu et al., 




were reported (median diagnosis age of 0.33 years) and 33% of cases were affected by a 
systemic disorder. Due to numerous de novo variants associated with cardiac disease 
observed as standing variation in ExAC, the association of this type of variant with disease 
onset is questioned. Thus, these alterations are less involved in monogenic disease models or 
present less risk as contributors for cardiac disease (Paludan-Muller et al., 2017). 
4.2.4 Interpretation on genetic variants according to the guidelines of the 
American College of Medical Genetics and Genomics 
In this work the guidelines of the American College of Medical Genetics and Genomics were 
used to interpret the pathogenicity of detected variants (Figure 6, Richards et al., 2015). 
Different aspects influential on the outcome of pathogenicity, like population data, 
computational and predictive data, functional data, segregation data and de novo data, were 
used to evaluate variants. The categories allele data, other databases or other data were not 
included into the evaluation, because these aspects could not be properly applied for this 
cohort. The principle of this method was to activate fields or arguments in the afore mentioned 
sections with graded impacts of the pathogenic character (supporting, moderate, strong and 
very strong). The sum of all arguments then determined the overall pathogenicity of the variant, 
in this work categorized as uncertain (VUS), likely pathogenic (LP) or pathogenic (P). This 
method was developed in 2015 and underwent refinement to the current implication described 
in this chapter. Thus, only the highest argument activated for one section is now counted for 
the interpretation of pathogenicity (Abou Tayoun et al., 2018). 
For population data two points were important. The absence of variants in population 
databases, including rare variants with a minor allele frequency of 0.01% and less, and the 
statistically enriched occurrence of these variants in disease population databases. For the 
first point the MAF was chosen to be lower than 0.1% to exclude variants acting as a modifying 
factor for further analysis. Recent studies showed modifying aspects of variants distinguishing 
a mild phenotype from a severe one (Gifford et al., 2019). Therefore, the threshold for exclusion 
should not be too low. The threshold to activate this field for a moderate pathogenic argument 
was chosen to be 0.01% to consider the prevalence of CMP in the population (Lek et al., 2016: 
rare variant defined with MAF < 0.1%; Kelly et al., 2018: MAF < 0.004% recommend for MYH7 
variants). For the second point disease databases like the Atlas of Cardiac Genetic Variation 
are necessary to calculate statistical values for the enrichment of variants in CMP patients 
(Odds Ratio > 5 is usually used). Data from cohort studies with CMP phenotypes can be used 
additionally to increase statistical relevance. Limitations here are the lack of disease databases 
and missing updates on the existing ones. A Database collecting the sequencing results of 




first approaches were implemented but further refinement is needed (variants listed without 
case numbers or frequency of the detected variant, Landrum & Kattman, 2018). 
The second category, computational and predictive data, is mainly determined by predictive 
online tools and databases. For the supporting argument PP3 the predicted effect of a variant 
was considered for the pathogenicity. Therefore, the procedure was optimized in the way, that 
at least two out of three tools had to predict an altering effect. Thus, different outcome of 
predictive tools were taken into consideration. The moderate arguments PM4 and PM5 as well 
as the strong argument PS1 were conditional on their availability on disease databases. To 
determine the validity for these arguments the occurrence of variants was checked on ClinVar. 
The very strong argument PVS1 depended on available data on loss of function effects of 
genes, when absent or degraded. The knowledge from knockout mice makes it difficult to apply 
if the heterozygous state was not analyzed and limits the possibilities to interpret PVS1. The 
population database gnomAD implemented values on their site to estimate the effect of 
truncating variants in a gene for such circumstances. Thus, the value Probability of being loss-
of-function intolerant (pLI) and the ratio observed single nucleotide variation to expected single 
nucleotide variation (o/e) were introduced. Important here is the occurrence and frequency of 
truncating variants in the population database. Therefore, the observed truncating variants are 
compared to the amount of calculated expected variants resulting in an o/e value or ratio. This 
value is further used to calculate the pLI, which represents the probability of belonging to genes 
affected by haploinsufficiency (Lek et al., 2016). Thresholds for both terms should be chosen 
stringent and it is important to consider protein length for the confidential interval (CI) of o/e . 
GnomAD suggests a threshold for the upper CI<0.35 of the 90% confidential interval and an 
pLI≥0.9. Thus, it is expected, that truncating variants in genes affected by haploinsufficiency 
are less frequent than calculated and the o/e ratio is reduced. As described before published 
data for null variants and haploinsufficiency as well as frequently occurring P and LP truncating 
variants on ClinVar were considered for the activation of the argument PVS1. 
For the section functional data mainly described effects of variants or domains of the affected 
proteins were used to activate the corresponding fields. One exception is the supporting field 
PP2. Similar to PVS1 the calculated value Z-score and o/e of the population database gnomAD 
were used to estimate the effect of missense variants. The suggested threshold for the Z-score 
was ≥3.09 and for the upper 90% CI again <0.35 (Samocha et al., 2014; Lek et al., 2016). For 
functional relevance frequency of pathogenic and benign variants were additionally checked 
on ClinVar when needed. The fields PM1 and PS3 are mainly reliable on literature or 
databases with gathered information taken from published facts regarding the function and 
impact of variants or functional domains. Especially these categories are vaguely defined and 
can be interpreted differently. It can be argued that only distinct results restricted by examined 




experiment would be excluded as false negative. On the other site well characterized functional 
domains can be very long with regions in which variants can be tolerated may resulting in 
variants determined as false positive. Thus, the interpretation of functional data has to become 
more distinct and uniformly assessed. 
In contrast, the sections segregation and de novo data are well defined. For segregation data 
the occurrence of variants in affected family members is determined in meioses. A threshold 
of at least three meioses is considered as describing the supporting character of this argument 
and therefore activated (Kelly et al., 2018). With increasing evidence and higher numbers of 
affected family members carrying the same variant, this argument is gaining more value and 
can be upgraded (≥5 meioses for moderate, ≥8 meioses for strong). Fields regarding the de 
novo character of a variant are similarly dependent on the detection of variants in family 
members. The moderate character of a variant detected only in an affected index patient and 
absent in unaffected parents can be upgraded to strong when paternity is determined. 
In conclusion, Richards et al. introduced a tool to better estimate the pathogenic character of 
genetic alterations. The approach was complex and well thought, but not clear enough in some 
arguments. The availability of new predictive tools and ongoing functional assessment of 
genetic variation is necessary for refinement of this method, but especially functional effects 
of variants are rarely proven and need further investigation before linking more genes to 
specific phenotypes. 
4.2.5 Implications for genetic diagnosis in pediatric cardiomyopathy cohorts 
Whether whole genome sequencing (WGS) or whole exome sequencing (WES) in CMP will 
be used as a diagnostical tool to provide extensive insight into the underlying genotype is 
currently highly debated (Cirino et al., 2017). One major concern in this field is the paucity of 
genetic and functional evidence for variants detected by WGS (Minoche et al., 2019). In 
another study, WES yielded in a diagnosis rate of more than 50% in DCM patients with an 
onset <18 years (Herkert et al., 2018). Other recent publications stated rates of 26% to 39% 
for the identification of pathogenic variants in pediatric CMP (Ouellette et al., 2018; Vasilescu 
et al., 2018). The results of this work suggest genotype determination in pediatric CMP patients 
as soon as possible to induce appropriate therapeutic treatment. Here, a major focus should 
be on sarcomere genes as most frequently group for detected VOI. Therefore, genetic testing 
by NGS improves risk stratification for pediatric CMP patients and can be of much use in 
familial cases to diagnose potential CMP cases exposed to a genetic burden (Wilcox & 
Hershberger, 2018). With this approach the majority of genetic causes for CMP probably will 
be detected, but severe cases with unclear genotypes need further analysis. With increasing 




and WGS becomes demanding (Gifford et al., 2019). Additionally functional analysis of genetic 
alterations have to be implemented more to better understand disease mechanisms and 
improve the interpretation of VOI. 
4.3 Increased numbers of genetic variants in a cardiomyopathy patient 
may present a higher risk factor 
As mentioned before, in 38% of all cases the probability is high, that the genetic basis for the 
development of a CMP was detected with at least one P or LP variant. Concluding this result, 
62% are still unresolved. One explanation could be the occurrence of CMP initiated by 
environmental factors. A virus infection of the myocardium could lead to more severe 
symptoms resulting in a DCM. The involvement of a variant in a gene unknown to have an 
effect on the development of the heart would be another explanation. A third possibility is the 
existence of complex phenotypes. In theory in this scenario not only one variant is the genetic 
basis of the CMP. Thus the monogenic approach is shifting to an oligogenic one. The 
contribution to the cardiac remodeling in these cases is open for discussion and 
experimentation, but Gifford et al. showed in 2019 that at least three variants in cardiac genes 
contributed to the development of a severe LVNC. Patient specific heterozygous missense 
variants in the genes MYH7, myocardin-related transcription factor B (MKL2) and NK2 
homeobox 5 (NKX2-5) led to an early onset of the CMP. Severe events were reported for three 
children, all carrying variants in the afore mentioned genes. The father was asymptotic but 
showed subtle signs of LVNC. He carried the two variants in MYH7 and MKL2, whereas the 
mother, without any signs of CMP, carried a variant in NKX2-5. During whole-exome 
sequencing only variants detected in all three children were included. Further filtering for 
cardiac expression left only three variants, two overlapping with the father in MYH7, MKL2 and 
one overlapping with mother in NKX2-5. The authors augmented with evidence in genetically 
modified mice and human induced pluripotent stem cell–derived cardiomyocytes, that NKX2-
5 operated as a genetic modifier in this case and is therefore lowering the threshold to develop 
the disease and its severity. Of note, the MAF of the variant in NKX2-5 was only 0.0012 and 
would have been sorted out in our cohort. Hence the definition of rare variants should be further 
discussed. 
In the cohort described in this study the number of VOI, including variants determined as VUS, 
P and LP, was correlated with MACE’s in section 3.1.4. Aside from the results that DCM and 
RCM had the most severe disease progression and patients with genetic CMP had worse 
prognosis than sporadic cases, the number of VOI affected the disease progression 




one VOI. This strengthens the hypothesis of oligogenic disease onset and a modifying 
character of some detected genetic alterations. 
4.4 TNNI switch in cases with homozygous TNNI3 variants 
In this study TNNI3 variants were of note, because they were detected quite frequently (six 
VOI, third most frequent gene) and heart tissue of two patients with either DCM (1-II:1, 
p.Arg69Alafs*) or LVNC (2-II:3, c.24+2T>A) carrying homozygous truncating TNNI3 variants 
were available (Table S 8). Heterozygous TNNI3 variants described as disease causing are 
already published in numerous cases with DCM, HCM, and RCM. Nevertheless, homozygous 
alteration of TNNI3 is a rarely described (Burke, Cook, Seidman, & Seidman, 2016). So far, 
three homozygous TNNI3 cases in DCM patients have been reported. These three cases 
comprised the missense variant p.Ala2Val (DCM), the synonymous and exonic splice site 
variant c.G150A (p.Lys50Lys) and a genomic deletion containing the exon 8 of TNNI3 and the 
entire TNNT2 gene (Belkaya et al., 2017; Murphy et al., 2004; Streff et al., 2019). The absence 
of the TNNI3 protein in cardiac tissue was shown in this work for patients carrying homozygous 
and truncating TNNI3 variants. Furthermore, TNNI1 was upregulated probably to compensate 
the lack of TNNI3. The TNNI1 protein presents the fetal isoform of troponin I and therefore 
these results suggest an impairment of TNNI isoform switch form fetal to postnatal cardiac 
development. Thus, the absence of TNNI3 actually resulted in restrained signaling to 
downregulate TNNI1, normally observed in the troponin I switch during postnatal cardiac 
development and human induced pluripotent stem cell–derived cardiomyocytes maturation 
(Bedada et al., 2014; Sasse et al., 1993). Actually, this switch is already described in mice and 
was now proven in human tissue (Huang et al., 1999). It is believed that TNNI1 partly 
compensates the absence of TNNI3 but is also depleted after a certain amount of time. Thus, 
the postnatal heart is functional but is increasingly constrained in its properties over time. Both 
patients carrying homozygous truncating TNNI3 variants were diagnosed with young age (1.1 
and 0.8 years old) and suffered from adverse cardiac events (HTX at 1.8 years of age and 
death after 1.3 years), supporting the afore mentioned model. On molecular level TNNI 
switching regulates Ca2+ sensitivity, the ability to respond to adrenergic stimulation of the 
contractile system and resistance to hypoxia and acidosis (Schiaffino, Gorza, & Ausoni, 1993). 
To conclude, a restrained TNNI1 to TNNI3 switch in CMP patients carrying a truncating and 
homozygous TNNI3 mutation may prevent adequate adaptation to postnatal heart physiology. 
Although the cardiac specific n-terminus mediates interaction with the regulatory n-terminus of 
the cardiac TNNC1 (Hwang, Cai, Pineda-Sanabria, Corson, & Sykes, 2014), its specific role 




In the remaining cases of CMP carrying a heterozygous variant a depletion of TNNI3 and an 
increase of TNNI1 compared to controls was not observed. Thus, different disease 
mechanisms probably determine the progression of the disease in these patients. The onset 
and development of the CMP in these individuals coincides with this statement (onset ≥ 1.8 
years, occurrence of adverse events ≥ 3.4 years, Table S 8). The clustering of VOI near the c-
terminus suggest impaired interaction with other sarcomere genes like TPM1 or cardiac actin 
(ACTC1). At least for patient 3-II:1 mRNA and protein levels were determined but presented 
no clear result. The available heart tissue was limited and therefore protein levels of all 
sarcomere protein remained to be tested. Especially levels of TPM1 and ACTC1 could have 
revealed new functional insights because of reported interaction sites of TNNI3 with these 
proteins (van den Wijngaard et al., 2011; Akhter, Bueltmann, Huang, & Jin, 2014; Zhang, 
Akhter, Mottl, & Jin, 2011). 
4.5 PRDM16 in patients with cardiomyopathy 
 As mentioned before, the rate of pediatric CMP cases with known genotypes does not exceed 
far above 50% for all described disease genes so far. To exceed these limitations, the search 
for such genes is ongoing and the function of many newly described genes is unknown or 
rarely described. Such gene is PRDM16. First described in 2013 in association with CMP the 
cardiac function of this gene remains unknown due to the absence of further publications (Arndt 
et al., 2013). In an approach to determine the minimal overlapping genomic sequence of 1p36 
deletion syndrome patients with CMP involvement, a sequence including PRDM16 exons four 
to 17 was determined. Truncating and missense variants were then observed in patients 
diagnosed with primary non-syndromic DCM and LVNC. In further genetically modified zebra 
fish experiments the effect of a truncating variant on adverse heart development was 
confirmed. In this work PRDM16 was detected as the fourth most frequent gene with 17 VOI 
after MYH7, TTN and MYBPC3 in an extended cardiac phenotype cohort of 285 patients. 
These VOI were not age specific but tended to be detected more often in males. Interestingly 
variants in PRDM16 were detected in all six different phenotypes included in this cohort. Most 
of these patients were affected by LVNC with 8 patients possibly due to the high number of 
LVNC cases recruited in this cohort (6.7% detection rate). For HCM and DCM cases VOI were 
detected in two individuals each. Thus, the rate of PRDM16 variants were lower with 4.2% and 
3.7%. Although two patients carried PRDM16 variants for RCM and ARVC cases the 
population has to be increased to determine statistically relevant terms (RCM: n = 8, ARVC: n 
= 4). The sub cohort of myocarditis only expressed a rate of 1.9%. Nevertheless, these 
observations suggest, that PRDM16 may influence general cardiac disease mechanisms in 




(Kodo et al., 2016; Bjork, Turbe-Doan, Prysak, Herron, & Beier, 2010). Another study predicts 
an increased variant burden for truncating but nor for non-truncating variants due to the number 
of observed rare variants in the population database gnomAD (MAF < 0.0001, Mazzarotto et 
al., 2020). Seven truncating and 1900 non-truncating variants in 120147 alleles in gnomAD 
controls were compared to six truncating and non-truncating variants each detected in 444 
affected LVNC patients using the Fisher’s Exact test. A significant enrichment was determined 
for truncating variants. Similar values can be calculated within the extended cohort of this work. 
Three pathogenic and truncating variants, detected in LVNC patients, are significantly 
enriched, when processed the same way as described in the publication mentioned before (p 
< 0.00001). Therefore, PRDM16 can be described as specific for LVNC cases. The difference 
between truncating and non-truncating variants coincides with the o/e values, Z-scores and 
the pLI for PRDM16 in gnomAD described in section 4.2.4 (Z-score (missense) = 1.35, o/e 
(missense) = 0.87, pLI (truncating) = 1, o/e (truncating) = 0.08). Nevertheless, the impact of 
missense variants in this gene remains unknown and requires more functional insight. So far, 
no homozygous PRDM16 variant was reported. The detection and analysis of such a variant 
could increase insight into the disease mechanism of this gene. At least in mice homozygous 
truncating variants were shown to be lethal in early fetal stages (Bjork, Turbe-Doan, Prysak, 
Herron, & Beier, 2010). 
4.6 Functional data of PRDM16 variants 
The function of PRDM16 was mainly assessed in brown and beige fat tissue and its myoblastic 
precursors (Ohno, Shinoda, Spiegelman, & Kajimura, 2012). Other tissue specific publications 
linked the function of PRDM16 with the processes of hematopoiesis and neurogenesis (Aguilo 
et al., 2011; Baizabal et al., 2018; Chuikov, Levi, Smith, & Morrison, 2010). Until this point 
functional knowledge for PRDM16 in cardiac context is rare and only available from knockout 
experiments in mice, zebra fishes and human induced pluripotent stem cells. Mechanistic 
insights of truncating and non-truncating variants of PRDM16 are unknown. Here, an approach 
was started to investigate the effects of such variants. 
4.6.1  Mutation of PRDM16 affects subcellular localization 
To investigate the subcellular location of PRDM16, HEK293 cells were transfected with 
PRDM16 constructs and immunostained with PRDM16 specific antibodies. In former studies 
PRDM16 was detected in the nucleus supporting a role of PRDM16 as transcriptional regulator 
(Baizabal et al., 2018; Dempersmier et al., 2015). In this work, it is shown, that PRDM16 is not 




publications (Pinheiro et al., 2012). Overexpression of PRDM16 in HEK293 cells showed 
fluorescence signals in the nucleus and the cytoplasm. Thereby, cells were observed with the 
signal entirely in the nucleus, whereas other cells mainly showed PRDM16 expression in the 
cytoplasm. This suggests a cytosolic function of PRDM16 for instance in initial histone 
modification (Pinheiro et al., 2012). Additionally, protein tagged expression of PRDM16 
seemed to shift the signal into the nucleus (EGFP- and FLAG-tag). Therefore, different 
observations were determined with tagged and untagged PRDM16. Results gathered with 
tagged PRDM16 constructs may have to be reevaluated or viewed with caution (e.g. Chen, 
Huang, Pan, Zhu, & Wang, 2018; Takahata et al., 2009). Most work published on PRDM16 so 
far describes knockout approaches or experimentation with overexpressed and tagged 
PRDM16. Endogenous PRDM16 is partly cell type specific and lowly concentrated in cells and 
detection is thus challenging. In this work, to reduce artificial influences the untagged protein 
was used to analyze the expression of PRDM16 in cells. In further experiments, it was shown 
that overexpressed PRDM16 accumulated at the nuclear membrane. In three dimensional 
images the signal of PRDM16 is mainly distributed around the nucleus and not directly located 
within the nucleus. Due to the absence of a nuclear localization sequence, PRDM16 has to 
interact with proteins located to the nucleus. So far interaction with such nuclear localized 
protein was not proven but seems highly regulated with the strong accumulation of PRDM16 
at the nuclear membrane (Figure 25). Otherwise functions outside the nucleus were already 
described (Pinheiro et al., 2012). 
Overexpression of CMP PRDM16 variants revealed different subcellular localization pattern. 
The PRDM16 frameshift variant p.R525Pfs*79 accumulated in the nuclei. Therefore, the 
truncating PRDM16 variant was not eliminated by regulatory mechanisms such as nonsense-
meditated decay (as described before for TNNI3 in this work or MYBPC3, Carrier, Schlossarek, 
Willis, & Eschenhagen, 2010; Seeger et al., 2019). The afore mentioned accumulation may 
induce dysregulated nuclear function and transcription e.g. impaired chromatin or nuclear 
envelope modeling (Pinheiro et al., 2012). The PRDM16 missense variants p.E271K and 
p.P291L were more abundant in the cytoplasm while the variants p.N816S and p.L887P 
accumulated in the nucleus. 
The introduction of truncating and missense variants seems to change properties of the protein 
in such way, that PRDM16 is differently transported through the cell. Therefore, mechanisms 
including methyltransferase activity and methylation of histone 3 outside of the nucleus 
(Pinheiro et al., 2012) or activation of gene expression in the nucleus through transcription 
factors/regulators like mitochondrial brown fat uncoupling protein 1 (UCP1) and PPAR-gamma 
coactivator 1-alpha (PGC1α, Ohno, Shinoda, Spiegelman, & Kajimura, 2012; Dempersmier et 
al., 2015) can be impaired with changed concentrations of PRDM16. In conclusion, these 




4.6.2 N-terminal protein tags and patient-specific cardiomyopathy variants 
influence subcellular localization of PRDMD16 
Using Western blot the expression of the untagged protein was again compared with 
expression of PRDM16 conjugated with n-terminal protein tags (EGFP/FLAG). Of note here 
were the detection of a PRDM16-specific band higher than expected and the occurrence of a 
double band mainly observed in the untagged protein. Due to uniformly loading PRDM16 with 
the detergent SDS during sample preparation, intrinsic features such as charge were 
eliminated (Reynolds & Tanford, 1970; Smith, 1984). Therefore, the observed higher molecular 
weight and the occurrence of double bands were probably associated with post-translational 
modifications. In a former study, SUMOylation of PRDM16 was described to stabilize the 
protein (Chen, Huang, Pan, Zhu, & Wang, 2018). Here, three SUMOylation sites were 
predicted (Figure 20) and one was already published at position p.K915. With 11 kDa the 
difference between expected and appearing bands can be caused by triple SUMOylation (~30 
to 35 kDa), whereas one SUMOylation site would be positioned before the amino acid 525, 
because the frameshift variant was observed with ~10 kDa difference. For the untagged protein 
an additional band was observed with 10 to 20 kDa difference below the corresponding 
PRDM16 bands determined with the tagged protein. The same difference was determined 
before (Chen, Huang, Pan, Zhu, & Wang, 2018). It was suggested that this difference 
represents the shift between a stable and unstable form of PRDM16 due to SUMOylation. An 
antibody for SUMO 2/3 was applied to HEK293 samples with overexpressed PRDM16 but no 
specific band was observed due to complex SUMOylation patterns in the cell (appearance of 
many bands). Co-immunoprecipitation would be an alternative approach to further investigate 
the covalent binding of SUMO. With side-directed mutagenesis predicted SUMOylated amino 
acid residues can be exchanged or deactivated and the distinct SUMOylation sites would be 
exposed. Furthermore, treatment of PRDM16 transfected cells with SUMOylation inhibitors 
can additionally confirm the published data (Chen, Huang, Pan, Zhu, & Wang, 2018). The 
inhibition would result in reduced molecular weight of PRDM16. In vitro experiments in which 
PRDM16 is SUMOylated or deSUMOylated can also end in promising results. Other post-
translational modifications are also possible as predicted in Figure 20, but the change in 
molecular weight is too drastic to be caused by these alterations. With Western blot similar 
results were obtained for the frameshift variant (PRDM16_v3fs). This variant was not degraded 
and therefore not affected by regulatory mRNA or protein degradation (discussed in 4.6.1). 
To investigate differences in expression in the nucleus and cytoplasm the 
corresponding fractions were separated with specific lysis buffers and centrifugation steps for 
each fraction. Because this procedure allows concentration of the lysates, an endogenous 




endogenous PRDM16 seems to be expressed in very low concentrations, although HEK293 
cells are believed to have one of the highest PRDM16 expression levels in cultured cell types 
(Thul et al., 2017, https://www.proteinatlas.org/). In overexpressed form there are at least small 
visible effects, when expressed with missense variants of PRDM16. The expression pattern 
between nucleus and cytoplasm exhibits different amounts of PRDM16 for each fraction and 
also for the upper and lower band of PRDM16, suggesting the variants influence the switch 
between localization in the nucleus or cytoplasm and the stable or unstable form of PRDM16. 
Thus, hyperstabilization of PRDM16 mutants in the nucleus is a possible disease mechanism. 
The experiment was performed at least four times and although the separation worked fine 
(lamin C and β-tubulin bands) the results were too heterogenous to generate a clear result. In 
three of the four experiments the wt was expressed weakly, suggesting more limited and 
unstable expression or more sensitive dose-dependency. 
In conclusion, the introduction of patient-specific variants of PRDM16 in HEK293 cells result 
in changed localization and stabilization properties, but this cell culture approach seems limited 
for the purpose of stable PRDM16 expression for further functional insight. There is evidence, 
that the stability of PRDM16 is controlled by its state of SUMOylation, but further 
experimentation is necessary. 
4.6.3 Patient-specific cardiomyopathy variants influence protein stability of 
PRDM16 
With another approach the protein turnover of PRDM16 was analyzed. The expression of 
PRDM16 transfected cells was inhibited with cycloheximide for different time intervals from 0 
to 24 h. The harvested cells were then analyzed with Western blot and the half-life T1/2 of the 
corresponding protein was determined. The T1/2 for the PRDM16 wt was 7.8 h and is consistent 
with published data (Chen, Huang, Pan, Zhu, & Wang, 2018). Surprisingly, the stability of the 
frameshift variant PRMD16_v3fs was drastically increased with 49.5 h. With such elongation 
the exponential fit is not very accurate, because the curve seems almost linear. To increase 
accuracy the incubation with CHX has to be elongated. These observations suggest 
aggregation of the truncated PRDM16 protein or hyperstabilization after nuclear translocation 
(aggregation in myopathy, Meister-Broekema et al., 2018). These findings are consistent with 
published data, that PRDM16 is regulated by stabilizing processes (Ohno, Shinoda, 
Spiegelman, & Kajimura, 2012; Chen, Huang, Pan, Zhu, & Wang, 2018). As for the other 
constructs an elongation to 10.5 and 12.2 h was observed for variants PRDM16_v4 and 
PRDM16_v5, whereas the half-life of variants PRDM16_v1 and PRDM16_v2 was shortened 
to 4.8 and 2.7 h. When compared with the results presented in Figure 26, similarities can be 




and decreased in stability, whereas for PRDM16_v4 and PRDM16_v5 increased detection was 
observed in the nucleus and PRDM16 carrying these variants seemed more stable. Therefore, 
the stability of PRDM16 probably is associated with localization in the cell. But whether due to 
higher stability more PRDM16 can be transported into the nucleus or due to localization in the 
nucleus the protein is protected from degradation remains unclear. However, the link between 
stability and localization raises the need to understand the implementation of SUMO to stabilize 
the protein. To gain validity, here again, a set of four attempts have been applied, but 
heterogenous results especially for wt did not confirm the determined results. As seen in Figure 
30 the signal detected for PRDM16 seems weak for wt compared to the other variants and 
although the same amounts of protein were applied. Further results for PRDM16_wt were even 
weaker and more difficult to detect, suggesting cytotoxic effects of high PRDM16 
concentrations in the cell. 
To conclude, different variants of PRDM16 resulted in decrease or increase of stability and 
thus an effect of these variants was observed. This suggests similar effects may can be 
observed in patients carrying PRDM16 variants and favor cardiac remodeling. Opposing 
results were observed for the variants PRDM16_v1 and PRDM16_v2 compared to 
PRDM16_v3fs to PRDM16_v5 similarly observed as in localization approaches (Figure 26). 
Therefore, stability can be associated with localization. Nonetheless, one limitation occurred 
repeatedly, affecting the expression of the wt in all experiments, seemingly weakened in almost 
all experiments suggesting some cytotoxic effect of PRDM16 in the cell. 
4.7 Limitations 
With 80 pediatric cases affected by primary CMP more patients than originally planned were 
recruited. Nevertheless, patients with RCM and ARVC were underrepresented in this cohort. 
Furthermore, extension of the families with deep phenotyping if available may increase insight 
into the genetic mechanism and segregation of VOI detected in CMP genes. This would also 
increase the detection of carriers with pathogenic CMP variants and therefore potential CMP 
patients in familial cases. With more segregation data, evidence for the pathogenicity of VOI 
would increase. Although 126 VOI were detected, only 38% of patients were observed with at 
least one P or LP variant. Thus, the genetic basis in 62% of pediatric CMP cases remains 
unclear. To increase this rate whole exome and genome sequencing could be applied to 
identify genetic alteration outside of the selection of disease genes investigated in this work. 
Although the number of variants in possible disease genes would increase, but the functional 
characterization to estimate its pathogenicity and the complexity of the genotype would 
increase too. There are also economic advantages for the panel-based procedure used in this 




the methods. Further insight or elucidation of CMP cases can be gained through investigation 
of complex phenotypes as discussed in 4.3. To better understand disease mechanisms can 
also increase the rate of clarified genotypes. 
Further limitations were presented during pathogenicity assessment using the ACMG 
guidelines (Figure 6, Richards et al., 2015). When released in 2015, many arguments of this 
guideline were phrased with a large range of interpretation. Meanwhile, several studies 
suggested restrictions on the guidelines generating more distinct results (Abou Tayoun et al., 
2018; Kelly et al., 2018; Brnich et al., 2019; Riggs et al., 2020). Prediction tools for this purpose 
are constantly improved and became more precise, but functional data remains essential for 
pathogenicity interpretation of genetic variants. Furthermore, the ACMG needs to address 
distinct regulations on how and when arguments in the category “Functional data” are activated 
and in which degree. Until disease mechanisms are not fully resolved these guidelines have 
to be adapted to the current knowledge. One example for these circumstances are presented 
through the high number of P and LP variants for MYH7 and MYBPC3, functionally better 
characterized than most other CMP genes, and low numbers of P and LP variants in genes 
not well characterized, such as LDB3 or DSP. Another example is the impact of more than one 
modifying variant forming a complex phenotype and initiating a severe phenotype (Gifford et 
al., 2019). 
The main issue for investigating the effects of homo- and heterozygous TNNI3 variants was 
missing heart biopsies. The available tissue was used to determine the amounts of some 
sarcomere and Z-disk genes. With more samples investigation of TNNI3 interaction partners 
could have been extended. Especially for the heterozygous missense variants accumulated at 
the c-terminus of TNNI3 no heart tissue was available and possible changes in interaction with 
described interaction partners like TPM1 and ACTC1 (van den Wijngaard et al., 2011; Akhter, 
Bueltmann, Huang, & Jin, 2014; Zhang, Akhter, Mottl, & Jin, 2011). Further functional analysis 
is required to better understand the adverse influence of these genetic variants. To mimic the 
structural setup of the heart engineered heart tissue (EHT) composed of human induced stem 
cell- derived cardiomyocytes could be used for such purpose. Biopsies of other cell types like 
fibroblasts or peripheral blood can be taken from patients carrying TNNI3 variants and 
differentiated to cardiomyocytes (Takahashi et al., 2007; Yamanaka, 2010; Mannhardt et al., 
2016). In EHT’s force production of the contractile sarcomere system can be measured. 
Additional immunostaining experiments of 2D cardiomyocyte culture may reveal disrupted 
interactions between the sarcomere proteins and give further insights into to the mechanisms 
of the disease onset caused by TNNI3 variants. 
The overexpression of PRDM16 in human cell lines works in principal and promising results 
can be achieved in such settings. Furthermore, PRDM16 expression seems highly regulated. 




knocked out PRDM16 is believed to be dose-dependent to function normally and cytotoxic 
when overdosed or reduced. This suggest, heterozygous knockout and knockin models to 
introduce CMP-specific VOI in animals and cells are better suited to investigate the effects of 
PRDM16 modification. Again, induced pluripotent stem cell-derived cardiomyocytes can be 
used to overcome restrictions to functionally examine PRDM16 variants in similar ways as 
described for TNNI3. Further implementing additional readouts such as increasing reactive 
oxygen species levels would strengthen evidence for the effect of PRDM16 variants (Chuikov, 
Levi, Smith, & Morrison, 2010). Additionally, PRDM16 production in E. coli did not yield 
significant amounts of protein. Therefore, in vitro approaches could not be implemented. For 
in vitro experiments other expression systems like yeast, human cell lines or cell-free 
expression within cell lysates rather than in living cells to decrease cytotoxic effects of PRDM16 
should be tested to gain high yields for PRDM16 (Gregorio, Levine, & Oza, 2019). 
4.8 Outlook 
This study describes the identification of genetic defects in known CMP disease genes and 
performed functional analysis of CMP associated VOI identified in PRDM16. Thus, this work 
covers research on genetic CMP disease mechanisms and biochemical characterization of 
PRDM16. Both areas are of vital interest to explore CMP pathogenesis, appropriately manage 
CMP patients, and to explore translational approaches for diagnosis as well as potential 
therapies. 
This work focused on a relatively large pediatric CMP cohort. Further strengthening of the main 
findings gained in this study can be achieved by expanding the number of DCM, HCM, and 
LVNC patients. Together with advanced clinical characterization this may identify CMP specific 
subgroups that are of either high or low risk to develop severe CMP courses. Such information 
would be critical for appropriated patient management. The relative high number of CMP 
patients without detected VOI can be due to multiple aspects for instance insufficient 
interpretation of VOI, unknown genetic disease mechanisms, genomic alterations affecting 
known disease genes, or oligomeric disease mechanisms. In this regard is the analysis of CMP 
patients without VOI for other genomic alterations a promising approach. WES or WGS will 
facilitate identification of genetic defects in novel CMP disease genes or chromosomal 
alterations affecting non-coding or genomic regions. Improved interpretation of VOI will be 
facilitated by appropriated gene/protein specific assays allowing efficient functional analysis of 
missense variants. This would help to identify critical alterations in vitro or in vivo. 
An interesting aspect of this work is the observation that oligomeric VOI induce more severe 
phenotypes. Oligomeric disease mechanisms or the identification of genetic modifier VOI are 




genetic modifier and their impact on well-defined pathogenic or likely pathogenic CMP VOI. 
Such analysis must be performed in larger cohorts to ensure sufficient power to identify or 
validate candidate VOI. Complementary analysis in vivo or in vitro will be essential to model 
the tissue specific interplay of different VOI. 
Here, PRDM16 was identified as frequently mutated in pediatric and adult CMP. This 
unexpected finding should motivate further biochemical exploration of PRDM16 in the context 
of CMP. The molecular understanding of PRDM16 was mainly achieved from studies in 
adipocytes and adipose tissue. These studies identified PRDM16 as transcriptional integrator 
of critical transcription factors such as C/EBP, CTBP1/2, PGC1b, PPAR, or PPAR (Fog, 
Galli, & Lund, 2012). Moreover, PRDM16 exposes histone H3K4 and H3K9 methyltransferase 
activity regulating chromatin organization and transcriptional programs (Pinheiro et al., 2012; 
Zhou et al., 2016). The activity of transcriptional programs is highly specific in postmitotic 
cardiomyocytes. Thus, identification of chromatin regions controlled by PRDM16 and 
epigenetic marks in heart tissue is of critical value for further understanding of PRDM16 in the 
heart. Another aspect of transcriptional mechanisms inducing CMP is their activation during 
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Table S 1: CMP-relevant Genes and classification into functional groups 
Functional 
classification Gene name Gen Protein 
Chromo- 
some Transcript ID Exon Function  
Sarcoplasmic 
reticulum 
calreticulin 3 CALR3 CALR3 Chr19 ENST00000269881  
NM_145046 
9 Ca2+ binding protein within SR 
 dolichol kinase DOLK DOLK Chr9 ENST00000372586 
NM_014908 
1 dolichol kinase within SR; involved in GPI-
anchor, N- and O-linked protein 
glycosylation  
 phospholamban PLN PLN Chr6 ENST00000357525 
NM_002667 
2 regulation of cardiac ATP2A2 Ca2+ ATPase, 
critical regulator Ca2+ homeostasis 
 ryanodine receptor 2 RYR2 RYR2 Chr1 ENST00000366574 
NM_001035.2 
105 Ca2+ channel releasing Ca2+ from SR into 
cytoplasm, regulation of cardiomyocyte 
contractility 
Sarcolemma ATP binding cassette 
subfamily C member 9 




38 regulation of KCNJ11 potassium channel 
 caveolin 3 CAV3 CAV3 Chr3 ENST00000343849 
NM_033337 
2 scaffolding protein of caveolae, regulation of 
G-protein alpha subunits and potassium 




potassium channel 4 
HCN4 HCN4 Chr15 ENST00000261917 
NM_005477.2 
8 hyperpolarization-activated ion channel with 
slow activation and inactivation, exhibiting 
weak selectivity for potassium over sodium 
ions, cAMP regulated 
 hemochromatosis HFE HFE Chr6 ENST00000357618 
NM_000410.3 
5 transferrin receptor binding, regulation 
endocytosis of iron loaded transferrin 
 junctophilin-2 
 
JPH2 JPH2 Chr20 ENST00000372980 
NM_020433.4 
6 formation of junctional membrane complexes 
between plasma membrane and SR, 
regulator of Ca2+ signaling  
 sodium channel protein 
type 5 subunit alpha 
SCN5A SCN5A Chr3 ENST00000413689 
NM_001099404.1 
28 mediates voltage-dependent Na+ 
permeability of excitable membranes 
Z-disc actinin alpha 2 ACTN2 ACTN2 Chr1 ENST00000366578 
NM_001103.2 




 ankyrin repeat domain 
1 
ANKRD1 ANKRD1 Chr10 ENST00000371697 
NM_014391.2 
 
9 myofibrillar stretch-sensor Z-disc, 
transcription factor that negatively regulates 
cardiac gene expression 
 cysteine and glycine 
rich protein 3 
CSRP3 CSRP3 Chr11 ENST00000533783 
NM_003476 
7 scaffolding protein at Z-disc, actin binding, 
regulation of actin dynamics myogenic 
transcriptional cofactor 
 four and a half LIM 
domains 1 
FHL1 FHL1 ChrX ENST00000394155 
NM_001159702.2 
8 mechanosensor at Z-disc, transcriptional 
cofactor 
 four and a half LIM 
domains 2 
FHL2 FHL2 Chr2 ENST00000344213 
NM_201555.1 
7 mechanosensor at Z-disc, transcriptional 
cofactor 




14 Interaction with actin, stabilization sarcomere 
during contraction 
 myozenin 2 MYOZ2 MYOZ2 Chr4 ENST00000307128 
NM_016599.4 
6 Z-disc organization by interaction with 
several proteins, myofibrillogenesis, 
calcineurin signaling 
 myopalladin MYPN MYPN Chr10 ENST00000358913 
NM_032578 
20 scaffold at Z-disc; binds nebulette, nebulin, 
-actinin 
 nexilin F-actin binding 
protein 
NEXN NEXN Chr1 ENST00000334785 
NM_144573.3 
13 F-actin binding, maintenance Z-disc and 
sarcomere integrity 
 PDZ and LIM domain 3 PDLIM3 PDLIM3 Chr4 ENST00000284770 
NM_014476 
7 crosslinking of F-actin with -actinin-2 
 titin-cap, telethonin TCAP TCAP Chr17 ENST00000309889 
NM_003673 
2 binds titin at Z-disc, part of mechanosensing 
system, interaction of Z-disc and T-tubules  
 vinculin VCL VCL Chr10 ENST00000211998 
NM_014000.2 
22 F-actin binding, mechanosensing, cell-matrix 
and cell-cell adhesion, linker of Z-disc 
proteins to catenin cadherin dystroglycan 
Sarcomere 
thick filament 
myosin binding protein 
C, cardiac 
MYBPC3 MYBPC3 Chr11 ENST00000545968 
NM_000256.3 
35 integrates myosin heavy chain and F-actin, 
modulation of muscle contraction and 
sarcomere organization 




39 major component of cardiac muscle thick 
filament, muscle contraction, fast myosin 








40 major component of cardiac muscle thick 
filament, muscle contraction, slow myosin 
isoform, ATPase activity 
 myosin light chain 2 MYL2 MYL2 Chr12 ENST00000228841 
NM_000432.3 
7 stabilizes S1 neck region of myosin heavy 
chain  
 myosin light chain 3 MYL3 MYL3 Chr3 ENST00000292327 
NM_000258.2 
7 stabilizes S1 neck region of myosin heavy 
chain  
 myosin light chain 
kinase 2 
MYLK2 MYLK2 Chr20 ENST00000375985 
NM_033118.3 
13 essential for muscle contraction cycle, 
phosphorylates specific position of myosin 
light chain 
 titin TTN  TTN Chr2 ENST00000589042 
NM_001267550.1 
363 central sarcomere scaffolding protein 
required for assembly, protein interaction 
platform, regulation of sarcomere resting 
length and passive stiffness  
Sarcomere 
thin filament 
actin, alpha 1, skeletal 
muscle 
ACTA1 ACTA1 Chr1 ENST00000366684 
NM_001100 
6 globular G-actin form F-actin fibers; essential 
part of the contractile apparatus thin filament 
 actin, alpha, cardiac 
muscle 1 
ACTC1 ACTC1 Chr15 ENST00000290378 
NM_005159.4 
7 globular G-actin form F-actin fibers; essential 
part of the contractile apparatus thin filament 
 troponin C1, slow 
skeletal and cardiac 
type 
TNNC1 TNNC1 Chr3 ENST00000232975 
NM_003280.2 
6 binds the switch region of troponin I in a Ca2+ 
dependent manner to activate contraction  
 troponin I3, cardiac 
type 
TNNI3 TNNI3 Chr19 ENST00000344887 
NM_000363.4 
8 inhibitory subunit of troponin, regulation thin 
filament Ca2+ sensitivity  
 troponin T2, cardiac 
type 
TNNT2 TNNT2 Chr1 ENST00000236918 
NM_001276345 
16 binding of troponin complex to tropomyosin  
 tropomyosin 1 TPM1 TPM1 Chr15 ENST00000403994 
NM_001018005.1 
9 coiled coil protein that lies along thin filament 
and blocks myosin binding sites on actin 
under resting calcium concentrations  
Nuclear 
envelope 
emerin EMD EMD ChrX ENST00000369842 
NM_000117 
6 formation and stabilization of cortical nuclear 
actin network, cellular signaling 
 lamin A/C LMNA LMNA Chr1 ENST00000368300 
NM_170707.3 
12 nuclear lamina and chromatin organization, 




 transmembrane protein 
43 
TMEM43 TMEM43 Chr3 ENST00000306077 
NM_024334.2 
12 nuclear envelope structure at inner nuclear 
membrane, interaction with emerin, 
mechanotransduction, gene expression 
Mitochondria cytochrome c oxidase 
assembly homolog 
COX15 COX15 Chr10 ENST00000370483 
NM_001320975 
9 heme A biosynthesis, porphyrin synthesis 
 DnaJ heat shock 






6 peptide translocation inner membrane to 
matrix, subunit of HSP40/HSP70 complex, 
mitochondrial chaperone 
 frataxin FXN FXN Chr9 ENST00000377270 
NM_000144 
5 heme biosynthesis, protection against iron-






protein), alpha subunit 
HADHA HADHA Chr2 ENST00000380649 
NM_000182 
20 fatty acid beta-oxidation and in lipid 
metabolism 
 cytochrome c oxidase 
assembly protein 
SCO2 SCO2 Chr22 ENST00000252785  
NM_001169111 









15 complex II mitochondrial electron transport 
chain, transfer of electrons from succinate to 
ubiquinone, involved tricarboxylic acid cycle 
 tafazzin TAZ TAZ ChrX ENST00000601016 
NM_000116 
11 synthesis/remodeling of cardiolipin, 
phospholipid-lysophospholipid transacylase, 
important for mitochondrial energy 
production 
Desmosome desmocollin 2 DSC2 DSC2 Chr18 ENST00000280904 
NM_024422 
16 part of desmosome junctions, cell-cell 
adhesion, interaction intermediate filaments 
 desmoglein 2 DSG2 DSG2 Chr18 ENST00000261590 
NM_001943.3 
15 part of desmosome junctions, cell-cell 
adhesion, interaction intermediate filaments 
 desmoplakin DSP DSP Chr6 ENST00000379802 
NM_004415.2 
24 anchoring of intermediate filaments to 
desmosomes, essential for desmosomal 
plaque formation 
 plakophilin 2 PKP2 PKP2 Chr12 ENST00000070846 
NM_004572.3 
14 links cadherins to intermediate filaments, 





 junction plakoglobin JUP JUP Chr17 ENST00000393931 
NM_002230.2 
14 cytoplasmic component of desmosomes, 







EYA4 EYA4 Chr6 ENST00000355167 
NM_172105.3 
20 tyrosine phosphatase of histone H2AX; 
impact for DNA repair, stress response and 
apoptosis 
 GATA zinc finger 
domain containing 1 
GATAD1 GATAD1 Chr7 ENST00000287957 
NM_021167 
5 part of chromatin complex recruited to 
methylated H2K4me 
 NK2 homeobox 5 NKX2-5 NKX2-5 Chr5 ENST00000329198 
NM_004387.3 
2 transcriptional activation of myocardial 
lineage together with GATA4, 
transcriptionally controlled by PBX1 




17 transcriptional regulator of adipocyte 
development, interaction e.g. PPAR, 
C/EBP and PGC1, regulator of TGF- 
signaling, has histone methyltransferase 
activity (H3K9me1, H3K9me3) 
 RNA binding motif 
protein 20 
RBM20 RBM20 Chr10 ENST00000369519 
NM_001134363.1 
14 mRNA splicing regulator of a specific target 
genes, important regulator of TTN slicing 
 T-box 20 TBX20 TBX20 Chr7 ENST00000408931 
NM_001077653.2 
8 transcriptional activator/repressor in cardiac 
development, interacts with GATA4 and 
NKX2-5, repression of TBX2 
Dystrophin 
complex 
desmin DES DES Chr2 ENST00000373960 
NM_001927.3 
9 intermediate filament; connecting Z-discs, 
sarcomere, sarcolemmal cytoskeleton, 
nucleus and mitochondria; sarcomeric 
microtubule anchor 
 dystrophin DMD DMD ChrX ENST00000357033 
NM_004006.2 
79 anchors ECM to F-actin cytoskeleton, ligand 
dystroglycan 
 dystrobrevin alpha DTNA DTNA Chr18 ENST00000444659 
NM_001390.4 
22 interacts with dystrophin 
 sarcoglycan beta SGCB SGCB Chr4 ENST00000381431 
NM_000232.4 
6 linker between F-actin and ECM 
 sarcoglycan delta SGCD SGCD Chr5 ENST00000435422 
NM_000337.5 
8 linker between F-actin and ECM 
 sarcoglycan gamma SGCG SGCG Chr13 ENST00000218867 
NM_000231 









BRAF BRAF Chr7 ENST00000288602 
NM_004333.4 
 
18 phosphorylates MAP2K1, part of MAPK 
signaling pathway, transmission of mitogenic 
signals 
 CBL proto-oncogene CBL CBL Chr11 ENST00000264033 
NM_005188.3 
 
16 E3 ubiquitin-protein ligase, ubiquitination → 
degradation, negative regulator of cell 
surface receptors e.g. FGFR1/2, EGFR, KIT  
 HRAS proto-oncogene, 
GTPase 
HRAS HRAS  Chr11 ENST00000610977 
NM_001130442 
5 small GTPase, RAS signaling pathway, 
growth factor signaling 
 KRAS proto-oncogene, 
GTPase 
KRAS KRAS Chr12 ENST00000311936 
NM_004985 
5 small GTPase, RAS signaling pathway, 
growth factor signaling, regulating cell 
proliferation, critical for tumor development 
 mitogen-activated 





11 essential component of MAPK pathway, 
growth factor signaling, regulating diverse 
cellular functions, upstream activated by 
RAF1, downstream activation of ERK1/2 
 mitogen-activated 





11 essential component of MAPK pathway, 
growth factor signaling, regulating diverse 
cellular functions, upstream activated by 
RAF1, downstream activation of ERK1/2 
 mindbomb E3 ubiquitin 
protein ligase 1 
MIB1 MIB1 Chr18 ENST00000261537 
NM_020774 
21 ubiquitination of Delta receptors, positively 
regulates the Delta-mediated Notch 
signaling  
 NRAS proto-oncogene, 
GTPase 
NRAS NRAS Chr1 ENST00000369535 
NM_002524 
7 small GTPase, RAS signaling pathway, 
growth factor signaling, regulating cell 
proliferation, critical for tumor development 
 protein kinase AMP-
activated non-catalytic 
subunit gamma 2 
PRKAG2 PRKAG2 Chr7 ENST00000287878 
NM_016203.3 
16 AMP/ATP-binding subunit of AMPK, 
regulation of cellular energy metabolism by 




 protein tyrosine 
phosphatase, non-
receptor type 11 
PTPN11 PTPN11 Chr12 ENST00000635625 
NM_001330437 
15 regulator unfolded protein response in ER, 
dephosphorylation EIF2AK3/PERK, tumor 
development 
 Raf-1 proto-oncogene, 
serine/threonine kinase 
RAF1 RAF1 Chr3 ENST00000251849 
NM_002880.3 
17 serine/threonine-protein kinase linking 
membrane-associated RAS GTPases with 
MAPK signaling, key regulator of cell fate  
 SHOC2, leucine rich 
repeat scaffold protein 
SHOC2 SHOC2 Chr10 ENST00000369452 
NM_007373.3 
9 regulatory subunit of protein phosphatase 1, 
activation of RAF1 kinase, MAPK signaling 
pathway activation, growth factor signaling 
 SOS Ras/Rac guanine 
nucleotide exchange 
factor 1 
SOS1 SOS1 Chr2 ENST00000402219 
NM_005633.3 
23 guanine nucleotide exchange factor (GEF) 
for RAS GTPases, promotion of RAS 
activation, regulates MAPK3 phosphorylation 
 transforming growth 
factor beta 3 
TGFB3 TGFB3 Chr14 ENST00000238682 
NM_003239.2 
7 regulates mesenchymal development, 







BAG3 BAG3 Chr10 ENST00000369085 
NM_004281.3 
4 activator of autophagy and HSP70 
chaperone system, nucleotide exchange 
factor HSP70 complex, adaptor protein 




4 detection of misfolded proteins, targeting to 
the HSP70 complex, prevention of protein 
aggregate formation, cardioprotective, 
stabilization of cyto- and nucleoskeleton, 
stress inducible 
 heat shock protein 






3 detection of misfolded proteins, induction of 
autophagy, prevention of protein aggregate 
formation, chaperone activity, disassembly 




fibrillin 1 FBN1 FBN1 Chr15 ENST00000316623 
NM_000138.4 
66 structural component of 10-12 nm diameter 
ECM microfibrils, structural and regulatory 
function in load-bearing connective tissue, 




 laminin subunit alpha 2 LAMA2 LAMA2 Chr6 ENST00000421865 
NM_000426.3 
65 ECM glycoprotein, mediates interaction to 
dystrophin complex 
 laminin subunit alpha 4 LAMA4 LAMA4 Chr6 ENST00000230538 
NM_001105206.2 




fukutin FKTN FKTN Chr9 ENST00000223528 
NM_006731 
10 biosynthesis of phosphorylated O-mannosyl 
trisaccharide, required for -dystroglycan 
synthesis, protein glycosylation 
 fukutin related protein FKRP FKRP Chr19 ENST00000318584 
NM_001039885 
4 biosynthesis of phosphorylated O-mannosyl 
trisaccharide, required for -dystroglycan 
synthesis, protein glycosylation 
Cytoskeleton Alstrom syndrome 
protein 1 
ALMS1 ALMS1 Chr2  ENST00000613296  
NM_015120.4 
23 centrosome and basal body associated 
protein, pericentriolar and cilia transport, 




glucosidase alpha, acid GAA GAA Chr17 ENST00000302262 
NM_000152 
20 hydrolysis of lysosomal glycogen to glucose 
 galactosidase alpha GLA GLA ChrX ENST00000218516 
NM_000169 
7 hydrolysis of -D-galactose residues in -D-
galactosides 
 lysosomal associated 
membrane protein 2 
LAMP2 LAMP2 
CD107b 
ChrX ENST00000434600  
NM_001122606.1 
9 binding of target protein and delivery to 
lysosomes, protein degradation, required 
fusion autophagosomes and lysosomes, 
antigen presentation  
Others transthyretin  TTR TTR Chr18 ENST00000237014 
NM_000371.3 
 
4 thyroid hormone-binding protein, transport of 






Table S 2: Scheme to interpret the pathogenicity of genetic variants according to guiedelines of the ACMG given by the publication. For each category (population data, 
etc.) the strongest argument will be activated for each variant. The sum of arguments in all categories is determining the pathogenicty of a genetic variant (Figure S 1). 
Diagnosis Supporting Moderate Strong Very strong Conclusion 
Population data 
 
Absent or low MAF in 
gnomAD/population 
databases PM2 
Prevalence in affecteds 
statistically increased 






Multiple lines of 
computational evidence 
support a deleterious effect 
on the gene /gene product 
PP3 
Novel missense change at 
already as pathogenic 
described amino acid PM5 
Protein length changing 
variant PM4 
Same amino acid change 
as an established 
pathogenic variant PS1 
Predicted null variant 
in a gene where LOF 
is a known mechanism 
of disease PVS1 
Functional data Missense in gene with few 
benign and lots of path. 
missense variants PP2 
Mutational hot spot or well-
studied functional domain 
without benign variation PM1  
Well-established 





Cosegregation with disease 
in multiple affected family 
members PP1 
Increased segregation data More increased 
segregation data 
 
De novo data 
 
De novo (without paternity & 
maternity confirmed) PM6 
De novo (paternity and 







Table S 3: Scheme to interpret the pathogenicity of genetic variants according to guiedelines of the ACMG in optimized form (description see Table S 2).  
Diagnosis Supporting Moderate Strong Very strong Conclusion 
Population data 
 
PM2 check MAF and only 
include variants with MAF < 
0.0001 
PS4 activate with 
calculated OR > 5, 
cohorts from literature + 
ACGV for affected and 








HSF → run prediction tools 
(requirement for splice site 
variants in PM4) 
PM5 check ClinVar for P/LP 
variants at same aa position 
PM4 coding sequence: be 
aware of small deletions in aa 
repeats; splice site: PP3 
positive as requirement 
PS1 check ClinVar for 
P/LP variant with same 
aa exchange 
PVS1 use o/e ratio 
(upper CI < 0.35) or pLI 
(≥ 0.9) from gnomAD; 
check ClinVar for 
truncating variants; 
check literature for LoF 
Functional data PP2 use o/e ratio (upper CI 
< 0.35) or Z-score (> 3.09) 
from gnomAD; check 
ClinVar for missense 
variants; check literature 
PM1 check ClinVar/literature 
for influence of missense 
variation 








PP1 Variant segregates in ≥ 
3 meioses (every affected 
member!) 
PP1 Variant segregates in ≥ 5 
meioses (every affected 
member!) 
PP1 Variant segregates 
in ≥ 8 meioses (every 
affected member!) 
 
De novo data 
 
De novo (without paternity & 
maternity confirmed) PM6 
De novo (paternity and 






Figure S 1: Counting scheme to interpret the pathogenicity of genetic variants according to the ACMG 




Table S 4: Detection of genetic VOI from 80 index patients with pediatric CMP 














Pathogenic and likely pathogenic genetic variants 
ACTC1 NM_005159.4 c.328G>A p.A110T DCM, HTX CMP-77 0 
Likely pathogenic 
(PM2, PM6, PP2-3) 
yes no 
ACTN2 NM_001103.2 c.574C>T p.R192* LVNC, HTX CMP-10 0.000008122 
Pathogenic 
(PVS1, PM2, PM6) 
yes yes 
DSC2 NM_024422.3 c.1034T>C p.I345T ARVC CMP-33 0.000008133 
Likely pathogenic 
(PS3, PM2, PP3) 
no no 




LAMP2 NM_001122606.1 c.222_223delTA p.Y74* HCM  0 
Pathogenic 











 NM_000256.3 c.927-2A>G - HCM CMP-31 0.00003235 
Pathogenic 
(PS3-4, PM4, PP1) 
no no 








 NM_000256.3 c.2308G>A p.D770N HCM CMP-69 0.00001625 
Pathogenic 
(PS1, PS4, PM1) 
no no 
 NM_000256.3 c.2572A>C p.S858R DCM, HTX CMP-09 0 
Likely pathogenic 
(PS2, PM2, PM5) 
? yes 
MYH7 NM_000257.2 c.677C>T p.A226V HCM  0 
Likely pathogenic 
(PS4, PM1, PP3) 
? no 
 NM_000257.2 c.1063G>A p.A355T HCM CMP-22 0 
Pathogenic 
(PS1, PS4, PM1) 
? no 
 NM_000257.2 c.1283C>A p.A428D LVNC CMP-27 0 
Likely pathogenic 
(PM1-2, PP1, PP3) 
no yes 




 NM_000257.2 c.1987C>T p.R663C HCM CMP-28 0 
Pathogenic 
(PS1, PS4, PM2) 
no no 
 NM_000257.2 c.1988G>A p.R663H HCM CMP-43 0.00001443 
Pathogenic 
(PS1, PS4, PM1) 
? no 
 NM_000257.2 c.2710C>T p.R904C DCM CMP-44 0.000004061 
Pathogenic 
(PS1, PS4, PM1) 
? no 




PRKAG2 NM_016203.3 c.1199C>A p.T400N HCM  0 
Pathogenic 









TNNI3 NM_000363.4 c.24+2T>A (homozygous) - LVNC CMP-01 0.00001254 
Pathogenic 
(PVS1, PS3, PM2) 
? yes 




 NM_000363.4 c.574C>T p.R192C RCM, HTX CMP-58 0 
Pathogenic 
(PS1, PS3-4, PM2, PM6) 
yes no 
 NM_000363.4 c.582C>A p.N194K DCM CMP-80 0 
Pathogenic 
(PS1, PM1-2, PM6) 
yes no 
 NM_000363.4 c.624dupT p.E209* RCM, HTX CMP-29 0 
Likely pathogenic 
(PM1-2, PM4, PM6) 
yes yes 




 NM_000364 c.620-622delAGA p.K207del DCM, HTX CMP-74 0 
Pathogenic 
(PS1, PM1-2, PM6) 
yes no 
 NM_000364.2 c.812+1G>A - HCM  0 
Pathogenic 
(PS1, PS3, PM2) 
no no 
TPM1 NM_001018005.1 c.257C>T p.A86V LVNC CMP-34 0 
Likely pathogenic 
(PM1-2, PP1_moderate, PP3) 
no yes 








Genetic variants of uncertain significance (VUS) 
ACTN2 NM_001103.2 c.278G>A p.R93Q LVNC CMP-24 0.00002525 Uncertain significance no no 
BAG3 NM_004281.3 c.280A>T p.I94F DCM  0.0006493 Uncertain significance ? no 
 NM_004281.3 c.881G>A p.R294H DCM, HTX  0.00003663 Uncertain significance ? no 
 NM_004281.3 c.1634C>G p.P545R DCM  0.00009385 Uncertain significance no no 
CBL NM_005188.3 c.805A>G p.M269V LVNC CMP-24 0.00001218 Uncertain significance no yes 
DMD NM_004006.2 c.2169-7_2169-4delGTCT - HCM CMP-43 0.00003417 Uncertain significance ? no 
 NM_004006.2 c.2273A>C p.D758A RCM, HTX CMP-25 0.0002632 Uncertain significance no yes 
 NM_004006.2 c.5723A>T p.D1908V HCM, HTX  0.0002101 Uncertain significance no yes 
 NM_004006.2 c.8996C>T p.A2999V RCM, HTX CMP-29 0.0000112 Uncertain significance no yes 
DSC2 NM_024422.3 c.304G>A p.E102K DCM  0.0007482 Uncertain significance no no 




 NM_024422.3 c.802A>G p.T268A DCM  0.0001444 Uncertain significance no no 
DSG2 NM_001943.3 c.1003A>G p.T335A DCM  0.0005089 Uncertain significance ? no 
 NM_001943.3 c.2001+3C>G - LVNC  0.000008136 Uncertain significance no yes 
DSP NM_004415.2 c.2774G>A p.R925Q RCM, HTX  0.0002309 Uncertain significance no no 
 NM_004415.2 c.4961T>C p.L1654P LVNC, HTX  0.00002849 Uncertain significance no no 
 NM_004415.2 c.5178C>A p.N1726K DCM, HTX  0.0006893 Uncertain significance no no 
 NM_004415.2 c.7916G>A p.R2639Q DCM, HTX CMP-74 0.000853 Uncertain significance no no 
 NM_004415.2 c.7994C>T p.T2665M DCM CMP-80 0.00004338 Uncertain significance no no 
 NM_004415.2 c.8524C>T p.R2842C HCM CMP-69 0.000007384 Uncertain significance no no 
DTNA NM_001390.4 c.1757C>T p.P586L HCM  0.0001263 Uncertain significance no no 
EYA4 NM_172105.3 c.59A>G p.D20G RCM  0.000008132 Uncertain significance ? no 
 NM_172105.3 c.971-3T>C - LVNC, HTX CMP-10 0.00006461 Uncertain significance no yes 
FBN1 NM_000138.4 c.902G>T p.G301V DCM, HTX  0.0001876 Uncertain significance ? no 
FHL1 NM_001159702.2 c.283C>T p.R95W HCM  0.0006232 Uncertain significance no no 
FHL2 NM_201555.1 c.143G>A p.G48D DCM  0 Uncertain significance no yes 
 NM_201555.1 c.337C>T p.R113C DCM  0.000395 Uncertain significance ? no 
JPH2 NM_020433.4 c.572C>G p.P191R DCM  0.0005276 Uncertain significance no no 
 NM_020433.4 c.1306C>T p.R436C DCM  0.00003236 Uncertain significance no no 
 NM_020433.4 c.1896G>C p.E632D RCM, HTX CMP-58 0.00007797 Uncertain significance no no 
JUP NM_002230.2 c.1714C>T p.R572W DCM, HTX CMP-09 0.00001219 Uncertain significance ? no 
LAMA4 NM_001105206.2 c.514G>A p.G172S HCM CMP-69 0.0002224 Uncertain significance ? no 
 NM_001105206.2 c.1959T>C p.D653 ARVC CMP-33 0.0009604 Uncertain significance no yes 
 NM_001105206.2 c.2171G>A p.R724K DCM, HTX CMP-12 0.0007326 Uncertain significance ? yes 
 NM_001105206.2 c.4645A>T p.N1549Y HCM  0.0001988 Uncertain significance ? yes 




 NM_001171610.1 c.664G>A p.A222T HCM CMP-42 0.0003646 Uncertain significance ? no 
 NM_001171610.1 c.778G>A p.G260S DCM  0.0000469 Uncertain significance ? yes 
 NM_001171610.1 c.982G>A p.A328T LVNC CMP-34 0.000004062 Uncertain significance no yes 
 NM_007078 c.1792T>C p.C598R HCM CMP-31 0 Uncertain significance no yes 
 NM_001171610.1 c.1978C>A p.P660T HCM CMP-22 0.000007219 Uncertain significance no yes 
LMNA NM_170707.3 c.986G>C p.R329P HCM CMP-22 0 Uncertain significance ? yes 
MYBPC3 NM_000256.3 c.961G>A p.V321M DCM  0.0003261 Uncertain significance no no 
 NM_000256.3 c.2873C>T p.T958I HCM CMP-42 0.000156 Uncertain significance ? no 
MYH6 NM_002471.3 c.3010G>T p.A1004S HCM CMP-43 0.0009523 Uncertain significance ? no 
 NM_002471.3 c.5348G>A p.R1783H HCM  0.00003248 Uncertain significance no no 
MYH7 NM_000257.2 c.475G>A p.D159N LVNC, HTX  0 Uncertain significance ? yes 
 NM_000257.2 c.1425G>T p.Q475H LVNC  0 Uncertain significance no no 
 NM_000257.2 c.2890G>C p.V964L DCM  0.0004256 Uncertain significance no no 
 NM_000257.2 c.3169G>A p.G1057S HCM  0.000008121 Uncertain significance no no 
 NM_000257.2 c.4501G>T p.E1501* DCM  0 Uncertain significance no yes 
 NM_000257.2 c.5767A>G p.K1923E DCM  0 Uncertain significance ? yes 
MYL2 NM_000432.3 c.421G>A p.A141T DCM, HTX  0 Uncertain significance ? no 
MYLK2 NM_033118.3 c.4G>A p.A2T DCM, HTX CMP-77 0.0009884 Uncertain significance no no 
 NM_033118.3 c.425G>T p.G142V LVNC, HTX CMP-10 0.00008924 Uncertain significance no yes 
MYOZ2 NM_016599.4 c.659T>C p.M220T HCM CMP-22 0 Uncertain significance no yes 
MYPN NM_001256267.1 c.259C>G p.P87A DCM  0.0000433 Uncertain significance no no 
 NM_001256267.1 c.802C>T p.P268S RCM, HTX CMP-58 0.0004756 Uncertain significance no no 
 NM_001256267.1 c.970C>T p.H324Y HCM CMP-28 0 Uncertain significance no yes 
 NM_001256267.1 c.2150C>T p.T717M DCM, HTX  0.00004467 Uncertain significance ? yes 




NEXN NM_144573.3 c.893C>G p.T298R HCM CMP-42 0.0001605 Uncertain significance ? no 
 NM_144573.3 c.1572_1574delAGA p.E525del DCM, HTX  0.0001556 Uncertain significance ? yes 
 NM_144573.3 c.1572_1574delAGA p.E525del DCM CMP-01 0.0001556 Uncertain significance ? yes 
 NM_144573.3 c.1619T>C p.M540T DCM, HTX  0.000004072 Uncertain significance ? yes 
NKX2-5 NM_004387.3 c.355G>T p.A119S DCM  0.0009725 Uncertain significance no no 
PKP2 NM_004572.3 c.1536T>A p.N512K DCM, HTX  0.00001446 Uncertain significance no yes 
 NM_004572.3 c.2200A>G p.T734A DCM, HTX  0.00001083 Uncertain significance ? no 
 NM_004572.3 c.2365A>G p.I789V DCM  0.0003105 Uncertain significance ? yes 
PRDM16 NM_022114.3 c.1110C>A p.D370E LVNC, HTX  0.000004112 Uncertain significance ? yes 
 NM_022114.3 c.2296G>A p.G766S HCM CMP-22 0.0002788 Uncertain significance ? no 
 NM_022114.3 c.2372G>A p.G791D RCM, HTX  0 Uncertain significance no yes 
 NM_022114.3 c.2447A>G p.N816S RCM, HTX CMP-25 0.0002405 Uncertain significance no no 
RAF1 NM_002880.3 c.974A>C p.Q325P DCM CMP-44 0.00001804 Uncertain significance ? no 
RBM20 NM_001134363.1 c.298C>T p.L100F DCM  0 Uncertain significance no yes 
RYR2 NM_001035.2 c.1699G>C p.A567P DCM, HTX  0.000008299 Uncertain significance ? yes 
 NM_001035.2 c.4273A>G p.T1425A HCM CMP-38 0.00005876 Uncertain significance ? no 
 NM_001035.2 c.8162T>C p.I2721T HCM  0.0005919 Uncertain significance no no 
 NM_001035.2 c.9655G>A p.V3219M DCM  0.00007581 Uncertain significance ? no 
SCN5A NM_001099404.1 c.998+5G>A - DCM  0.000213 Uncertain significance ? no 
 NM_001099404.1 c.1577G>A p.R526H HCM  0.00006255 Uncertain significance ? no 
SOS1 NM_005633.3 c.3841_3843dupAAG p.E1281dup DCM CMP-01 0.000004065 Uncertain significance ? yes 
TAZ NM_000116.3 c.29C>G p.P10R LVNC CMP-24 0 Uncertain significance ? yes 
TBX20 NM_001077653.2 c.208G>A p.G70S DCM  0 Uncertain significance no yes 
 NM_001077653.2 c.994C>T p.P332S DCM, HTX  0.0000366 Uncertain significance no yes 




TMEM43 NM_024334.2 c.1177C>T p.R393W LVNC  0.000008133 Uncertain significance no yes 
TNNC1 NM_003280.2 c.25G>A p.V9I DCM, HTX  0 Uncertain significance ? yes 
TNNI3 NM_000363.4 c.307C>T p.R103C HCM CMP-22 0.000007216 Uncertain significance ? no 
TNNT2 NM_000364.2 c.808G>A p.V270I DCM  0 Uncertain significance no yes 
TPM1 NM_001018005.1 c.340G>C p.E114Q DCM, HTX  0 Uncertain significance no yes 
TTN NM_001267550.1 c.25064-4A>G - RCM  0.000008577 Uncertain significance no yes 
 NM_001267550.1 c.39709+1G>T - RCM, HTX  0 Uncertain significance no yes 






Table S 5: Selection of genetic variants and complex genotypes 














Truncating TTN variants 
TTN NM_001267550.1 c.25064-4A>G* - RCM  0.000008577 Uncertain significance no yes 
 NM_001267550.1 c.39709+1G>T* - RCM  0 Uncertain significance no yes 
 NM_001267550.1 c.68329+2_68329+3insTT* - RCM CMP-25 0.00009578 Likely pathogenic no yes 
 NM_001267550.1 c.85891delG p.A28631Lfs*3 DCM  0 Likely pathogenic no yes 
Homozygous variants 
NEXN NM_144573.3 c.1572_1574delAGA p.E525del DCM, HTX  0.0001556 Uncertain significance ? yes 
TNNI3 NM_000363.4 c.24+2T>A* 
p.Ala8_Ala9insG
luArgAlaAlaGly* 
LVNC CMP-01 0.00001254 Pathogenic ? yes 
Hemizygous variants 
DMD NM_004006.2 c.2169-7_2169-4delGTCT* - HCM CMP-43 0.00003417 Uncertain significance ? no 
 NM_004006.2 c.2273A>C p.D758A RCM CMP-25 0.0002632 Uncertain significance no yes 
 NM_004006.2 c.5723A>T p.D1908V HCM  0.0002101 Uncertain significance no yes 
 NM_004006.2 c.8996C>T p.A2999V RCM CMP-29 0.0000112 Uncertain significance no yes 
FHL1 NM_001159702.2 c.283C>T p.R95W HCM  0.0006232 Uncertain significance no no 
TAZ NM_000116.3 c.29C>G p.P10R LVNC  0 Uncertain significance ? yes 
 NM_000116.3 c.355G>A p.V119M LVNC CMP-24 0 Likely pathogenic no yes 
Index patients with compound heterozygous variants 
DSC2 NM_024422.3 c.304G>A p.E102K DCM  0.0007482 Uncertain significance no no 
 NM_024422.3 c.802A>G p.T268A DCM  0.0001444 Uncertain significance no no 
          
MYBPC3 NM_000256.3 c.2572A>C p.S858R DCM CMP-09 0 Likely pathogenic ? yes 
 NM_000256.3 
genomic deletion of 
MYBPC3 gene 
- DCM CMP-09 0 Pathogenic no yes 




Index patients with >1 pathogenic and/or likely pathogenic variant 
MYBPC3 NM_000256.3 c.1805C>T p.T602I LVNC CMP-27 0.000009848 Likely pathogenic no no 
MYH7 NM_000257.2 c.1283C>A p.A428D LVNC CMP-27 0 Likely pathogenic no yes 
          
DSC2 NM_024422.3 c.1034T>C p.I345T ARVC CMP-33 0.000008133 Likely pathogenic no no 
































m 11,8 14:23896042 c.1988G>A p.R663H 0.000014 P no yes yes yes 10750581 
DCM f 0,0 14:23893328 c.2710C>T p.R904C 0.000004 P no yes yes yes 
20573160 
29212898 
LVNC m 5,9 14:23897862 c.1425G>T p.Q475H 0 VUS no no no yes 21750094 
LVNC m 0,2 14:23901875 c.475G>A p.D159N 0 VUS yes no - - - 
DCM f 0,3 14:23893148 c.2890G>C p.V964L 0.000426 VUS no yes no yes 
23349452 
19412328 
HCM m 7,4 14:23898214 c.1357C>T p.R453C 0 P no yes yes yes 
1552912 
17495353 
DCM m 6,2 14:23882991 c.5767A>G p.K1923E 0 VUS yes no - - - 
HCM m 15,2 14:23899059 c.1063G>A p.A355T 0 P no yes yes yes 
12707239 
20031618 
HCM m 16,2 14:23891465 c.3169G>A p.G1057S 0.000008 VUS no yes no yes 15358028 
LVNC f 11,7 14:23898288 c.1283C>A p.A428D 0 LP yes no - - - 
HCM m 5,3 14:23896043 c.1987C>T p.R663C 0 P no yes yes yes 
11133230 
15358028 
HCM f 0,7 14:23900849 c.677C>T p.A226V 0 LP no yes - - - 
DCM f 0.2 14:23886380 c.4501G>T p.E1501* 0 VUS yes no - - - 
































DCM f 0,1 11:47358972 c.2572A>C p.S858R 0 LP yes no - - - 
HCM m 
2,5 11:47364249 c.1504C>T p.R502W 0.000054 




15,9 11:47369975 c.772G>A p.E258K / 
p.Glu258fsX41 
0.000019 
P no yes yes yes 
17908752 
9562578 
HCM m 15,9 11:47356625 c.2873C>T p.T958I 0.000156 VUS no yes no yes 18957093 
DCM m 0,2 11:47367887 c.961G>A p.V321M 0.000326 VUS no yes no yes 21750094 
HCM m 
16,9 11:47360071 c.2308G>A p.D770N 0.000016 
P no yes yes yes 
22555271 
15519027 
LVNC f 11,7 11:47362781 c.1805C>A p.T602I 0.00001 LP no yes - - - 
HCM m 15,9 11:47367923 c.927-2A>G - 0.000032 P no yes no yes 9562578 






Table S 8: Phenotypes and genotypes of families with TNNI3 variants 






























33 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 







29 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 












11 26 25 
DCM, severe MR 
and TR, RVSP 46 
mmHg 
no SR, iRBB no 
symptomatic with CHD 
after vaccination; sus-
pected myocarditis; 
implantation of LVAD at 










1 7 (+4.4) 6 (+2.9) 
33 
(+5.2) 




deep recesses in 
the apex and 
lateral wall 
yes SR, normal no 
histology from LV 
biopsy: deep recesses 
covered by endocardium 
highly suspicious of 
LVNC; see pedigree in 
Figure S2; death at 1.3 y 
after LVAD implantation 
and sepsis 
Family 3 
3-I:1 no TNNI3 variant 33 N/A N/A N/A N/A N/A N/A 
MRI: mild dilated 
LA, function and 
size of LV normal 
N/A SR, normal no 
Arterial hypertension, no 
symptoms, no 
medications 
3-I:2 no TNNI3 variant 38 9 N/A 44 35 64 62 normal no SR, normal no 
















LVAD implantation at 4 
y, HTX at 4.5 y, death at 
5 y 




              
Family 4 
4-I:1 N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A 
died from SCD at age 30 
with pathology of HCM 
at autopsy 



















multiple family members 
with SCD< 40 y, LGE: 
septal and inferoseptal; 
ICD implantation at 11 y, 
NYHA II-III 
Family 5 
5-I:1 no TNNI3 variant 32 13 N/A 53 22 43 57 normal no 
discordant T-




no symptoms, no 
medications 
5-I:2 no TNNI3 variant 30,4 8 N/A 50 38 68 N/A normal no SR, normal normal 






















implantation at 2.7 y, 















DCM, mild MR, LA 
slightly enlarged 
 
no SR, normal no 
no symptoms; twin 
brother died of acute 











Figure S 2: Extended pedigree of family 2. Genotypes are shown as wt or mut, representing the wildtype or 
altered (mutated) allele. For individuals with no genotype no samples for sequencing were available. Phenotypes 
and the variants on coding sequence and protein level are indicated. Males are represented with squares and 






Figure S 3: Sequences of index patients and family members carrying a TNNI3 variant. Shown are the DNA 





Figure S 4: Sequences from controls and a CMP-affected individual of NGS-generated data analyzed with 





Figure S 5: Sequences from controls and a CMP-affected individual of NGS-generated data analyzed with 





Figure S 6: Sequences from controls and a CMP-affected individual of NGS-generated data analyzed with 





Figure S 7: Sequences from controls and a CMP-affected individual of NGS-generated data analyzed with 
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